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DEVELOPMENT OF A VASCULARIZED, INDUCED PLURIPOTENT STEM CELL-
DERIVED LIVER-TISSUE MIMIC FOR THERAPEUTIC APPLICATIONS 
Venkat Madhav Ramakrishnan 
November 23, 2015 
  
 This dissertation describes the incorporation of several technologies (stem cells, 
gene therapy, tissue engineering and regenerative medicine) into a single project that 
aims to produce a liver-tissue mimic for therapeutic applications. The liver is arguably 
one of the most complex organs in the body. In addition to its remarkable capacity to 
regenerate, it performs a host of vital functions. As a result, its impairment has 
widespread systemic consequences. The work described herein focused on the liver in the 
context of cardiovascular disease and used the heritable disorder Familial 
Hypercholesterolemia (FH) as a clinical disease model. As (a) the only definitive cure for 
FH is currently liver transplant and (b) the availability of quality liver organs for 
transplant is critically low, these studies seek to develop a liver-tissue mimic comprised 
of two parts: functional hepatocyte-like cells (derived from induced pluripotent stem 
cells, or iPSC) and vascular support (provided by adipose-derived stromal vascular 
fraction (SVF)). 
 The dissertation is divided into six sections. Chapter I provides an introductory 
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overview and lists the aims and hypotheses for the dissertation. Chapter II provides a 
four-part background discussing cholesterol metabolism, the liver organ, stem cells, and 
the vasculature. Chapter III describes our efforts to generate a proof-of-concept liver-
tissue mimic, using HepG2 as a hepatocyte model cell source and SVF cells as the 
vascular support system. As vascular support is critical for parenchymal survival and 
function, Chapter IV examines the mechanisms of spontaneous SVF vascular self-
assembly. Chapter V discusses development of a patient-specific, therapeutic cell system. 
FH-patient dermal fibroblasts were programmed into iPSC using modRNA technology, 
and eventually subjected the iPSC to directed differentiation into hepatocyte-like cells1. 
Yet, as the iPSC were derived from an FH patient, the cells required functional 
restoration of their LDL-R in order to impart any therapeutic benefit. To accomplish this, 
a novel episomal LDL-R plasmid containing (a) upstream regulatory control sequences 
that confer physiological feedback control of LDL-R expression and (b) Epstein-Barr 
sequences for episomal retention and replication was used. To mitigate any potential 
concerns associated with viral vectors, the iPSC were derived and corrected using non-
viral modalities. These cells were combined with an SVF derived vascular support 
system to assess iPSC-HLC survival characteristics in vivo. Chapter VI provides a 
comprehensive discussion regarding our experimental efforts. 
 These experiments demonstrate the development of a vascularized, iPSC-
derived hepatocyte liver-tissue mimic that could potentially be used for therapeutic 
applications, such as for the treatment of FH. Efforts to create this tissue engineered liver 
construct were guided by three aims: (1) Assess the role of adipose SVF in providing 
vascular support to implanted parenchymal cells, (2) Evaluate and define the 
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mechanism(s) of SVF vascular self-assembly, and (3) Restore the functionality of 
monogenic-deficient FH cells. These studies provide several proofs-of-principle towards 
the development of effective cell-based treatments, not only for FH, but also for other 
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DISSERTATION INTRODUCTION & SPECIFIC AIMS 
 
Multiple genetic diseases of the liver, including fulminant hepatic failure, non-
alcoholic fatty liver disease (NAFLD), alpha-1 antitrypsin (A1AT) deficiency, and 
familial hypercholesterolemia (FH), are only functionally cured by orthotopic liver 
transplant. Yet, existing deficiencies in transplant teleology (the requirement for 
immunosuppression, the risk of rejection, and consequent loss of quality of life) have 
launched efforts to regenerate cells and tissues to mitigate such dysfunction.  
Induced pluripotent stem cells (iPSC) are a novel, theoretically limitless source of 
cells that could potentially address these issues and others, as they can differentiate down 
any cell lineage and be derived autologously, eliminating any need for the 
immunosuppression associated with transplant. However, iPSC from genetically impaired 
patients would differentiate into syngeneic replacement cells that are fully compatible 
with the host, but just as dysfunctional as targeted diseased tissue. Therefore a critical 
need in advancing iPSC as a cell-based therapeutic is an appropriate strategy for 
correcting the clinical deficiency. Though genetic origin of disease often has multiple 
sources, monogenic disorders could theoretically be corrected by the introduction of a 
single functional gene product. One example of monogenic disease is Familial 
Hypercholesterolemia (FH), characterized by dysfunction of the LDL-cholesterol 
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receptor (LDLR). FH has been extensively studied and represents a suitable model for 
investigating the functional correction of genetically dysfunctional iPSC, which can then 
be used to generate a liver tissue mimic. 
Efforts to restore the functionality of primary and derived hepatocytes have 
resulted in varying degrees of success. LDLR-containing corrective plasmids have been 
delivered to hepatocytes via adeno-associated2 and retroviral vectors3. In numerous 
instances, the high transduction efficiencies afforded by viral vectors yielded significant 
reductions in plasma LDL cholesterol (LDL-C). However, concerns about transgene 
activation, insertional mutagenesis4, and oncogenesis5 (all of which can result in patient 
morbidity and/or mortality) hamper broad clinical use of such viral vectors for gene 
therapy. Non-viral transfection modalities represent a practical alternative, but these 
typically suffer from transient expression and do not provide long-term resolution. Our 
approach to address these issues is utilization of a novel corrective plasmid that was 
designed to be episomal and non-integrating, stably transfected, and physiologically 
sensitive6. The latter feature is especially relevant, as corrective LDLR plasmids lacking 
physiologic sensitivity could force cells to internalize LDL-C without regulation or 
inhibition, leading to toxic cholesterol saturation and eventual cell dysfunction7. 
The generation of a supportive vasculature is also important, as it would serve as 
a vital conduit for parenchymal nutrient delivery and metabolic byproduct expulsion. The 
literature provides evidence of implanted parenchymal cell death in the absence of a 
vascular supply. Investigations have also demonstrated a need for co-cultured support 
cells that enhance parenchymal viability8. Such findings suggest that a stable, functional 
microvasculature is required for parenchymal cell survival and function. We have already 
 3 
demonstrated that adipose-derived stromal vascular fraction (SVF) is an easily accessible, 
heterogeneous mixture of cells capable of providing stromal and vascular support to 
implanted parenchymal hepatocytes9. In our hands, SVF cells formed a functional 
microcirculation that spontaneously assembled, interfaced with these hepatocytes, and 
anastomosed with surrounding host vasculature. Hepatocytes were able to internalize 
peripherally injected circulating LDL-C, providing further evidence for the formation of a 
functional, SVF-derived vasculature at the host-parenchyma interface. The nuclei of cells 
cultured without SVF exhibited characteristics of apoptosis, whereas those cultured with 
SVF appeared intact and ostensibly healthy. This combination of hepatocytes with SVF 
cells formed the basis for a functional liver-tissue mimic. 
In conclusion, we aim to use a monogenic disease model for exploring the non-
viral, functional restoration of genetically dysfunctional iPSC. Corrected iPSC will be 
used to engineer and generate hepatocyte-like cells that will be assessed for restored 
functionality as well as for evidence of maturation in the presence of an SVF cell co-
culture. The reciprocal effect of the parenchyma on the newly developed, surrounding 
microvasculature will also be assessed. The development of a functional tissue mimic 
lays the groundwork for further exploration into the architecture, size, and scalability of 
engineered organoids specific to various dysfunctional phenotypes. This translational 
project will contribute to the development of cell-based therapies and other autologous, 
transplantable organs.  
Globally, I hypothesize that functionally corrected autologous FH-iPSC-
derived parenchymal cells, combined with stromal and vascular support, will form 
following implantation a functional tissue mimic that offers sustainable therapeutic 
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value in end-organ dysfunction. This hypothesis will be examined via the following 
specific aims: 
 
Aim 1: Assess the role of Stromal Vascular Fraction (SVF) cells in providing 
vascular support to implanted hepatocytes. 
Aim 1 Hypothesis: An SVF-derived vasculature enables the engraftment and 
function of implanted hepatocytes. 
Aim 1 Rationale: The hypothesis for this aim is predicated on SVF’s documented 
ability to rapidly self-assemble into vessels. We further postulated that SVF could 
likely form self-assembled vasculatures in the presence of hepatocytes. 
Aim 2: Define mechanisms of human SVF vascular assembly. 
 Aim 2 Hypothesis: Wnt5a mediates hSVF vascular assembly. 
Aim 2 Rationale: Our preliminary data indicates that the pan Wnt-release inhibitor 
IWP2 inhibits endothelial cell (EC) networking in SVF, implicating all Wnt 
isoforms in EC network formation. The literature has suggested that Wnt5a is 
implicated in processes such as perivascular recruitment, vascular sprouting, 
vascular pruning, and tight-junction maintenance, all of which are intimately 
associated with EC. 
Aim 3: Restore the functionality of monogenic-deficient FH parenchymal cells. 
Aim 3 Hypothesis: A non-viral, non-integrating episomal plasmid containing a 
wild-type LDL receptor (LDL-R) cassette will restore LDL-R functionality to FH-
iPSC-derived hepatocytes. 
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Aim 3 Rationale: The technology and function of an episomal LDL-R-containing 
plasmid has already been demonstrated in the literature. Additionally, iPSC have 
been shown to generate autologous hepatocyte-like cells (HLC) in addition to a 
variety of other parenchymal cell types. Further, iPSC can be easily cultured and 






BACKGROUND & LITERATURE REVIEW 
 
PART I: CHOLESTEROL & DISEASE 
 
Cholesterol Production 
The liver is the primary organ responsible for cholesterol regulation in the body10. 
Cholesterol is an important constituent of cell membranes and several cellular 
byproducts, including steroids, hormones, and bile11. Systemic cholesterol homeostasis is 
tightly regulated, between inputs (such as cholesterol obtained through cell synthesis or 
through the diet) and outputs (such as the byproducts described above). Therefore, a 
long-term increase in plasma cholesterol is a result of deregulated homeostasis leading to 
accelerated development of cardiovascular disease (e.g. atherosclerosis, cardiac 
infarction) and death12.  
Before discussion of the implications of cholesterol in disease, it is important to 
outline the mechanisms of cholesterol synthesis and metabolism (Figure 1). The process 
of cholesterol synthesis begins with Acetyl CoA, a central intermediate in lipid 
metabolism13. The breakdown of glucose or amino acids yields Acetyl CoA, whose 
downstream products include fatty acids and ketone bodies, triglycerides, phospholipids, 
eicosanoids, and cholesterols, as well as carbon dioxide, water, and ATP (energy) in 
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cellular respiration. Specifically, with respect to cholesterol, Acetyl CoA is converted to 
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) and then Mevalonate, whose generation is 
mediated by the enzyme HMG-CoA reductase (HMGCR). HMGCR serves as the rate-
limiting step of cholesterol synthesis and a target for several pharmacological therapies 
(discussed below). Additionally, the ultimate conversion of Acetyl CoA to Mevalonate 
constitutes the first stage of cholesterol synthesis. The second stage converts Mevalonate 
into several 5-carbon building blocks, while the third stage generates lipid intermediates 
of biological importance. For instance, one of these intermediates, Farnesyl phosphate, is 
a branch point intermediate in ubiquinone and dolichol synthesis. Ubiquinone is an 
important electron carrier in the electron transport chain, and dolichol is an important 
endoplasmic reticulum anchor involved in N-linked glycosylation. Thus, these 
intermediates play vital roles in cell metabolic and homeostatic processes. The fourth and 
final stage of cholesterol synthesis involves the cyclization of the intermediate Squalene 
into a 4-ringed structure with a steroid nucleus, hydrocarbon side chain, and single 








Figure 1. General, conceptualized mechanism of cholesterol synthesis from Acetyl-CoA. 
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Cholesterol Transport 
The transport of cholesterol around the body is also another important 
consideration. For instance, cholesterol is not water-soluble and, therefore, requires a 
vehicle for transportation12. To this end, it is packaged as a cholesterol ester (CE) within 
one of several lipoproteins, all of which act as cholesterol and triacylglycerol (TAG) 
transporters from cholesterol-producing cells to peripheral recipients. Enzymes known as 
acyl CoA-cholesterol acyl transferases (ACAT) or phosphatidylcholine cholesterol acyl 
transferases (PCAT) take long fatty acid chains and append them to cholesterol 
molecules, generating CEs. While ACAT acts intracellularly and PCAT acts 
extracellularly, these are two different enzymes that act at two different sites but 
ultimately perform the same function – yielding the same CE product. While the bulk of 
cholesterol within a lipoprotein is stored as CE, the phospholipid monolayer of the 
lipoprotein itself contains varying proportions of unesterified cholesterol, depending on 
the identity of the lipoprotein12.  
There are four main classes of lipoproteins, all of which are complexed with 
specific carrier proteins known as apolipoproteins12. Chylomicrons (typically complexed 
with APOB48, APOC2, APOC3, and/or APOE) are synthesized in the intestine and are 
responsible for the transport of dietary cholesterol and triglycerides from the intestines to 
the liver and other tissues. In this case, since lipids originate from the diet, this pathway is 
considered to be an exogenous lipid transport pathway. Chylomicrons typically have the 
highest TAG composition (85% of their weight), but also transport CE (3% wt) and free 
cholesterol (1% wt). After the removal of APOC2 and its TAG stores, chylomicrons 
become significantly smaller and are termed chylomicron remnants, which go back to the 
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liver for degradation14. Very low-density lipoproteins (VLDL; can be complexed with 
APO-B100, APOC1, APOC2, APOC3, and APOE) are made in the liver. VLDL serves 
to transport newly synthesized TAG and cholesterol to the extrahepatic tissues for storage 
as fat. Since these lipids originate from the liver, the VLDL-mediated pathway is 
considered to be the endogenous pathway for lipid transport. These lipoproteins hold 
considerably more CE than chylomicrons (at 12% wt) as well as unmodified cholesterol 
(7% wt) but significantly less TAG (50% wt). Low-density lipoproteins (LDL) are 
ultimately generated from VLDL by the removal of TAG during VLDL metabolism. 
LDL contains the highest density of CE (37% wt) and free cholesterol (8% wt), but the 
second lowest concentration of TAG (10% wt). Lastly, high-density lipoproteins (HDL; 
complexed with APOC1 and APOC2, but also associated with APOA1, APOA2, 
APOA4, APOC3, APOD, and APOE) are synthesized in the liver and intestine. In 
addition to harboring intermediate amounts of CE and free cholesterol (15% wt and 2% 
wt, respectively), HDL actually has a significantly higher density of proteins (55% wt) 
and phospholipids (24% wt). HDL plays a significant role in a process known as reverse 
cholesterol transport (RCT), since it primarily collects cholesterol from peripheral 
locations and transports it back to the liver for processing. It also contains the enzyme 
LCAT, converting the cholesterol from chylomicrons and VLDL remnants into CE12. All 
of these lipoproteins play intermediary, interactive roles in a larger cascade.  
HDL and LDL are the two most clinically relevant lipoproteins. LDL cholesterol 
is often termed “bad cholesterol”, while HDL cholesterol is often termed “good 
cholesterol”15. Though this is somewhat simplistic, there is some truth to these 
viewpoints. First, to physically compare the two molecules, LDL has a diameter of 22nm 
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and a mass of 3000kDa. It can hold a significant amount of CE, and is associated with a 
single 500kDa Apolipoprotein B molecule16. HDL, on the other hand, is a much smaller 
molecule, having a diameter between 5-12nm17,18 and most commonly associating with a 
28kDa Apolipoprotein A molecule19. The lipid-protein bonds in LDL are arranged as 
beta-sheets, making the two components inseparable. These same bonds in HDL form 
alpha-helical structures, which can freely dissociate and change structure. As cholesterol 
is one of many energy sources, it requires less energy (i.e., it is easier) for the body to 
utilize the cholesterol stored in HDL molecules versus LDL molecules. Secondly, higher 
HDL levels can confer a protective effect on the heart, lowering the risk for heart attack 
and stroke. This is partly because HDL is thought to have scavenger-like properties that 
enable it to clear the LDL cholesterol. Liver sinusoidal cells have an abundance of HDL 
receptors that then facilitate HDL clearance20. This said, peripheral tissues largely derive 
their cholesterol from LDL. Therefore, while excessive LDL can be harmful (discussed 
below), a moderate amount is beneficial, if not required. 
 
LDL Cholesterol Metabolism and Regulation  
LDL cholesterol and the LDL-R participate in an intricate form of metabolic 
regulation. In 1977, Brown, Goldstein, and colleagues were the first to describe LDL 
metabolism as a process involving receptor-mediated endocytosis (RME)21. In this 
process, LDL cholesterol binds to the LDL receptor (LDL-R), a protein that spans the 
plasma membrane and contains a cysteine-rich Apolipoprotein B binding site. Once 
endocytosed, LDL cholesterol is contained within an endosome. The endosome merges 
with a cell lysosome; the CEs within LDL are hydrolyzed, releasing pure cholesterol. The 
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cell then utilizes this cholesterol to supplement its plasma membrane or for steroid and 
hormone production16. As for the LDL-R, it can either be recycled back to the cell 
surface, or broken down and reconstituted by the endoplasmic reticulum (ER). From the 
ER, the new LDL-R is routed to the cell membrane via the Golgi complex12. 
While LDL and the LDL-R possess a fairly simple relationship in terms of 
binding and internalization, the more complicated and fascinating aspect is the precise 
control that is exerted on LDL-R expression and endogenous cholesterol production. The 
German scientist Rudolph Schoenheimer and colleagues were the first to describe the 
existence of an overall cholesterol feedback loop22. Schoenheimer placed mice in glass 
flasks and fed them a sustained cholesterol-infused or control diet over a period of one 
month. After sacrificing and dissolving the mice in an ether-sodium hydroxide-alcohol 
steam bath, he measured the total cholesterol content of each flask. Interestingly, mice 
given a cholesterol-free diet yielded flasks with a higher cholesterol content than those 
from mice given cholesterol-laden diets. The experiment indicated that animals can 
generate cholesterol, and stop making cholesterol when it is present in the diet.  
In 1975, Brown and Goldstein described LDL-R regulation in human fibroblasts, 
noting that the receptor was under feedback regulation and influenced by exogenous 
cholesterol levels in the culture media23. In 1986, Brown and Goldstein discovered a 
feedback suppression mechanism within cells that kept the amount of membrane 
cholesterol at a constant level. This was, in large part, due to mediation of the cells’ 
endogenous production of cholesterol by HMGCR24, which made enough cholesterol to 
maintain membrane fluidity. The 1990s and 2000s brought on a greater understanding of 
the ‘cholesterol sensing mechanisms’ that drive LDL-R expression and HMGCR activity. 
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Yokoyama was the first to describe the existence of the sterol response element binding 
protein (SREBP)25, a transcription factor that resides on the endoplasmic reticulum. Once 
translated, SREBP binds the protein Scap26-28, the protein that detects membrane sterol 
levels29  through direct binding of cholesterol30. A deficiency in membrane cholesterol 
levels induces the SREBP-Scap complex to bind a complex of vesicular proteins known 
as COPII31. COPII facilitates the internalization of SREBP and Scap into the Golgi 
apparatus, where proteases cleave the SREB proteins into transcriptionally active 
segments27,28,32. These segments then enter the nucleus to initiate LDL-R and 
HMGCR33,34 gene transcription, ultimately forcing the cell to produce more endogenous 
cholesterol and scavenge circulating LDL cholesterol with greater efficiency through 
increased receptor expression. An excess of membrane cholesterol (with cholesterol 
levels comprising greater than 5% of total lipids) results in (a) cholesterol binding 
directly to Scap30, (b) an alteration in the configurations of Scap35 and COPII31, and (c) 
the binding of Scap to a COPII binding inhibitor known as Insig36. 
 
Implication of Cholesterol in Heart Disease 
The pathophysiology of atherosclerosis has been demonstrated to be intimately 
dependent on circulating cholesterol levels. While we take it for granted today that higher 
LDL levels yield atherosclerotic plaques, this direct relationship was unknown to us as 
recently as a century ago. Here, we examine several key studies that ultimately 
characterized this interaction. 
One of the earliest contributors to our understanding of cholesterol in heart 
disease was Russian scientist Alexander Ignatowski, who, in 1907, published a study in 
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which he fed full-fat milk, eggs, and meat to rabbits in an effort to understand their 
effects on atherosclerotic development37. Five years later, Nicolai Anichkov conducted a 
similar experiment, substituting the milk, eggs, and meat with boluses of cholesterol38. In 
both cases, Ignatowski and Anichkov observed the development of aortic atherosclerosis 
and confirmed a relationship between dietary cholesterol and atherogenesis.  
In 1953, Ancel Keys, a Mayo Clinic scientist who eventually popularized the 
relationship between diet and health, began a pioneering study on the epidemiology of 
myocardial infarction across seven different countries. He demonstrated that those with 
higher fat intakes exhibited higher levels of serum cholesterol. Because western diets 
were known to contain more fat than eastern diets, Keys assessed the role of diet in 
coronary events for Japanese males situated in Japan, Hawaii, and California. Here, he 
noticed that males in California had a higher fat intake and increased number of coronary 
events compared to those living in Hawaii and Japan39.  
In that same decade, John Gofman, a prominent physician and researcher at the 
University of California, Berkeley, was the first to identify the presence of VLDL, LDL, 
and HDL in serum by centrifugation40. He and E. Virginia Dobbin, a dietician at a local 
hospital, then demonstrated the link between increased dietary fat intake and the resulting 
increases in serum LDL cholesterol41. Gofman was also the first to study LDL and HDL 
levels in heart attack patients compared to healthy controls. He demonstrated that heart 
attack patients had significantly increased LDL and significantly decreased HDL levels 
compared to their healthy counterparts.  
Several other studies have also focused on the role of HDL in cardiovascular 
dysfunction19. Most notably, the Framingham Heart Study (one of the longest, 
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continuously running studies) elucidated in 1988 that high levels of HDL cholesterol 
reduced the risk of death from heart disease42. While HDL can potentially mitigate LDL 
oxidation (discussed below)43-45, HDL levels below normal can also independently 
indicate cardiovascular dysfunction even in the presence of low LDL cholesterol levels46. 
Conversely, a recent study demonstrated that mutations in which HDL was increased did 
not necessarily confer a cardio-protective effect, suggesting that HDL levels alone may 
be unable to overcome particular genetically mediated modes of cardiovascular 
dysfunction47. Still, though much of today’s therapies focus on therapeutically lowering 
LDL levels, the use of HDL to target heart disease is under increasing investigation48.  
In sum, these key studies dictate a critical interplay between HDL and LDL 
cholesterol levels and their implications in heart disease. Diet plays a critical role in the 
prevalence of particular cholesterol subtypes. Diets high in fat lead to a greater incidence 
of LDL-driven coronary events, while HDL plays a more regulatory role and can even 
have therapeutic benefit in sufficient concentrations. However, since LDL cholesterol is 
the key driver of atherosclerosis and heart disease, we will next look at the mechanism of 
its involvement. 
 
Pathophysiology of Atherosclerosis 
Today, we have a direct mechanism for LDL’s involvement in forming 
atherosclerotic plaques. While all blood vessels are lined with endothelial cells, 
atherosclerosis is a condition that uniquely affects only the arterial endothelium. The 
development of a fatty streak (the origins of atherosclerotic plaques) can be broken down 
into roughly seven distinct steps: (1) lipoprotein transport, (2) lipoprotein retention, (3) 
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lipoprotein modification, (4) monocyte adherence, (5) monocyte chemotaxis, (6) 
monocyte differentiation, and (7) the formation of foam cells49.  
The earliest atherosclerotic lesions, termed ‘fatty streaks’, are formed at arterial 
sites that experience significant turbulent blood flow and sustained hemodynamic stress, 
both of which can damage the lining endothelium. While normal arterial endothelial cells 
resist the binding of circulating monocytes and other immune cells, a dysfunctional 
endothelium at these sites serves as a recruiter for such cells by up-regulating the 
adhesion molecules required for their binding50. Furthermore, endothelial dysfunction 
impairs tight junctions, enhancing permeability and facilitating the entry of LDL into the 
sub-intimal space51. The oxidation of LDL further seeds the lipoprotein beneath the 
endothelium as well as modify the lysine residues on Apolipoprotein B. Further oxidation 
leads to an exacerbation of monocyte chemotaxis; more monocyte-macrophages are 
recruited to the LDL-filled sub-endothelial space and bind the modified Apolipoprotein B 
using scavenger receptors. Once LDL is internalized, the monocytes take on a foamy 
appearance and are thusly termed foam cells49. Foam cells then secrete a variety of 
cytokines that promote inflammation, causing resident smooth muscle cells to proliferate 
and secrete collagen. This results in an enlargement of the fatty streak to a full-fledged 
plaque, which can severely narrow or completely occlude a vessel, or can rupture and 
embolize16. 
 
Familial Hypercholesterolemia and LDL-R Dysfunction 
 Though some have elevated LDL cholesterol levels because of poor diets, a 
significant number have genetic deficiencies that predispose them to high levels of 
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circulating LDL and, ultimately, accelerated cardiovascular disease development. One 
such group of patients is those suffering from Familial Hypercholesterolemia (FH), a 
disease characterized by pathologically high levels of plasma LDL cholesterol due to 
dysfunctional LDL-R. Though Brown and Goldstein were the ones who described the 
existence of the LDL-R in the mid-1970s52-54 and discovered its regulation in the 1980s24, 
Müller was among the first to clinically describe FH in 1938, as an “inborn error of 
metabolism” that was inherited in an autosomal dominant manner55. Further, he 
demonstrated that the unusually high plasma LDL cholesterol levels in FH resulted in a 
consequent 20-fold increased incidence of heart attacks.  
 It wasn’t until many decades later that Khachadurian described the bimodal 
inheritance of FH in homozygous (have two defective LDL-R alleles, one inherited from 
each parent) or heterozygous variants (having only one defective LDL-R allele)56. 
Untreated, homozygotes (seen in ~1 in 106) exhibit severely elevated cholesterol levels as 
high as 600-1000 mg/dl, while heterozygotes exhibit more moderate elevations of 300-
600 mg/dl. Though the standard assumption is that 1:500 have the heterozygous variant, 
it is as frequent as 1:200 to 1:100 in Scandinavian populations, suggesting that the 
disease is in fact under-diagnosed57. This buildup of cholesterol can have broad systemic 
effects. In addition to non-lethal symptoms, such as the formation of xanthomas and 
xanthelasmas (visible collections of cholesterol in the joints and eyes, respectively), 
patients also exhibit accelerated cardiovascular disease. To this end, untreated 
homozygotes can die of heart failure as early as their teens, while untreated heterozygotes 
can die in their 30s or 40s58,59 
 As stated before, these clinical manifestations are largely due to inherited defects 
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in the LDL-R. To date, over 1200 mutations affecting the LDL-R have been identified60. 
These mutations affect LDL-R functionality in at least one of six ways: (1) LDL-R is not 
made, (2) LDL-R is not transported to the surface, (3) the binding domain of LDL-R is 
altered, preventing LDL from binding to LDL-R, (4) LDL can bind, but LDL-R cannot 
be internalized, and (5) LDL-R are not recycled and are rapidly degraded in the 
lysosome61. 
 However, there are other, much less prevalent, non-LDL-R-mediated modalities 
that lead to the same clinical presentation as that seen with LDL-R dysfunction-induced 
FH. For instance, mutations in Apolipoprotein B prevent LDL cholesterol from binding 
to LDL-R, affecting about 10% of individuals with FH62. In another example, in 2009, 
Horton and colleagues described the role of proprotein convertase subtilisin/kexin type 9 
(PCSK9), an enzyme secreted by the liver and other organs63. A gain-of-function 
mutation in PCSK9 allows PCSK9 to bind the LDL-R and prevent receptor cycling after 
the receptor and ligand have been internalized. In doing so, the number of surface LDL-R 
decrease and result in an increase in plasma LDL levels similar to those seen with FH. 
Conversely, a loss-of-function PCSK9 mutation, described by Cohen in 2006, can lead to 
significant reductions in both LDL levels and heart attacks compared to the general 
population64. To this end, pharmaceutical companies have sought to reproduce this effect 
with drugs that act as PCSK9 inhibitors. 
 
Current FH Therapies 
 There are several pharmacologic agents that are used to treat FH, though none of 
these therapies offers a definitive cure. The most prominent example are statins, which 
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are considered to be a mainstay of FH therapy and act by blocking the activity of 
HMGCR and, consequently, cells’ endogenous cholesterol production. A better 
understanding of this comes from reconsideration of the LDL-R and endogenous 
cholesterol production via a feedback loop (described in the ‘LDL Cholesterol 
Metabolism and Regulation’ section above; also see Figure 2). When statins block 
HMGCR activity, they block endogenous cholesterol production. With the cells unable to 
produce their own cholesterol, they are forced to scavenge LDL cholesterol to meet their 
membrane cholesterol requirements. Consequently, their expression of the LDL-R is up-
regulated, allowing the cells to internalize more LDL through receptor-mediated 
endocytosis65. This, in turn, lowers peripheral, circulating LDL cholesterol levels and 
imparts a therapeutic effect.  
 Statins have had a profound impact on cardiovascular therapy and are amongst the 
most widely prescribed class of drugs on the market today66. This, in large part, has to do 
with the overwhelming evidence showing the dramatic effect of statins on lowering the 
plasma LDL levels in dogs67, humans68, and human FH heterozygote patients69 (in whom 
“a single functional [LDL-R gene] is present and susceptible to activation by cholesterol 
deprivation”16).  
 However, statins have some significant drawbacks. Implicit in the description 
above is the fact that statins require a functional LDL-R in order to elicit any benefit. 
Thus, homozygous FH patients lack functional LDL-R and, therefore, are minimally 
benefitted by statins alone70 and, at a minimum, require the administration of other 
supplemental agents. Statins also harbor side effects such as myalgias and can increase 




Figure 2. General schematic of the LDL-R feedback loop. (A) In a normal, functional 
system, the binding of LDL to the LDL-R has an inhibitory effect on the activity of HMG-
CoA Reductase (HMGCR) within the cell. If the cell obtains enough cholesterol through 
the LDL-R, endogenous cholesterol production ceases and expression of the LDL-R on 
the cell surface is down-regulated. (B) In FH, the LDL-R is dysfunctional. This 
dysfunction impairs the negative feedback on HMGCR, leading to increased production 
of endogenous cholesterol regardless of circulating LDL levels. Statins act to block 
HMGCR and increase LDL-R, but statins only exert a therapeutic effect if LDL-R is 
functional. Many FH patients have completely dysfunctional LDL-R and are therefore 
refractory to treatment with statins. 
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skin rashes, and neurological side effects.  
 In many instances, statins are coupled with other drugs to amplify their 
therapeutic effect2. For example, niacin, one of the oldest drugs used for managing 
circulating lipid levels, has been shown to independently lower LDL cholesterol by up to 
20% while raising HDL levels by as much as 31%71. In another example, PCSK9 
inhibitors act to mimic the loss-of-function mutations seen with PCSK9, rendering it 
unable to prevent LDL-R cycling and consequently making more LDL-R available at the 
cell surface for binding to LDL cholesterol. In conjunction with statins, PCSK9 inhibitors 
significantly reduce circulating LDL levels72. Third, bile acid sequestrants such as 
cholestyramine or cholesevelam bind bile in the intestines and prevent their reabsorption 
via the enterohepatic circulation. Thus, excess bile is removed in the feces. With a 
shortage of bile in the body, the liver converts excess cholesterol into bile and 
consequently reduces the amount of cholesterol in the body71. As a final example, 
Ezetimibe is an agent that acts at the intestinal brush border to inhibit cholesterol 
absorption via lacteals73. Though it has significantly reduced LDL cholesterol levels in 
some trials, other trials have indicated that it can actually increase LDL cholesterol and 
independently contribute to atherogenesis, negating any potential therapeutic benefit74. 
 Pharmacologic therapies such as these are not completely effective in the face of 
severe disease. Patients must resort to more invasive options. For instance, homozygous 
FH patients may require lipoprotein apheresis, a dialysis-like process that physically 
extricates LDL cholesterol from the blood. However, this approach has several 
drawbacks. Patients with extremely elevated cholesterol levels may be required to 
undergo apheresis with increasing frequency. This presents with several challenges, 
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namely that (a) the reduction in circulating cholesterol is not permanent (cholesterol 
rebound), (b) like dialysis, the patient is at risk for infections at the vascular access site, 
and (c) with the requirement for increased visits, quality of life is reduced while cost of 
care is increased75.  
 Because liver hepatocytes have the highest density of LDL-R in the body76, liver 
transplant provides the only known cure for FH. In one study, the pediatric recipients of 
normal LDL-R via liver transplant achieved a clinical resolution of their symptoms and in 
the case of one patient, even a reversal of their atheromatous lesions77-79. However, 
transplant is not without its own challenges. Hampered by a low availability of quality 
organs to start with, transplant is also mitigated by non-ideal donor-host compatibility, 
necessitating lifelong immunosuppression and resulting in an increased susceptibility and 
adverse response to common infections. Furthermore, transplants are expensive, often 
costing several hundreds of thousands of dollars. Above all, the procedure itself carries 
significant risk and can lead to death. 
 
Restoring LDL-R Functionality in FH  
 To date, the only definitive cure for FH is liver transplant. However, quality 
hepatocytes (and liver organs) are in short supply and transplantation has several practical 
issues. Thus, there are several genetic strategies for mitigating the LDL-R defect present 
in FH. Broadly put, these efforts rely on either transplanting healthy hepatocytes into 
patients80-83, delivering the corrected LDLR gene directly to hepatocytes (discussion with 
Wade-Martins as well as 84,85), correcting LDLR in cells ex vivo before their eventual (re-
)implantation3,86,87, or genetically correcting pluripotent cells for eventual implant88 or 
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differentiation1,89. 
 However, before discussing specific approaches to treating FH, we should first 
consider the characteristics of these approaches in isolation. Regenerative medicine has 
significantly advanced due to the advent of gene therapies and transgene delivery90. One 
major driver of gene therapy has been the use of viral vectors, which in general, can 
infect a wide variety of cell types in an efficient manner via a predictable mechanism. 
However, viruses have also been associated with significant safety risks91. In one case, it 
has even resulted in death92. To understand these dynamics, we will discuss details 
regarding the four main classes of viral vectors – retroviruses (and lentiviruses), 
adenoviruses, and adeno-associated viruses. 
 Retroviruses traditionally replicate their single stranded RNA and convert this 
into double stranded DNA, which can then integrate into the host genome and utilize host 
machinery for viral propagation. From this point, viral particles can bud from infected 
cells and go on to infect other cells. Because retroviruses are naturally highly efficient at 
performing this process, they are often generated to be replication-deficient for scientific 
applications to curtail the likelihood of an adverse outcome93. Despite this, these viruses 
still harbor significant limitations. First, they are traditionally not ideal for situations in 
which transient gene expression is desired, though a more recent effort has highlighted 
the effectiveness of removing integrase in potentially yielding a transient outcome94. In 
scenarios where a long-term, stable outcome is desired, transgene integration facilitated 
by viral reverse transcriptase is still required, though adversities have arisen from 
insertional mutagenesis95. Secondly, many retroviruses have difficulty in infecting non-
dividing cells96-98, though lentiviruses (a class of retroviruses) such as HIV-1 can infect 
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resting cells99 with varying efficiencies100. To this end, in treating FH, Grossman and 
colleagues used retroviral vectors to transduce a functional LDL-R into five FH 
patients101, though only one patient exhibited a significant reduction of LDL levels. This 
highlights another limitation – efficient retroviral transduction into the liver to 
sufficiently restore LDL clearance is still challenging102. A fourth limitation is that some 
retroviruses are quite large (upwards of 150nm in diameter in some cases)103. In the 
context of the liver, this is important as its vasculature is sinusoidal and fenestrated, and 
these fenestrations facilitate the transendothelial passage of various biomolecules into 
parenchymal hepatocytes104,105. Additionally, other resident liver cells, such as Kuppfer 
Cells and the endothelial cells comprising sinusoids (LSEC) can also actively take up 
various vectors106-108. All of these factors serve as barriers that reduce the efficiency of 
gene therapies to treat genetically dysfunctional hepatocytes. 
 Adenoviruses have been another option for therapeutic applications. They are 
desirable as they can carry a relatively large gene payload – for instance, up to 30kb of 
36kb of wild-type adenoviral DNA can be replaced by foreign DNA109,110. Though they 
can be used for transient gene expression, their involvement in inducing host 
inflammatory responses is not desirable111. Though second- and third-generation 
adenoviruses can offer prolonged transgene expression and reduced immunogenicity112-
115, more attention has been turned to adeno-associated viral vectors. 
 Adeno-associated viruses (AAV) are desirable as they are not associated with 
pathogenicity, exhibited relatively low immunogenicity, and can offer stable, episomal 
transgene expression116. However, their ability to accommodate only small gene packages 
(~5kb) due to their small size (~22nm)117 means not only are they more ideally suited for 
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traversing liver fenestrations, but also that larger genes must delivered in a piecemeal 
fashion by multiple AAV vectors and re-assembled in vivo by homologous 
recombination118-120. Because all of these pieces have to be delivered to the same cell for 
the transgene to be functional, this obviously poses an impediment to high efficiency and 
may require the use of higher viral concentrations. Additionally, several species have pre-
existing antibodies to AAV, further limiting their efficiency121,122. While AAVs recently 
received European approval for the treatment of familial hyperchylomicronemia (a 
deficiency of lipoprotein lipase)123, AAV delivery to the liver has been shown to elicit 
liver-tissue damage, likely through a T-cell mediated mechanism124-126. 
 With respect to viral delivery of LDL-R transgenes, though reductions in LDL-C 
have been reported for relatively short time periods post transfection127,128, viral vector 
LDLR delivery does not yield full amelioration of the FH LDLR deficiency. This is 
likely because of long-term reductions in transgene expression as well as a diminished 
degree of vector delivery to target cells3,129. Additionally, strong promoters that appear to 
benefit LDL-C regulation in the short term often drive LDLR transgenes. For instance, 
some have reported no cytotoxicity with constitutive LDLR expression127. However, this 
is controversial since uncontrolled LDLR expression has also been shown to cause 
lipoprotein cytotoxicity130,131. 
 Hibbitt and colleagues developed a non-viral plasmid (pEHZ-LDLR-LDLR) 
containing Epstein-Barr virus OriP and EBNA1 for episomal retention and stable 
replication with a Hygromycin-B antibiotic selection cassette6 (Figure 3). To control the 
LDLR transgene expression, the plasmid contains 10kb of upstream genomic DNA 




Figure 3. A schematic of the episomal LDL-R-containing plasmid (generated by Hibbitt 
and colleagues) shows several key features: 1) A wild-type LDL-R gene is preceded by 
10kb of upstream regulatory control sequences, which house the sterol response elements 
that confer physiological sensitivity to the plasmid. 2) The plasmid confers Hygromycin-B 
resistance. 3) Epstein-Barr Viral Nuclear Association factor-1 (EBNA-1) facilitates 
nuclear localization and maintenance, and is supported by OriP. Note: plasmid is not 
drawn to scale; locations of various cassettes in this schematic do not reflect their actual 
position, size, or relation to one another in the plasmid. 
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functionality assessments, the plasmid conferred physiologically responsive receptor-
mediated LDL internalization to the Ldlrnull CHO-a7 cell line1,6,132 and retained an in vivo 
episomal localization in hepatocytes for 270 days after transfection. These data 
demonstrate the potential of the pEHZ-LDLR-LDLR system as a gene therapy for treating 
FH. 
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PART II: THE LIVER AND HEPATIC SUBSTITUTES 
 
 As this dissertation project seeks to recapitulate particular aspects of hepatocyte 
function in the context of a liver-tissue mimic, we should briefly consider the liver 
anatomy, its cellular organization, major functions, blood supply, and other related 
functions. However, to best orient ourselves, we will begin with an overview of liver 
development. 
 
Hepatobiliary Embryological Development 
Our discussion of the liver in the context of cardiovascular dysfunction is 
particularly fortuitous, as these two systems are intimately related – even in development. 
There is a considerable degree of interplay between liver and heart growth; in fact, the 
liver’s embryological function is primarily cardiovascular in nature, serving to shunt 
blood from maternal circulation and umbilical cord directly to the fetal heart and 
circulation.  
To better understand this interplay, consider the interactions between two germ 
layer derivatives – the primitive ventral endoderm (which gives rise to the liver) and 
cardiac mesoderm (which gives rise to the heart). The cardiac mesoderm is required for 
liver formation. In the 1960s and 70s, the French scientist Le Douarin studied the 
interactions between endoderm and mesoderm in developing, chimeric avian embryos. 
She demonstrated that a piece of primitive gut was unable to develop into a liver by itself, 
and that hepatogenesis was only achievable in the presence of cardiac mesoderm133. 
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Furthermore, a juxtacrine interaction between the two developing tissues was required, as 
the placement of a barrier abrogated the formation of glycogen-storing hepatocytes134. 
During hepatogenesis, the ventral endoderm tissue expresses a large degree of 
FGF receptor 4 (FGFR-4)135 and FGF receptor 1 (FGFR-1)136, while the cardiac 
mesoderm only expresses FGFR-1136. Of these, FGFR-1 is required for endodermal 
development137. In 1999, Jung demonstrated that FGF-1 and FGF-2 can act as signals that 
promote liver development138. Additionally, FGF-8 promotes outgrowth of the liver bud, 
though it is not necessary for the induction of hepatogenesis. Interestingly, FGF has a 
local effect because of its high affinity for the extracellular matrix139. This is of particular 
importance to portions of the ventral endoderm that do not closely oppose the cardiac 
mesoderm; a lack of local, cardiac mesoderm-derived FGF causes ventral endoderm to 
develop into pancreatic tissue instead140. Therefore, while the ventral endoderm can 
develop into pancreatic tissue by default, the presence of FGF inhibits pancreatic 
development and promotes hepatogenesis. Furthermore, this FGF is cardiac mesoderm-
derived141. As a second example, the dorsal endoderm can readily differentiate into 
hepatoblasts in the absence of surrounding tissues. However, in the presence of the dorsal 
mesoderm, the dorsal endoderm does not undergo hepatogenesis, and instead undergoes 
gut development. These examples indicate that there are positive and negative 
differentiation factors that finely modulate hepatic development based on movement and 
signaling140.  
Hepatogenesis can be described as a two-step process140. We have already 
discussed the first step, during which cells of the ventral endoderm differentiate down the 
hepatic lineage. The second step is comprised of the differentiation of hepatoblasts into 
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hepatocytes, which depends on additional stimulation by the Septum Transversum (ST) 
mesenchyme. Mesenchymal interaction may also be necessary for hepatogenesis142. The 
ST is an intermediary cellular layer between the endoderm and cardiac mesoderm that 
later develops into the epicardium and diaphragm143. The ST is also a rich source of 
BMP4. Multiple studies have demonstrated that the ST, and its abundance of BMP4, are 
vital to hepatogenesis. Cultures of ventral endoderm sans ST mesenchyme failed to yield 
a liver. Likewise, BMP4null mice also failed to develop a liver. Lastly, when both the 
ventral endoderm, cardiac mesoderm, and ST mesenchyme were all present, the addition 
of Noggin (a BMP4 antagonist) blocked hepatogenesis and resulted in no albumin 
expression142, even though previous studies demonstrated that FGF alone could drive 
hepatogenesis138,140. 
Within this complex milieu of hepatocyte development, hepatic cords begin 
coalescing around immature endothelial cells known as angioblasts. These cords begin to 
grow and organize at the expense of the ST, which eventually also forms the liver 
capsule143. The influence of VEGF/Flk1 signaling drives the angioblasts to take on a 
sinusoidal phenotype; these sinusoids then act as gestation templates for the three-
dimensional growth of hepatic cords into liver cell plates. At the same time, Notch 
signaling promotes the differentiation of hepatoblasts into cholangiocytes, the cells of the 
biliary tree144. 
In sum, liver development is an incredibly complex process, defining a 
collaboration between the developing cardiovascular and GI systems. This process is 
significant to this dissertation project, as the pluripotent stem cells used in our 
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experiments undergo similar sequences of differentiation into hepatocytes with several of 
the same growth factors mentioned above.  
 
Liver: Gross and Microscopic Anatomy 
 The human liver is an encapsulated organ that is divided into four key areas, or 
lobes – the left, right, caudate, and quadrate lobes145. These lobes are subdivided into nine 
segments, all of which are numbered after the nine terminal subdivisions of the portal 
vein. Approximately 75% of the liver blood supply is derived from the portal vein 
(receiving derivatives of the mesenteric veins and arcades), while the hepatic artery (an 
aortic descendant) provides the remaining 25%. Thus, (1) venous blood from the portal 
vein is rich in nutrients and (2) blood from the hepatic artery is rich is oxygen. This dual 
blood supply constitutes the portal circulation145.  
 Microscopically, the liver largely comprised of parenchymal hepatocytes, which 
are arranged as a series of hexagonal lobules (Figure 4). Each lobule is divided into 
sixths, with each sixth constituting a liver acinus, the functional unit of the liver (Figure 
4)145. At the vertices of each lobule are trios of vascular and biliary structures collectively 
referred to as portal triads, each of which contains a hepatic artery, portal vein, and bile 
duct. A central vein lies at the center of each liver lobule. Given this organization, blood 
and nutrients travel from the periphery of a hexagonal lobule past all of the hepatocytes 
within an acinus towards the central vein (Figures 4 and 5). Each lobule is subdivided 
into three different zones of oxygen and nutrient exposure (Figure 4). Hepatocytes 
situated within Zone I (periportal zone) are closest to the portal triad and receive the most 
nutrients, but are also subjected to the highest degree of drug- or toxin-induced damage.  
 32 
 
Figure 4. Schematic of a hepatic lobule, with portal triads (or tracts, shown with an 
arrow), a hepatic acinus (bounded by dashed lines) and zones of oxygenation and 
nutrient distribution. PV = portal vein, BD = bile duct, HA = hepatic artery, CV = 
central vein. 
 
Figure 5. Schematic of fenestrated liver sinusoids lined with endothelial cells (*). Arrows 
indicate the flow of bile or blood. Also shown is the Space of Disse in-between 
hepatocytes and the sinusoids. 
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Zone II is the area in-between Zones I and III. Zone III (perivenous zone) surrounds the 
central vein and contains hepatocytes that have minimal oxygen supply but are most 
resistant to damaging drugs and toxins. From here, the central vein empties into hepatic 
veins, which drain into the inferior vena cava and returns to the heart.  
 The liver plays chief roles in cholesterol metabolism (previously discussed), 
osmotic balance, and the bulk transport of proteins145. For all of these processes, the liver 
requires a unique sinusoidal, fenestrated, discontinuous vasculature (Figure 5). The 
presence of a discontinuous basement membrane as well as gaps and fenestrations, in the 
endothelial lining allow large proteins and macromolecules to leave hepatocytes to enter 
the circulation, and vice versa. To this end, liver sinusoidal endothelial cells (LSEC) are a 
subset of endothelial cells and are replete with unique identifiers (such as the Mannose 
receptor, L-SIGN, LYVE-1, VAP-1, and Stabilin-1 and -2)146. Sinusoidal vessels link 
peripheral portal veins with central veins. 
 Hepatocytes within liver lobules and acini are arranged into sheets of cells that are 
separated from this sinusoidal vasculature by perisinusoidal voids termed the Spaces of 
Disse145 (Figure 5). Macrophages of the liver, known as Kuppfer cells, have been shown 
to reside in the Spaces of Disse as well as the sinusoidal lumen147. Kuppfer cells target 
and sequester bloodborne pathogens before sinusoidal blood reaches the surrounding 
hepatocytes. Hepatocytes, in turn, extend microvilli into this Space to facilitate nutrient 
absorption. In various pathologies (discussed in detail below), the basement membrane 
can become continuous and thickened (a process known as capillarization)148,149, while 
the Spaces of Disse are obliterated. Both of these morphological changes detrimentally 
affect the hepatocytes’ ability to obtain nutrients and filter toxins and other metabolites 
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from the blood and vice versa. 
 Hepatic stellate cells (also known as Ito cells) also reside in the Spaces of 
Disse145. The majority of their existence is spent in a quiescent state; their role in this 
state is still under investigation. Some studies suggest that hepatic stellate cells are liver 
progenitor cells that mediate liver regeneration and normal cell turnover150-152. In 
instances when the liver is damaged, stellate cells are activated and lay down significant 
amounts of collagen – similar to the functions of many fibroblasts and perivascular cells 
– leading to the development of scar tissue and fibrosis. 
 
Liver Dysfunction: Other Examples 
 A discussion of the liver would not be complete without briefly acknowledging 
some other modes of liver dysfunction other than FH. For example, liver failure is a 
broad classification of organ failure that can lead to systemic dysfunction145. As 
discussed above, because the liver plays a crucial role in cholesterol metabolism, a 
dysfunctional liver can lead to cardiovascular disease. The liver also acts as a major 
vascular reservoir and conduit, termed the portal system. In chronic liver failure (taking 
place over months to years), the microscopic organization of sinusoids and fenestrations 
undergoes capillarization. Outwardly, portal hypertension ensues, resulting in the 
development of varices at portacaval anastomoses (connections between liver and 
systemic circulation) due to the increased pressure. Esophageal varices (swollen, tender 
blood vessels in the lower esophagus), hemorrhoids (swollen vessels of the rectum), and 
caput medusae (dilated vessels around the belly button) are consequently exhibited. 
Additionally, liver hepatocytes are consequently starved of nutrients and oxygen, 
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propagating organ failure. However, as the liver filters systemic metabolites and toxins, a 
failing liver is unable to carry out these functions. Toxins accumulate in the bloodstream 
and can cause neurological symptoms (such as asterixis (flapping tremors) and mental 
disorientation and confusion (termed hepatic encephalopathy)) and multi-organ failure145.  
 To contrast, acute liver failure (also known as fulminant liver failure) is sudden, 
with hyper-acute failure taking place within 1 week, and acute failure occurring within 
the span of a month. Acute failure accelerates many of the outward symptoms present in 
chronic liver failure. Cerebral edema and problems with clotting and coagulation are 
hallmark features of acute disease. Causes of acute failure include drug (e.g., 
acetaminophen) and alcohol overdose, adverse reactions to particular drugs (such as 
tetracycline), and viral disease (hepatitis A or B, or Varicella in children leading to 
Reyes’ syndrome)145.  
 In a broader regard, the liver is a major producer of proteins and enzymes. 
Albumin is a major transport protein produced by the liver that resides in the blood 
plasma. It also maintains osmotic balance. In liver failure, the production of albumin is 
significantly reduced. Thus, fluid that would have normally been contained in albumin-
rich blood is no longer subjected to the same osmotic forces, and consequently collects in 
the interstitium and perivascular spaces. For this reason, patients with liver failure often 
present with ascites and edema. In another example, alpha-1 antitrypsin (A1AT) is an 
enzyme produced by the liver that acts in the lungs. As a protease inhibitor, A1AT 
protects the lungs from long-term exposure to neutrophil elastase, a local enzyme used 
for pathogen defense and cell maintenance. A failing liver does not produce sufficient 
amounts of A1AT, producing symptoms similar to A1AT deficiency, a heritable disorder. 
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Here, a lack of A1AT in the lungs results in unmitigated neutrophil elastase. Elastase 
persists for time periods much longer than normally allowed, leading to destruction of the 
intricate lung architecture and resulting in lung disease145. 
 In short, these examples are not intended to specifically discuss the full range of 
complex liver diseases. Rather, they are intended to demonstrate the key functionality of 
the liver and the systemic consequences of liver failure. Again, this dissertation focuses 
on the liver from a parenchymal and cardiovascular perspective. However, its key roles 
with regards to other organ systems are indisputable. 
 
Hepatocyte Cell Sourcing & Configurations 
 The liver is amongst the top organs sought for transplantation. Unfortunately, the 
demand for high-quality, compatible livers (over 30,000 in the US die annually of liver 
failure153) far outstrips its relatively meager supply. Over 16,000 US patients are 
currently waiting for a liver154, and only about 65% of liver transplant recipients survive 
after 5 years. Dialysis is an option that is available to kidney failure patients, but because 
the liver is highly complex and regulates numerous metabolic functions, there are 
currently few accessible stopgaps to prolong life in the face of liver failure. The major 
therapeutic option for people with liver failure is transplant. Further complicating care is 
the fact that the course of liver failure is very hard to predict155. These statistics 
demonstrate the dire need for a personalized, long-lasting, and widely accessible 
therapeutic system.  
 Four main biological approaches are being investigated for liver failure; these 
include hepatocyte transplantation, extracorporeal devices such as the bioartificial liver 
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(BAL), xenografts, and implantable constructs155. These approaches aim to expedite 
recovery, promote regeneration, or serve as a bridge-to-transplant. However, there are 
several considerations. First, hepatocyte transplantation depends on having a sufficient 
quantity of functional hepatocytes to (a) transplant and (b) elicit a therapeutic outcome. 
As livers are in short supply, hepatocytes (the liver parenchymal cell) are also in 
relatively short supply. Though many have attempted to culture and expand primary 
hepatocytes, these cells are difficult to culture as they depend on the liver 
microenvironment to survive. As such, in culture, they dedifferentiate and lose their 
polarity and function over time156,157. Others have tried to lengthen in vitro hepatocyte 
life with enhanced medias158-160; however, these specialized formulations are 
incompatible with patient exposure155. Several have developed cell lines (examples 
include HepG2161 and C3A162, HepZ163, HH25164, and HepaRG165,166) that closely 
approximate some primary hepatocyte functions, but these cell lines are either 
immortalized or tumor-derived. Though several lines have been used in clinical trials, the 
risk of oncogenic gene transfer is still of concern and hampers widespread clinical 
application.  
 Second, non-biological approaches to correct hepatic metabolic deficiencies 
(hemodialysis, hemoperfusion, and plasmapheresis) are less successful as they only 
partially and transiently recapitulate the vital functions that whole, healthy livers 
provide155. Extracorporeal devices such as BAL seek to mitigate these shortcomings by 
adding a hepatocellular element to the device. However, these devices have unique 
complications such as issues with the transport barrier, scale-up, cell exposure to shear 
stress, non-uniform perfusion, and cellular stability in suspension.  
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 Third, xenografts are another source for hepatocytes. Porcine hepatocytes are the 
most abundant alternative and have been used in pre-clinical and clinical trials167-170. 
Hepatocytes from rabbits, dogs, and rodents have also been used, albeit on a more limited 
scale. In numerous instances, porcine xenografts incorporated into BAL systems provided 
measurable therapeutic relief169. These xenografts are capable of producing sufficient 
amounts of albumin, though they express decreased CYP450 activity over time. Further, 
xenografts are subject to human immunologic reactions and could lead to zoonotic 
transmission171,172. Lastly, hepatocytes are responsive to species-specific signals that are 





PART III: STEM AND REGENERATIVE CELLS 
 
As one of the biggest challenges with liver transplant is inadequate supply, stem 
cells provide a potential avenue for generating the significant cell numbers required for 
producing enough therapeutic hepatocytes. This section provides a brief overview of stem 
cells, from embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) 
development, to ethical boundaries, to discussing various efforts in producing stem cell-
derived hepatocyte-like cells. 
 To begin, we should first acknowledge the differences between totipotent, 
pluripotent, multipotent, and unipotent cells. Cells that give rise to all embryonic and 
extraembryonic tissues, they are deemed totipotent174. If the cells give rise to only 
embryonic tissues (these cells are typically sourced from the inner cell mass of a 
blastocyst (i.e., the second stage of development post-fertilization)), they are termed 
pluripotent175. Adult stem cell populations that give rise to cell lines of related or single 
lineages are referred to as being unipotent or multipotent, respectively. Lastly, a key 
consideration with all of these cell designations is that once the cells have fully 
differentiated down a particular lineage, they lose their ability to differentiate into other 
tissue types (i.e., their differentiation potential)175. 
 Cloning, another topic common to both ESC and iPSC, was first established by 
Briggs and King in the 1950s176,177 and later perfected by John Gurdon in 1960s and 
70s178. In all of these studies, Briggs, King, and Gurdon made the seminal observation 
that a frog’s cells contain the genetic material required to clone entire frogs175. 
Additionally, it demonstrated that differentiated cells are maintained in such a state 
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through a series of epigenetic changes, and that these changes could potentially be 
reversed to force the cells into a de-differentiated state (through a process known as 
reprogramming). However, simply cloning cells has highlighted problems with genome 
integrity, ostensibly due to problems with reprogramming178-180. For these reasons, cloned 
cells may be useful for establishing a proof-of-principle but not for more detailed 
research endeavors.  
 Experimentation with pluripotent stem cells started in the 1950s, when cells were 
taken from mouse germ cell tumors known as teratocarcinomas (or alternatively, 
embryonic carcinomas181). These cells could be clonally expanded182 and were shown to 
maintain pluripotence by differentiating into the three embryonic germ layers – the 
ectoderm, mesoderm, and endoderm183. Thus, embryonic carcinoma cells could be used 
to model aspects of mammalian development. 
 Embryonic carcinoma cells (ECC) played a pivotal role in ESC and iPSC 
development in the late 1970s, when Miller and Ruddle demonstrated that the 
combination of ECC with thymus cells yielded a cell line with ECC properties devoid of 
all somatic features184,185. These studies were critical, as they demonstrated that (a) 
pluripotent phenotypes exert a dominant influence on differentiated somatic cells, (b) the 
ECCs contained some transferrable factor that induced pluripotence, and (c) if these 
factors existed, they should be identifiable175. 
 
Embryonic Stem Cells 
The transition from ECC to ESC took place after the implantation of mouse 
embryos outside the uterus resulted in the development of embryonic carcinomas186. This 
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finding led to the postulation that embryos themselves might have stem cells. In 1981, 
Evans and Kaufman187 and Martin188 successfully isolated mouse ESC (mESC) from 
blastocysts and developed in vitro culture conditions. These mESC were able to generate 
all three germ layers in vivo in spontaneously differentiated, tumor-like structures known 
as teratomas. A few years later, between 1984 and 1988, the basis for human ESC 
(hESC) development was formed when Andrews generated pluripotent stem cells (PSC) 
from a human teratocarcinoma line189; later on, clones from this line were exposed to 
retinoic acid to form neuron-like cells190. Pera and colleagues subsequently derived 
human embryonic carcinoma cells that were able to form all three germ layers, but 
exhibited chromosomal abnormalities and limitations in their ability to undergo 
spontaneous differentiation191.  
The mid 1990s marked key advances in hESC generation. In 1994, human 
blastocysts were donated by patients for research purposes; the inner cell mass of these 
blastocysts were able to be cultured for 2 passages, but exhibited normal karyotyping and 
maintained a stem cell-like morphology (i.e., a bunched appearance with a high nuclear-
to-cytoplasm ratio)192. Isolation of ESC from the blastocysts of rhesus monkeys193 and 
marmosets194 provided the first proof-of-concept for what could be expected with human 
cells. These non-human primate ESC were pluripotent and resembled human embryonic 
carcinoma cells in vitro. In 1998, Thomson made a significant leap when he and 
colleagues were able to use donated human blastocysts to derive ESC195. Several non-
clonal lines were established, all of which demonstrated pluripotence through teratoma 
assays. 
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In addition to practical issues with hESC maintenance of a normal karyotype, the 
long-term maintenance of unique characteristics, and a generalized need for improved 
differentiation protocols196, hESC are also shrouded in ethical controversies that hamper 
their widespread use in clinical therapies. While hESC are sourced from embryos that 
develop from eggs that have undergone in vitro fertilization195, these eggs are not 
fertilized in vivo and do not become fully formed fetuses. However, isolation of hESC 
require the early embryo to be destroyed, leading several to question the existence and 
degree of a moral status197. These challenges prompted researchers to find other avenues 
of generating pluripotent cells, and in particular, induced pluripotent stem cells. 
 
Induced Pluripotent Stem Cells 
 The generation of induced pluripotent stem cells (iPSC) depends on three key 
principles, namely (a) reprogramming, (b) the derivation and culture of pluripotent stem 
cell lines, and (c) the observation that transcription factors determine cell fate175. With 
respect to the last principle, several have made the observation that transcription factors 
associated with a particular lineage could drive pluripotent cells towards that same 
lineage198-200. Furthermore, these studies demonstrated that during lineage-specific 
differentiation, erroneous factors goading the differentiating cells into inappropriate 
lineages were automatically stifled. Progressing in a reverse direction, pluripotent stem 
cells were shown to induce pluripotence in somatic cells after cell fusion, suggesting that 
there are some transferrable factors that behave in a dominant fashion201,202. However, the 
identity of these factors remained unknown for several years. 
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 In 2003, Tokuzawa, Yamanaka, and colleagues developed an elegant screening 
mechanism for determining which transcription factors conferred pluripotence203. Using 
24 transcription factors associated with pluripotent stem cells, they methodically removed 
one transcription factor after another, ultimately discovering that a series of four factors 
(Oct4, Sox2, Klf4, and cMyc) were required to produce colonies that resembled mouse 
ESC204; these colonies were then termed induced pluripotent stem cells, or iPSC. A year 
later, the same feat was achieved with human cells205. These discoveries were so 
monumental that Yamanaka and Gurdon were jointly awarded the Nobel Prize in 
Medicine in 2012. To date, iPSC have been derived from several species, such as 
humans, pigs, rodents, and monkeys. In several these species, factors such as OCT4, by 
itself or in combination with SOX2206 KLF4207,208, cMYC204,209, and/or LIN28 and 
NANOG210, induced pluripotence in a variety of terminally differentiated, somatic 
tissues, indicating that there are several fundamental features of transcript networks that 
are evolutionarily conserved.  
 
iPSC and Reprogramming 
 As mentioned earlier, the use of factors to convert a terminally differentiated 
somatic cell into a pluripotent stem cell is termed reprogramming. As the ability to 
produce iPSC are predicated on the use of the four reprogramming (or “Yamanaka”) 
factors, the modality by which these factors are introduced is equally as important. In this 
section, we will discuss several methodologies as well as their advantages and any 
caveats. 
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The first efforts in reprogramming utilized constitutively active retroviral vectors. 
While retroviruses enabled an efficient delivery of the reprogramming transgenes, the 
transgenes themselves stably integrated into the host genome. Additionally, they could be 
inactivated by host methyltransferases211,212, leading to cell lines that were partially 
reprogrammed. As the transgenes were integrated, they were also susceptible to 
reactivation, propagating the formation of tumors in chimeric animal models213. To 
increase the efficiency of transgene delivery, lentiviruses were utilized, though many 
lentiviruses actually intensified other retroviral shortcomings and led to such robust 
transgene expression that differentiation was completely impeded214,215.  
Because inadvertent transgene expression can have undesirable consequences, 
efforts to mitigate this were subsequently pursued. Inducible lentiviral vectors improved 
on lentiviral performance by relying on indolent drugs to control transgene expression. 
For example, when somatic cells were placed in medium containing doxycycline, the 
reprogramming factors were expressed. Conversely, the removal of doxycycline from the 
cell medium led to an abrogation of reprogramming transgene expression214,216. 
A fourth reprogramming modality involves using inducible vectors in a two-step 
process known as secondary reprogramming217-220. In the first step, inducible lentiviral 
vectors are used on somatic cells as described above. Because the removal of the indolent 
drug terminates reprogramming, primary iPSC clones can be identified and differentiated 
into a terminal somatic cell type. As all primary iPSC are exposed to the same 
differentiation regimen, the resulting somatic cells are, theoretically, genetically identical. 
Introducing these iPSC-derived somatic cells to the same, indolent drug leads to a 
reactivation of the reprogramming transgenes, forcing the newly generated somatic cell 
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population to uniformly regress into a pluripotent state. This method of reprogramming is 
advantageous because it facilitates reprogramming on a large scale. Secondly, it enhances 
efficiency because a homogeneous population is being used (in the second step) to 
generate an iPSC population (hence the term “secondary reprogramming”). Thirdly, this 
reprogramming modality permits the comparison of genetically matched iPSC from 
different somatic cell populations175. However, these approaches still result in integration, 
which can permit transgene activation at any time as well as increase the likelihood for 
insertional mutagenesis. These pose obstacles for widespread clinical use.  
To counter these caveats, several non-integrating reprogramming approaches have 
recently been developed. Simply put, these approaches fall into one of three classes: (1) a 
complete obviation of integration, (2) transient integration, or (3) complete avoidance of 
nucleic acids in the reprogramming vectors. We can similarly assess these three classes as 
we did with the integrative modalities. 
Non-integrating adenoviruses221, Sendai viruses222, polycistronic mini-circles223, 
and self-replicating episomes224 have all been used to reprogram various human 
fibroblast lines. Because the reprogramming transgenes are not integrated, these 
modalities provide a unified proof-of-principle that transient transgene expression is 
enough for producing iPSC. While all of these methods obviate integration, a significant 
hit is taken with respect to reprogramming efficiency compared to traditional, integrative 
methods175, though reprogramming efficiency is not that significant a concern given iPS 
cells’ propensity to proliferate rapidly once formed. 
Another method involves using recombinant vectors that initially integrate into 
the host genome, but are later removed by the actions of Cre recombinase225. This 
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approach, known as integration-dependent gene delivery, is particularly advantageous 
when single mRNAs encoding multiple genes (i.e., polycistronic mRNA) are used226. 
However, the nature of transgene extrication is such that small segments of genetic 
material (i.e., “footprints”) are left behind. The long-term, downstream effects of such 
footprints are unknown. Similar to integration-dependent gene delivery, Piggybac 
transposons are mobile genetic elements that can efficiently transpose genetic material 
between vectors and chromosome in a “cut and paste” fashion227. The enzyme Piggybac 
transposase moves the reprogramming transgene from the donor vector for integration at 
TTAA sites on the recipient chromosome. After transgene expression occurs for a desired 
amount of time, an excision Piggybac transposase can be used to fully excise the 
transgene without leaving behind any foreign genetic material228. While this improves on 
some of the shortcomings associated with integration-dependent gene delivery, 
sequencing of candidate integration sites is required. Additionally, the effects of 
Piggybac transposase on the host genome have yet to be investigated. 
The next approach is perhaps most analogous to the early experiments in which 
pluripotent cells were cultured with somatic cells. This led to the hypothesis that there 
must be some transferable, dominant factor(s) that confers pluripotence. In 2010, Cho 
and colleagues delivered whole-cell extracts from ESC to somatic cells229. While 
laboratory-directed genetic manipulation was obviated, the methodology was not 
efficient. 
A methodology for delivering synthetic modified RNA (modRNA) was recently, 
successfully used for iPSC reprogramming230,231. The potential advantages of this 
strategy are that (a) transfection is transient, with a modRNA half-life of 12 hours232 and 
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(b) being mRNA based, modRNA avoids the possibility of genomic insertion, though it 
requires repeated transfection with c-Myc which could be potentially problematic233. In 
addition to these facets, modRNA is reported to yield one of the highest reprogramming 
efficiencies, approaching 2% in normal fibroblasts234.  
 
Challenges with iPSC 
Like ESC, iPSC face several challenges as well, but many of these can be 
overcome with alternative approaches to their generation and maintenance. However, 
while ESC and iPSC are similar in their ability to self-renew indefinitely, express genes 
associated with pluripotency, engage in spontaneous differentiation and teratoma 
formation, and form live animals235, there is some debate as to whether or not iPSC are 
truly functionally equivalent to ESC236. Several epigenetic control and gene expression 
patterns are similar between the two cell types213,237-239, though iPSC exhibit a propensity 
for tumor formation (Miura 2009), senesce prematurely240, exhibit differences in 
mRNA241 and micro RNA242 expression patterns.  
Another issue lies with iPSC supposed predilection for differentiating towards 
particular lineages, namely those of their source cells; in this instance, the cells are 
described as having epigenetic memory243. In 2010, Kim and colleagues sourced iPSC 
from fibroblast and blood cells, and found that the iPSC exhibited the same DNA 
methylation patterns as the cells from which they were derived244. Ji and colleagues 
subjected 8 iPSC lines to methylation analysis and determined that the lineage outcome 
was potentially orchestrated by changes in DNA methylation patterns245.  To corroborate 
these findings, that same year, Polo and colleagues looked at a full array of tissues and 
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noted that iPSC possessed an altered differentiation capacity compared to ESC246. 
However, recent findings suggest that these differences may be artifacts of the 
environments in which the iPSC were generated247, and that different labs’ emphases may 
in fact be leaving different signatures on the cells235.  
When pondering the issue of iPSC-ESC equivalence in light of this information, it 
is also important to consider that ESC can also be affected in similar ways. ESC have 
been shown to exhibit lineage propensity248 as well as differential gene expression 
patterns249. ESC and iPSC, despite their many similarities, are not absolutely equivalent 
and are even different from isolation onwards235. Therefore, more stringent, standardized 
methods for generating these cell types need to be developed, or we need to consider 
other means of overcoming these realities. 
Another consideration is that iPSC form teratomas more readily than ESC250. 
While this may not be problematic in fully differentiated cultures, like hESC, the 
efficiency of iPSC differentiation into terminal cell types has never reached 100%. In 
fact, efficiencies can vary between 1% to 80% depending on the lineage to which the 
iPSC are being directed251, though such variation could be attributed to the particular 
differentiation protocol being utilized. That said, the presence of even once 
undifferentiated iPSC in a culture that has 99.9% differentiation efficiency would, 
theoretically, be enough to form a teratoma. The US Food and Drug Administration 
considers iPS cells’ propensity for teratoma formation a barrier to clinical adoption. 
Consequently, this enhances the requirement for highly robust, efficient differentiation 
protocols as well as measures to remove undifferentiated cells from such cultures. For 
example, one strategy involves the selective, chemical ablation of only pluripotent stem 
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cells in differentiating cultures252,253. This approach spares fully differentiated cells and 
facilitates the elimination of pluripotent cells that can give rise to teratomas, though the 
long term genetic stability of iPSC-derived cells and tissues remains to be seen. In 
another example, Wu and colleagues recently described the development of a caspase-9-
based safety switch in their mouse iPSC lines254. Since their caspase-9 mechanism relies 
on dimerization to initiate cell suicide, all that is required is that cells be exposed to a 
chemical dimerizer (in their case, AP1903).  
Fifth, cMYC is an oft-present member of traditional reprogramming factor 
cocktails. Ectopic cMYC is associated with tumorigenicity255. While the omission of 
cMYC from pluripotent transcription factor cocktails do indeed yield iPSC208,233, 
reprogramming efficiency reduces significantly256. Still, if the presence of cMYC is a 
concern, reprogramming efficiency is less of a concern as iPSC proliferate rapidly once 
generated; in principle, only one iPS cell is required to then generate larger volumes of 
cells for downstream applications. 
Lastly, another concern for the generation and potential clinical use of iPSC are 
genomic integration of exogenous reprogramming factors and unwanted spontaneous 
transcriptional activation post genomic integration, both of which are associated with 
viral-vector technologies230,231,257. To avoid stable integration, DNA-based transgenes 
have also been delivered by non-integrating plasmids258, mini-circles223, and Epstein-Barr 
episomal vectors210. However, because the transgene is still DNA-based, spontaneous 
insertion259,260  and oncogenesis232,258,261 are still considerations. With DNA-free 
technologies, the risk of random genomic integration is obviated. This makes approaches 
such as modRNA particularly attractive. 
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In sum, iPSC have a theoretically limitless proliferation and differentiation 
potential that makes them attractive for cell-based therapies because of difficulties in 
culturing and correcting cellular dysfunction in primary cells (such as hepatocytes). 
Current strategies for (a) deriving iPSC from somatic cell sources non-virally, (b) 
enhancing differentiation efficiency, and (c) preventing tumorigenesis and teratoma 
formation better position iPSC as a clinically relevant, therapeutic cell source. 
 
Stem Cell Differentiation into Hepatocyte-Like Cells 
 The use of primary donor hepatocytes in a therapeutic capacity does not assure 
successful treatment in the face of liver failure262. While one obvious challenge in this 
regard is donor-recipient compatibility, a cirrhotic or diseased liver can provide a 
suboptimal environment for primary hepatocytes to thrive, let alone function263. While 
several workarounds include optimizing primary hepatocyte placement (for example, in 
the lymph nodes264, pluripotent stem cells offer unique promise in treating liver 
dysfunction. Despite the aforementioned challenges, pluripotent stem cells can be 
differentiated to directed cell types. Additionally, since hepatocytes are notoriously 
difficult to expand in culture, the ability of several types of PSC to rapidly proliferate in 
culture means that they can be scaled prior to differentiation and use. To this end, several 
efforts have utilized pluripotent stem cells to generate hepatocyte-like cells (HLC). 
 In 2009, Song was amongst the first to develop a multi-stage method for 
differentiating iPSC into HLC. iPSC were first committed to an endodermal lineage 
before being exposed to a sequence of factors that gradually matured the developing 
hepatocyte in three subsequent stages265. The resulting HLC expressed characteristic 
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hepatic markers alpha-fetoprotein (AFP; marker of immature hepatocytes) and albumin 
(marker of mature hepatocytes) by day 7. By three weeks after the start of differentiation, 
the HLC were able to participate in glycogen and urea synthesis and exhibited inducible 
P450 activity. Others have used similar methods to generate HLC from iPSC – for 
instance, Si-Tayeb and colleagues utilized a four-stage protocol to similar effect266, while 
Ishikawa obviated the use of exogenous factors entirely and relied on iPSC propensity to 
differentiate down a particular lineage, presumably based on epigenetic memory267.  
 However, Takebe and colleagues were the first to use iPSC-derived HLC to 
develop a human organoid – more particularly, an iPSC-derived liver-tissue mimic268. 
They first differentiated the iPSC in two stages, first committing the cells to an endoderm 
lineage before specifying them down a hepatic lineage. The cells were then combined 
with a stromal support system comprised of mesenchymal stem cells (MSC) and human 
umbilical vein endothelial cells (HUVEC), as Zaret and colleagues demonstrated that 
hepatogenesis is facilitated by adequate stromal and vascular support269. Upon placing the 
newly formed iPSC liver buds (iPSC-LB) in vivo atop the mesenteric circulation, the 
implant anastomosed with and was perfused by the surrounding mesentery. Furthermore, 
the iPSC-LB were able to rescue drug-induced liver failure. These findings provided us 
with a broad proof-of-principle that we sought to refine by using corrected, patient-
specific iPSC in conjunction with a clinically relevant, adipose-derived vascular support 
system.  
 With regards to iPSC-derived cells for the management of FH, work by Cayo and 
Fattahi were amongst the first to address patient-specific iPSC generation. Cayo and 
colleagues developed an FH-specific iPSC line using lentiviral-reprogramming vectors. 
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Additionally, they were the first to demonstrate that FH-iPSC could be used to form HLC 
(using the protocol developed by Si-Tayeb266) and that without correction of the LDLR, 
these HLC were deficient in their ability to take up LDL cholesterol270. Fattahi followed 
suit by used a retroviral reprogramming vector to generate iPSC from patient-specific 
fibroblast population89 before differentiating the cells using a modified version of a 
protocol developed by Basma and colleagues271. These cells were able to internalize 
lipids, produce and store glycogen, metabolize Indocyanine green, and uptake circulating 
LDL after correction via a lentiviral LDLR transgene vector that was constitutively 
expressed.  
 Though all of the aforementioned modalities yield HLC, no single assay can 
determine whether the resultant cells are analogous to primary hepatocytes. Rather, a 
combination of tests (such as consideration of cellular morphology, gene and protein 
expression profiles, and functional characterization) can help272. Additionally, while HLC 
are certainly “hepatocyte-like” based on their physical appearance and phenotype, the 
cells are often immature (as they express significant amounts of AFP) and possess 
significantly reduced cytochrome P450 activity272 compared to primary hepatocytes. 
Though these differences may be subtle, they pose some challenges for HLCs’ clinical 
applicability and therapeutic value as a standalone system. 
Our work in generating FH-iPSC-derived HLC seeks to combine several non-
viral, non-integrating innovative technologies to develop a clinically relevant cell 
therapy. However, the generation of a functional liver tissue mimic does indeed depend 
on a stromal and vascular supply. Our next section discusses the vasculature and its 
support system in greater detail. 
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PART IV: THE VASCULATURE 
 
Overview of Vascular Formation, Organization and Function  
A major goal of the studies described in this dissertation is the development of a 
functional microcirculation in a liver organ mimic using stromal vascular fraction cells 
derived from adipose tissue.  The presence of a vascular supply is critical to organ 
survival and function.   The studies performed utilize in vitro and in vivo experimental 
models that replicate aspects of blood vessel development observed in embryos as well as 
adult organisms undergoing physiologic and or pathologic blood vessel development.  
During embryonic development the blood vessels that invest all organs originate from a 
primitive tubular structure. These blood islands form through the process of 
vasculogenesis and are composed of primitive vessel-forming cells known as the 
hemangioblasts.  During subsequent embryogenesis, the blood islands exhibit cellular 
proliferation, migration and de novo vessel formation from existing vessels,  a process 
known as angiogenesis.  Further maturation of vessels through arteriogenesis and 
venulogenesis results in a hierarchy of structures collectively known as the 
microcirculation.     Strategies to create a new microcirculation from cellular components 
must incorporate the signals and cues that support embryonic and adult blood vessel 
formation, as the presence of an operative microvasculature is critical to organ survival 
and function.    
 The peripheral vascular system is broadly subdivided into five groups: arteries, 
arterioles, capillaries, venules, and veins. Arteries and arterioles carry oxygenated blood 
away from the lungs and heart and deliver it to the organs. Arteries are typically 
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comprised of three layers, or “tunics”: (1) The tunica intima is the endothelial lining, 
underneath which there is an internal elastic membrane (IEM). (2) The tunica media 
comprises the next layer outside the IEM and is composed of smooth muscle, which 
maintains vascular tonicity. Just around this layer is the external elastic membrane 
(EEM). (3) The tunica adventitia is the outer layer, comprised of fibroblasts, connective 
tissue, and perivascular nerves. Arterioles differ from this organization mainly in the 
extent and orientation of their smooth muscle composition and overall diameter – both 
are decreased; arterioles serve as bridges between arteries and capillary beds, and 
arterioles act to regulate the blood flow of the microcirculation. Venules drain blood from 
capillary beds into larger veins. Veins themselves are similar to arteries in terms of their 
organization; however, they appear larger and are less rigid in their structure, namely due 
to their considerably decreased amount of smooth muscle in the medial layers. 
Additionally, since veins represent the low-pressure side of the circulation, they exhibit 
valves as part of their intimal layer; these valves rely on surrounding skeletal muscle 
contractions to propel blood against gravity back to the heart while minimizing backflow.  
Capillaries are the intermediate vessels connecting arterioles with venules273. 
They are one cell layer thick and are comprised primarily of endothelial cells. 
Embryonically formed by vasculogenesis (de novo vascular formation)274-276, capillaries 
have a diameter of approximately 5-10 µm and normally function in conjunction with 
other capillaries as part of a capillary bed. Depending on an organ’s complexity and 
metabolic requirements, the number and arrangement of beds varies accordingly. This 
minute organization makes capillaries the ideal sites for gas, nutrient, and waste 
exchange. Three types of capillaries exist: continuous, fenestrated, and sinusoidal. 
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Continuous capillaries are comprised of endothelial cells that maintain tight junctions 
throughout, as well as a continuous basement membrane. This arrangement provides no 
room for larger molecules to freely traverse across the endothelial cells, and most 
transport is restricted to vesicles. The tight endothelial arrangement and continuous 
basement membrane are integral to the functionality of the blood-brain barrier, for 
example. To contrast, fenestrated capillaries are different in that they maintain a 
continuous basement membrane, but feature fenestrations (the Latin fenestra means 
“window”). These fenestrations are approximately 60-80 nm wide and facilitate small 
molecule and protein diffusion277. Lastly, the sinusoidal capillaries combine a fenestrated 
endothelial lining with a discontinuous basement membrane. This membrane features 
large openings (30 – 40 µm) and allow for the passage of red (~8 µm) and white (~25 
µm) blood cells as well as large proteins like albumin (~65 kDa). As such, organs such as 
the liver, spleen, and sites like the bone marrow and lymph nodes are replete with this 
type of capillary system. 
 
Endothelial Cells 
All blood vessels have an endothelial lining. Thus, vascular endothelial cells (EC) 
are a critical component of circulatory and systemic health. In addition to serving as a 
barrier, endothelial cells play active roles in vascular remodeling, the trafficking of 
hormones, recruitment and binding of neutrophils, fluid filtration (namely in the renal 
glomerulus), control blood vessel tone (via signaling with surrounding smooth muscle 
cells), and hemostasis. The cells are also able to adjust their numbers (by proliferating) 
and orientation (through branching) to better meet tissue metabolic needs273.   
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EC exert systemic and cellular influence through a variety of factors. For 
example, vasoactivity is mediated by bradykinin278, which can act on EC to balance 
tissue oxygen levels as well as overall vascular tone and diameter. Using 
mechanoreceptors to detect changes in cardiac output and, consequently, shear stress, EC 
can release nitric oxide (NO) via endothelial nitric oxide synthase (eNOS) to modulate 
the degree to which tissues are perfused279. eNOS production is also potentiated by 
vascular endothelial growth factor (VEGF), serotonin, bradykinin, and adenosine280. In 
addition to promoting vasodilation, NO also modulates inflammation, oxidative 
phosphorylation281, and thrombosis, all of which serve to maintain relative environmental 
quiescence282,283. EC-produced NO can also affect proliferation efficiency at the 
transcriptional level, blocking the translocation of NFκB and inhibiting the activity of 
various cyclins284. In addition to NO, EC can also produce endothelin and other 
prostanoids (potent vasoconstrictors)285 and prostacyclins (which also act as vasodilators 
in a manner independent of NO activity)286. Thus, EC are equipped to finely modulate 
vascular flow in the existing vasculature to affect perfusion and, ultimately, oxygen 
delivery. 
EC can also play a role in vascular remodeling through angiogenesis. 
Angiogenesis is the process by which new blood vessels are formed from existing ones. 
A whole host of factors are involved, but VEGF is amongst the most prominent and well-
studied of the angiogenic factors287. In vivo, the presence of low oxygen levels triggers 
the expression of hypoxia inducing factor-1 (HIF-1), which acts to boost local VEGF 
expression in EC. VEGF that is produced then has a paracrine effect on surrounding 
endothelium, leading to (1) EC migration towards a VEGF gradient, (2) new EC 
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producing proteases to be able to permeate existing extracellular matrices, (3) a 
proliferation of EC, and (4) the formation of tube-like structures. Once these tubes are 
perfused, local oxygen levels increase and the driver of HIF-1 signaling is removed in a 
feedback-looped manner, stopping angiogenesis. In the formation of more complex 
vessels, such as arterioles and venules, these vessel subtypes primarily depend on the 
formation of EC tubes and surrounding basement membranes. Depending on 
environmental requirements, different cell types (such as smooth muscle cells, adventitial 
cells, and mural cells) are recruited as needed.  
The reorganization of cultured endothelium into phenotypic cord-like structures 
has also been demonstrated in two-dimensional in vitro systems. In 1980, Folkman and 
Haudenschild reported that EC plated onto a collagen-coated dish formed tubes by 20 
days and an extensive network 10 days later288. A few years later, Madri and Williams 
used endothelial cells from rodent fat pads to demonstrate that connective tissues regulate 
the endothelial phenotype with respect to micro-anatomical structures, such as tubes289. 
In the presence of interstitial collagen for example, EC predominantly formed a 
monolayer, whereas with basement membrane collagen, the EC formed tube-like 
structures. Montesano and colleagues confirmed these findings, and showed that EC cord 
formation was indeed a collagen matrix-dependent process290. While this phenomenon 
occurs in the absence of other cell types, it yields capillary-like networks that carry no 
blood. However, it also demonstrates that the absence of blood flow and pressure are not 
required for basic EC network assembly and architecture9,287. The formation of EC cords 
in vitro could very well provide novel experimental models for understanding analogous 
processes in vivo. 
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The Stromal Vascular Fraction 
The generation of a stable, supportive vascular supply is critical to the 
development of large volumes of engineered tissue for implant. In normal host tissue, 
parenchymal cells often require intimate association with circulating factors, proteins, 
and products via a patent, well-distributed vascular supply. The literature provides 
evidence of in vivo implanted parenchymal cell death in the absence of a vasculature291-
295. This is largely because oxygen can only diffuse over a very short distance of no more 
than a few hundred microns. Additionally, depending on the site of implantation, 
parenchymal cells may not be able to utilize existing host vasculatures296. To circumvent 
these issues, it may be necessary to implant parenchymal cells with vascular support 
cells.  
The adipose-derived stromal vascular fraction (SVF) is a heterogeneous, cell 
population with tremendous vascularization potential9,297-299. SVF has been shown to 
spontaneously self-assemble into vessel-like networks of cells when placed in culture300. 
In vivo studies have established that adipose SVF, following implantation, forms 
functional, hierarchical vasculatures that anastomose with host vessels9,299 and perfuse 
implanted parenchyma1,9. These findings suggest that SVF may have potential 
therapeutic vascularization applications toward the accelerated formation of new 
microvascular structures in ischemic tissues. To this end, SVF has already been shown to 
promote revascularization in models of myocardial infarction301,302 and peripheral 
ischemic disease299,303,304. 
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The first isolations of SVF were conducted by Rodbell and colleagues, who used 
the enzyme collagenase to digest fat into buoyant adipocytes and a sedimented SVF 
pellet305-307. Though their efforts focused on only the isolated adipocytes, the first studies 
evaluating the cellular composition of SVF was published in the 1970s, when Wagner 
and Matthews used Rodbell’s fat digestion protocols to isolate and culture endothelial 
cells from the rodent epididymal fat pads308. Additionally, they noted the presence of 
perivascular cells as a multicellular, heterogeneous population that surrounded the 
developing vasculature. Later that decade, Van and colleagues isolated and cultured SVF, 
documenting an overall doubling time of 40 – 60 hours309. Though they originally 
thought SVF to be fibroblastic with lipid-storage potential, adipose-derived vasculatures 
were also initially thought to have mesothelial cells and not endothelial cells310, while 
others have stated that adipose tissue-derived vessels have endothelial cells as their major 
cell type311., though this study utilized omental fat instead of fat acquired from the 
epididymal fat pads or uterine horn. SVF is now known to have fibroblasts, mesenchymal 
stem cells, and endothelial cells, as well as smooth muscle cells, mural cells, 
macrophages, blood cells, and a whole cadre of other stem cell phenotypes9,312,313. While 
this mixed population more closely recapitulates the variety of cells seen in vivo, there is 
a lack of consensus regarding the specific proportions of these constituents to one 
another314, though Nunes and colleagues demonstrated the relative proportions of 
endothelial cells (CD31+), monocyte/macrophages (CD14+), multipotent cells (CXCR4+ / 
cMet+), and perivascular cells (PDGFR-B+) in fresh and cultured rat SVF cells9. 
A fundamental consideration with SVF is that it is heterogeneous and forms 
vasculatures that closely resemble those seen in vivo. For instance, host vessels in vivo 
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are organized such that larger vessels give off smaller branches, which in turn give off 
smaller branches, so on and so forth. The degree of branching (and consequently, surface 
area) constitutes a hierarchy that is dictated by local tissue oxygen and nutrient 
requirements. Hierarchy is a key feature of mature vascular systems315. As discussed 
above, pure EC cultures have a demonstrated ability to form cords and networks in 
vitro288,290. Additionally, Koh demonstrated that the EC in SVF are required for network 
formation, and that depletion of EC abrogated vascular assembly299. However, pure EC-
derived networks are largely uniform in diameter, lacking a hierarchical organization, and 
are therefore considered to be immature316,317. SVF is unique in that it not only has the 
EC required for vascular network assembly, but also a full cadre of support cells as well. 
These support cells are likely required for stabilization and maturation316,318-320. 
Additionally, SVF may be better able to adapt to different therapeutic applications as it is 
thought to bear a higher degree of plasticity than other vascular cell sources321, though 
cell sourcing from white adipose tissue versus brown adipose tissue yields site-specific 
differences322. 
Another point to emphasize is that SVF itself may promote healing. Adipose stem 
cells (also known as adipose-derived stromal cells; ASC) are considered to be a 
mesenchymal stem cell (MSC) subpopulation of SVF323. In addition to the fact that ASC 
appear to be immunoprivileged, these cells have been shown to migrate to sites of injury 
and release paracrine secretions that reduce inflammation324. This trait has been seen with 
both intraocular injections and tail vein injections, where the former stabilized the 
progression streptozocin-induced diabetic retinopathy324 and the latter mitigated systemic 
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inflammation, improved glucose tolerance, preserved pancreatic ß-cell mass, and 
increased ß-cell proliferation in the face of streptozocin treatment325.  
ASC have also been shown to directly play significant roles with the vasculature. 
For instance, Cai and colleagues were amongst the first to demonstrate that ASC impact 
capillary density and perfusion, and that these actions are mediated by hepatocyte growth 
factor (HGF)326. When placed with human microvessel endothelial cells, ASC improved 
endothelial network assembly and stability298. In trying to determine a mechanism for 
these outcomes, initial analyses revealed that these cells were positive for a full cadre of 
markers associated with stromal cells such as mesenchymal cells (CD10, CD13, CD90), 
pericytes (CD140a/b), and smooth muscle cells (alpha actin, calponin, and caldesmon). 
Immunohistochemical analysis of ASC-microvessel endothelial cell co-cultures showed 
that after extensive culturing, the cells encase the vascular lumen in much the same way 
as pericytes would. Again, determining the density of ASC per SVF isolation is difficult 
since specific markers have not been identified, though others such as PDGF-B and 
3G5298,313,327-329 and Pref1330 have been implicated. Additionally, since ASC exhibit 
variable abundance – white adipose tissue is enriched with ASC, for example322,323 – the 
sourcing of SVF and its subpopulations need to be taken into consideration.  
To determine a mechanism of interaction between ASC and endothelial cells, 
Merfeld-Clauss and colleagues performed a series of co-culture experiments, noting 
increases in overall extracellular matrix production, ASC expression of alpha smooth 
muscle actin, and endothelial expression of CD31331. Co-cultures yielded the highest 
degree of endothelial network formation, followed by ASC-conditioned media with the 
next highest density and ASC-fibroblast co-cultures with the lowest density. Not only do 
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these findings suggest that ASC-endothelial cell interactions are contact dependent, but 
also that these interactions progress in both directions (as ASC increased aSMA 
expression as well). This is evidenced in later studies, implicating Activin A as an ASC-
endothelial cell contact-initiated means of (a) inducing ASC smooth muscle cell 
differentiation300 and (b) impairing VEGF expression, reducing endothelial network 
formation332. Thus, there is a complex interplay between ASC and endothelial cells. A 
key takeaway is that ASC are a subpopulation of SVF, and SVF is also replete with 
endothelial cells9. Thus, there is reason to suspect that these mechanisms and others are 
already at play within this heterogeneous population. 
A third, clinical and translational, consideration with SVF is that it is easily 
isolatable. Adipose tissue can be easily acquired through minimally invasive means and 
subjected to enzymatic digestion, usually with Collagenase. The resulting digest can then 
be centrifuged and separated into three distinct layers: (1) adipocytes, which are buoyant, 
(2) collagenase solution, tumescent fluid, washing buffers, and cell debris, and (3) the 
SVF cell pellet at the bottom of the centrifuge tube. Though these steps can be performed 
manually, there is a growing interest in automating them333,334 for rapid application at the 
bedside or during an operation335. Further, such automation enhances the likelihood of a 
desirable, repeatable outcome and may mitigate the effects of lab-to-lab variations.  
In short, SVF contains a multitude of cell types that not only promote vascular 
networking, but vascular support as well. Additionally, SVF’s relative ease of isolation 






CHAPTER III  
GENERATION OF A FUNCTIONAL LIVER-TISSUE MIMIC USING ADIPOSE 
STROMAL VASCULAR FRACTION CELL-DERIVED VASCULATURES 
 
OVERVIEW 
A major challenge with therapeutic cell implantation is achieving 
microcirculatory integration between the implanted cells and host vasculature. Adipose-
derived stromal vascular fraction (SVF) cells were used vascularize an implant comprised 
of HepG2 human hepatocyte analogue cells. We hypothesized that the SVF cells would 
form a functional microcirculation via vascular assembly and inosculation with the host 
vasculature. Initially, we assessed the extent and character of neovasculatures formed by 
freshly isolated and cultured SVF cells and found that freshly isolated cells have a higher 
vascularization potential. Generation of a 3D implant containing fresh SVF and HepG2 
cells formed a tissue in which HepG2 cells were entwined with a network of 
microvessels. Implanted HepG2 cells sequestered labeled LDL delivered by systemic 
intravascular injection only in SVF-vascularized implants demonstrating that SVF cell-
derived vasculatures can effectively integrate with host vessels and interface with 





Tissue replacement is a strategy that can be used for the regeneration of different 
organs in scenarios such as organ failure. Cell transplantation offers an alternative to treat 
patients with organ failure, such as in liver diseases336,337. However, minimal engraftment 
is achieved with this approach336,338,339. One of the major caveats in tissue replacement 
therapies is to promote effective vascularization of the transplanted tissue in order to 
prevent death and promote engraftment of transplanted cells. Several approaches have 
been utilized in an attempt to promote vascularization of implanted tissues such as the 
delivery of angiogenic growth factors to recruit host vessels or co-implantation of 
endothelial and angiogenic signaling cells with target tissue cells (reviewed in 340,341). 
Although considerable progress has been achieved, significant obstacles still exist, such 
as the short half-life of growth factors in the tissues resulting in regression of newly 
formed vasculatures342,343 and potential sources of endothelial and angiogenic signaling 
cells for human transplants. Adipose-derived stromal vascular fraction (SVF) cells are an 
attractive cell population for transplantation studies since human adipose tissue is an 
easily accessible and dispensable tissue source that can provide large numbers of cells 
suitable for implantation with little donor morbidity and patient discomfort. In addition, 
SVF cell preparations have been shown to be safely and effectively transplanted to either 
an autologous or allogeneic host and can be manufactured in accordance with Good 
Manufacturing/Tissue Practice guidelines314. SVF cells are obtained from the enzymatic 
digestion of adipose tissue to single cells followed by discarding adipocytes. They are a 
mix of heterogeneous cell populations composed of endothelial cells, fibroblasts, 
perivascular cells, immune cells and undefined stem cell sub-populations314,319,344. The 
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potential of SVF cells to promote vascularization and improve organ function when 
delivered to sites of ischemia has been demonstrated in animal models of peripheral 
ischemic disease299,303,304 and myocardial infarction301,302. Here, our goal was to harness 
the vascularization potential of SVF cells in vivo to generate an effective vascular 
interface between host and transplanted liver cells that results in a functional tissue 
mimic. We show that (1) adipose-derived SVF cells have a potent intrinsic vascularizing 
potential, (2) culturing freshly isolated SVF cells retains this vascularization potential 
despite possible changes in cell populations, and (3) SVF cell-derived vasculatures form 
a functional interface between host and implanted parenchymal cells.	
 
MATERIALS & METHODS 
Ethics statement. All animal experiments were performed in compliance with 
institutional guidelines, as per US National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and were approved by University of Louisville Institutional 
Animal Care and Use Committee procedures and policies (IACUC #12059, 12060). 
Rodent and human SVF isolation. Adipose-derived SVF cells were isolated 
from the epididymal fat pads of male, retired breeder Sprague-Dawley rats (Charles 
River) under anesthesia [ketamine (40–80 mg/kg) and xylazine (5–10 mg/kg)]. Green 
fluorescent protein (GFP)-tagged SVF were obtained from Sprague-Dawley rats that 
ubiquitously express GFP (Rat Research and Resource Center, University of Missouri, 
Columbia, MO). Human SVF were isolated from adipose tissue obtained from 
abdominoplasty (IRB Exempt, #09.0037). Harvested fat was washed in 0.1% BSA-PBS, 
finely minced, and digested in 2 mg/ml type I collagenase solution (Worthington 
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Biochemical Company, Freehold, NJ, USA) for 40 min at 37°C with vigorous shaking. 
Adipocytes were removed by centrifugation, and the entire cell pellet was washed with 
0.1% BSA-PBS. Cells were either immediately used (Fresh SVF, fSVF) or plated into 
gelatin-coated plates (Cultured SVF, cSVF 5x104 cells/cm2) in fresh media (DMEM 
supplemented with 2mM L-glutamine, 50 µg/ml ECGS and 10% FBS). Cultured SVF 
were used at P0 after 5-7 days when cells reached confluence. 
Flow cytometry analysis. cSVF were dissociated with non-enzymatic Cell 
Dissociation Buffer (Sigma) after reaching confluence (P0) and fixed with 4% 
paraformaldehyde for 10 min at room temperature. Cells were blocked with PBS 
containing 5% fetal bovine serum (FBS) for 30 minutes on ice and incubated with the 
following antibodies in blocking buffer on ice for 1 hour: anti-CD14 (1:100), anti-CD31-
APC (1:500)(BD Biosciences); anti-cKit (1:100, Abcam); anti-CXCR4 (1:100, 
Ebiosciences); anti-c-Met (1:100), anti-PDGFRb (1:100, Santa Cruz Biotechnology) 
overnight at 4°C. Secondary antibodies used were anti-mouse-Alexa Fluor 488 (1:400) 
(Jackson ImmunoResearch) and anti-rabbit-Cy6 (1:500) (Jackson ImmunoResearch) for 
30min at 4°C. 
Microvessel isolation. Fat-derived microvessels (FMF) were isolated from rat 
epididymal fat by limited collagenase digestion and selective screening as previously 
described345,346. The collagenase used (type I; Worthington Biochemical Company, 
Freehold, NJ, USA) was lot tested to yield high numbers of fragments with intact 
morphologies. These vessel fragments have the potential to form a microcirculation 
composed of different vessel types 4 weeks post implantation in vivo in 3-dimensional 
collagen gels347. 
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HepG2 cell culture. HepG2 cells were cultured in T-75 tissue culture flasks in 
HepG2 growth media consisting of Dulbecco’s Modified Eagle’s Media high glucose, 
10% fetal bovine serum, 1X penicillin/streptomycin, and 1X L-glutamine (Invitrogen 
Camarillo, CA, USA). Media was changed every other day and cells were grown to 
confluence at which time they were prepared for Cytodex-3 culture as described below. 
Plasmids and Cell Transduction HepG2 were transduced with retrovirus to constitutively 
express GFP (pBMN-I-GFP) or Ds-Red as previously described348. 
Cytodex-3 cell culture. 50 mg of Cytodex-3 microcarrier beads (Sigma, St. 
Louis, MO, USA) were hydrated with 5 mL phosphate buffered saline (PBS) -Ca2+/-Mg2+ 
(Hyclone) for four hours with occasional mixing to avoid aggregation349,350. PBS solution 
was removed and washed out with freshly prepared 70% ethanol for a total of four 
washes.  The last 70% ethanol wash was carried overnight.  The following day, ethanol 
was removed and 10 mL of HepG2 growth media was added for a total of four washes.  
The last wash was removed and HepG2 cells were passaged into a resuspension of 1 x 
106 cells/mL.   6 x 106 cells were added to 4 mL of HepG2 media containing Cytodex-3 
beads and were gently mixed.  The bead-cell mixture was added to a 100 mm petri dish 
(BD Falcon) and incubated for three days at 37°C and 5% CO2 for optimal microcarrier 
coverage. 
Preparation of 3-dimensional constructs and in vivo implantation. To form 
the 3D constructs, fresh or cultured SVF (106 cells/mL) were suspended into 3mg/mL of 
collagen type I (BD Biosciences, San Jose, CA, USA) and 0.2 mL of the suspension was 
seeded into wells of 48-well culture plates. Constructs were implanted subcutaneously on 
the flanks of Rag1 mice as previously described351. To assess the potential of fresh and 
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cultured SVF to participate in the neovascularization process, fresh or cultured SVF from 
GFP rats (106 cells/mL) were seeded into collagen gels concomitantly with isolated FMFs 
(20,000⁄mL). FMF/SVF/collagen suspensions were pipetted into wells of a 48-well 
culture plate (0.2 mL⁄well) to form a 3D construct that were either cultured in DMEM + 
10% FBS or implanted subcutaneously on the flanks of Rag1 mice as previously 
described352. Alternatively, SVF were seeded in the presence of HepG2 cells before 
implantation. 
Construct analysis. Microvascular constructs were harvested at either 4 or 6 
weeks after implantation and fixed in 4% paraformaldehyde for 20 minutes. Samples 
were permeabilized with 0.5% Triton X-100 and rinsed with PBS. After blocking for two 
hours with 10% goat serum (Sigma), samples were incubated overnight with fluorescent 
or biotin conjugated lectins. Following three 15-minute washes in divalent cation-free 
(DCF)-PBS, samples were imaged en bloc with an Olympus MPE FV1000 Confocal 
Microscope and analyzed with Amira 5.2 (Visage Imaging, Inc., San Diego, CA, USA). 
SVF cells were identified by either constitutive expression of GFP (when obtained from 
animals that ubiquitously and constitutively express GFP) or labeling with 
TRITC/Fluorescein conjugated or Cy5-streptavidin GSI (rodent SVF) or UEAI (human 
SVF) lectin (Vector labs, Burlingame, CA, USA). To evaluate vessel perfusion in the 
implanted constructs, host mice were perfused intravenously with Dextran-TRITC 
2,000,000 MW for 15 minutes before the constructs were harvested. Confocal 
microscopy images with HepG2-GFP+ clusters were identified and examined for 
presence of GS1-Cy5+ vasculature, DiI-LDL, or both, and recorded in Microsoft Excel.  
Those images without HepG2-GFP+ clusters were not included. In addition, clusters void 
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of both GS1-Cy5+ vasculature and DiI-LDL were recorded.  The number of HepG2 
clusters associated with each variable were counted and graphed using SigmaPlot.  To 
determine if DiI-LDL uptake is correlated with the presence of GS1-Cy5+ vasculature, 
HepG2-GFP+ clusters positive for DiI-LDL were plotted against those clusters positive 
for GS1-Cy5 vasculature. The Pearson correlation coefficient was then calculated for 
statistical correlation between the two variables. 
 
RESULTS 
Cultured and fresh rodent SVF cells form vessels that are perfused. The 
development of a functional organ-tissue mimic relies not only on parenchymal cells, but 
also a vasculature that links this implant with the surrounding vasculature. The stromal 
vascular fraction (SVF) is an adipose-derived, heterogeneous single cell suspension that 
has been shown to inosculate with the host vasculature after implantation. SVF cells have 
also demonstrated vessel-like properties in culture as well. Therefore, fresh and cultured 
SVF (fSVF and cSVF, respectively) have therapeutic promise in vascularization 
applications.  In this aim, we hypothesized that we could use SVF to functionally 
vascularize implanted hepatocytes, thereby forming a liver-tissue mimic. To start, using 
SVF derived from rats constitutively expressing GFP, we were able to assess the nature 
and degree of interaction between SVF-derived vessels, implanted parenchymal cells, and 
the native host vasculature (Figure 6). In 3D collagen gel matrices, both fSVF and cSVF 
spontaneously assembled into perfused, vascular networks. In both populations, GFP+ 
cells were seen contributing to hierarchical, organized vasculatures reminiscent of mature 





Figure 6. Fresh and cultured SVF cells from GFP-transgenic rats were seeded in 3D 
collagen matrices and implanted for 4 weeks. Prior to explantation, host animals were 
perfused with dextran-TRITC. Here, we see that cultured cells are significantly impaired 
in their perfusion (*p = 0.001) and have significantly increased diameters (*p = 0.02) 
compared to fresh SVF isolates. Results shown as mean ± S.E.M. 
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instance, cSVF appeared to form a lower density of vessels when compared to fSVF. In a 
particular field of view, cSVF generated 59.2 ± 8 vessels, while fSVF generated 
considerably more – 94.2 ± 22. Additionally, there was significantly lower perfusion in 
cSVF-derived vessels as opposed to fSVF-derived vessels. To this end, 97.4 ± 0.8% of 
fSVF-derived vessels were perfused, versus the 86.7 ± 1.9% seen with cSVF. 
Furthermore, differences could be ascertained with the average vessel diameters of the 
two populations, with cSVF yielding a larger diameter (14.6 ± 2.3 µm) vs. fSVF (11.7 ± 
1.5 µm). In sum, these results broadly indicate that both cSVF and fSVF possess a 
proclivity to produce vessels with a similar organization. However, the two populations 
differ with respect to the magnitudes of various, quantifiable vascular parameters. 
 
Cultured and fresh rodent SVF cells participate in angiogenesis in different 
ways. We have shown that cSVF and fSVF can form perfused, hierarchical vessels in 
vivo. However, the next question that we asked was whether or not SVF-derived vessels 
could incorporate into an angiogenic bed. To test this, we relied on an angiogenic 
microvessel implant model, again comparing fSVF and cSVF cells. 
 Both cell types took active roles in forming new vessels through angiogenesis 
(Figure 7). To provide some context, early on, angiogenesis is defined by the formation 
of immature vascular networks. Here, we observed SVF intimately associating with the 
endothelial cells of this developing neovascular system. In implants assessed at later time 
points, we observed vascular systems that were a hybrid of GFP+ and GFP- cells, 
indicating that these vascular systems were chimeric in nature.  
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Figure 7. Fresh and cultured SVF cells differ in their ability to participate in 
angiogenesis. GFP-laden 3D collagen constructs were implanted in non-GFP mice for 
14 or 28d. The images and quantitation demonstrate that significantly fewer cultured 
SVF cells incorporate into developing vessels (*p = 0.01) and that most cultured SVF 
cells take perivascular positions. Results shown as mean ± S.E.M. 
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 What is most unique about these two populations is that fSVF yielded vessels in 
which GFP+ cells were part of both the main vascular tube as well as perivascularly. To 
contrast, cSVF cells predominantly occupied the perivascular space. Along the same 
lines, fewer cSVF cells were incorporated into the neovascular network (13 ± 6.6%, vs. 
24.6 ± 10.4% for fSVF). 
 
Cultured rodent SVF has fewer endothelial and progenitor cells than fresh 
rodent SVF. Given that we saw numerous quantifiable differences between cSVF and 
fSVF, we next wanted to determine if there were differences in the cellular composition 
of these populations that drove their respective phenotypes. Using flow cytometry, cSVF 
were observed to contain roughly 50% less CD31+ (presumably endothelial) cells than 
fSVF. Moreover, a similar trend was seen with respect to the number of cKit progenitor 
cells (Figure 8). Despite these differences, the proportions of CD14+ monocytes and 
macrophages, PDGF-Rß+ perivascular cells, and CXCR4 and cMet+ multipotent cells 
remained approximately the same.  Thus, the number of endothelial and progenitor cells 
in SVF may be diminished with culturing, while perivascular presence and functionality 
appear to be unaffected. 
 
Implanted parenchyma can be vascularized by human SVF cells. Thus far, 
cultured and fresh SVF cells have been shown to possess a unique vascularization 
potential. We therefore wanted to assess the role of these cells in the presence of an 
implanted parenchymal cell model – in this case, HepG2 model hepatocytes (Figure 9). 






Figure 8. Flow cytometry performed on cultured versus fresh SVF cells show 
compositional differences between the two cell populations, the most significant of which 
are reductions in CD-31+ endothelial cells (*p = 0.009) and cKit+ progenitor cells (*p = 










Figure 9. Figures A-C show human SVF within 3D collagen I gels that were implanted 
for 4 weeks, explanted, and labeled with UEA-1 TRITC. Figures D-F show that at 6 







sought to create a completely human mimic. Thus, because these SVF cells were isolated 
from discarded human lipoaspirate instead of from rat fat pads, we opted for a 6-week 
implant time instead of a 4-week implant time. This would allow us to begin accounting 
for potential species-dependent differences in network formation. 
 Our first observation was that indeed, like rodent SVF, human SVF was also 
capable of spontaneously self-assembling into a vascular network. However, at 6 weeks, 
it is possible that human SVF cells required even more time to reach the same degree of 
maturation as the rodent-derived SVF vascular networks seen at 4 weeks. Secondly, we 
wished to see if human SVF could spontaneously form a vascular network in the presence 
of parenchymal cells. To this end, we generated 3D constructs containing HepG2 (grown 
on cytodex beads to facilitate hepatocyte survival and function) and human SVF cells. 
Here too, human SVF spontaneously formed a vascular network. However, in this 
particular arrangement, human SVF networks could also be seen forming cage-like 
structures around HepG2 clusters (Figure 9). 
 
Human fresh SVF-derived vasculatures inosculate implanted parenchymal 
cells. Since we observed human SVF-derived vascular networks surrounding HepG2 
clusters, we next wanted to determine the degree of association between the vasculature 
and the parenchyma. Because HepG2 can bind and internalize LDL cholesterol similar to 
primary hepatocytes, this provided us with a suitable assay to assess SVF-vascular 
inosculation of the parenchyma. 
 After injecting fluorescent DiI-LDL cholesterol intravenously and allowing for 
sufficient circulation time, we observed the accumulation of DiI-LDL within implanted 
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HepG2 cells (Figure 10). Conversely, 3D constructs lacking SVF (but containing 
HepG2) were not able to localize DiI-LDL. To compliment these findings, image analysis 
revealed that in 3D constructs containing both cell types, 83% of HepG2 clusters were 
associated with either vasculatures or DiI-LDL internalization, while 67% were 
associated with both. 
 Thus, these findings indicate that human SVF cells form a vascular network that 




Figure 10. Figures A-D show confocal microscopy images of GFP+ HepG2, injected DiI-
LDL, and rodent SVF (labeled with GS1-Cy5) all co-localizing. Figures E-F demonstrate 
that without SVF, peripherally injected DiI-LDL does not accumulate in implanted 
HepG2 cells (E), though it does accumulate in the host liver (F). Figure G quantifies the 
association between GFP+ HepG2, GS1+ SVF, and DiI-LDL. Note that in HepG2-SVF 
implants, the majority of HepG2 are associated with LDL localization and SVF-derived 
endothelial cells (*p = 0.03, †p = 0.08). (H) This scatter plot demonstrates that in 
HepG2-loaded implants, an increase in GS1+ SVF clusters drives corresponds with an 
increased incidence of LDL co-localization in HepG2. 
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DISCUSSION 
The next stage of our effort involves combining parenchymal cells with a vascular 
supply. As mentioned earlier, the development of a stable vasculature is critical to the 
development of large volumes of engineered tissues. Because our goal is to ultimately 
create a liver-tissue mimic that serves as a therapy for those with Familial 
Hypercholesterolemia, we developed a proof-of-concept by combining HepG2 model 
hepatocyte cells with adipose-derived stromal vascular fraction (SVF) cells. With this 
combination, we were the first to generate a functional, vascularized liver-tissue mimic 
model.  
 To date, it has been difficult to engineer mature vascular systems capable of 
supporting tissues and organs 353,354. Several have attempted to use endothelial cells 
alone, but several have observed that multicellular, three-dimensional approaches are 
required to form mature vasculatures355-357. To this end, perivascular cells are considered 
critical constituents of the developing vasculature321,358. SVF cells show tremendous 
therapeutic potential, as they are a heterogeneous mixture of various cell types that can be 
applied in a variety of circumstances. The cells can be acquired relatively easily in 
lipoaspirates, obtained through minimally invasive means and even at the patient’s 
bedside. While this means that the cells can be acquired and used at the point of care333 
(Tissue Genesis Clinical Trial # NCT02234778), an added benefit is that the patient’s 
own cells can be used. This allows the entire process to remain autologous, minimizing 
the chance of rejection.  
Our findings indicate that cultured SVF can form perfused vasculatures in vivo as 
well. Thus, with regards to clinical applicability, a pooled, cultured supply of SVF cells 
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acquired from various donors could provide added convenience and potentially mitigate 
deficiencies present within any one isolate. Though one hurdle with this approach is that 
only cells from a low passage number can be utilized, one benefit here is that adipose 
cells are limited in their ability to incite a host immune response302,359. Therefore, while 
an autologous approach may be desirable, SVF allografts may also be clinically 
acceptable by providing a workaround under non-ideal circumstances. Additionally, the 
use of allografted SVF may facilitate the use of allogenic parenchymal cells205,360  
In this light, adipose-derived SVF cells constitute a vital part of the liver-tissue 
mimic. While previous attempts at vascularizing engineered liver grafts involved 
incorporating VEGF into constructs containing transplanted hepatocytes, it is unknown if 
any resulting vessels were perfused, or if those vessels enabled or enhanced hepatocyte 
functionality361. To contrast, freshly isolated, cultured and frozen SVF cells can all 
spontaneously form mature, hierarchical vasculatures. Furthermore, SVF cells have been 
used in Phase I clinical trials and are considered to be very safe362.  
To demonstrate SVF cell functionality in the context of a liver-tissue mimic, 
mimics with and without SVF were implanted for six weeks. Just prior to explantation, 
host animals were given fluorescent DiI-LDL cholesterol to assess SVF’s role in forming 
a functional interface between implanted HepG2 cells and the host vasculature. Our 
findings demonstrate that HepG2 cells within constructs containing SVF were able to 
internalize circulating DiI-LDL cholesterol. To contrast, mimics without SVF were not 
able to internalize DiI-LDL. These findings indicate that the SVF cells serve in a key 
capacity by functionalizing co-implanted parenchymal cells. Additionally, SVF-derived 
vessels have lumens, anastomose with the host vasculature, are perfused, and thus serve 
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as a conduit for circulating macromolecules. All of this suggests that SVF cells could be 
combined with parenchymal cells to enable and facilitate parenchymal metabolism of 
various biomolecules.  
Our liver-tissue mimic (comprised of parenchymal and SVF cells) was designed 
as a modular implant. This poses several potential advantages. First, let us consider the 
impact of a single module. In this case, our liver-tissue mimic would be responsible for 
LDL cholesterol uptake, but in other circumstances, such modules could be used for 
hormone production or drug clearance. Benefits of this approach are that (a) modules are 
easily scalable, and (b) their arrangement can be customized. For instance, modules of 
different compositions could be combined together to perform a whole host of functions. 
Second, a module like this could be implanted anywhere there is access to a host blood 
supply. The placement of a modular scaffold subcutaneously has the added benefit of 
being easily accessible, modifiable, and in deleterious circumstances, removable. With 
respect to FH, a modular liver-tissue mimic could be ideal. While FH patients have 
impaired LDLR function, their other liver functions are normal. Though curative from an 
LDLR standpoint, performing a full liver transplant could be heavy-handed, as 
transplant-associated complications may impair functions that were once normal. 
Therefore, an organ-mimic module may enable a targeted approach to treating a specific 
deficiency. Third, modules such as these could serve as drug toxicity testing platforms for 
testing drug effects on various parenchymal phenotypes. 
Cultured SVF cells can spontaneously form vasculatures at low passages, as 
mentioned earlier, though there are a few caveats. First, compared to cells that were 
freshly isolated, the proportion of cultured SVF cells that incorporate into neovessels is 
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decreased. Secondly, the positioning of these incorporated cells is different, as fresh 
isolates take on vascular and mural positions while cultured cells are predominantly 
located in the perivascular space. Third, culturing the cells decreases the quantity of 
CD31+ and cKit+ cells, suggesting that endothelial cell presence is diminished by 
culturing363-365. Because SVF-driven vasculogenesis is endothelial cell-driven299, and 
cultured SVF has fewer endothelial cells, cultured SVF possesses a reduced (but not 
nonexistent) ability to form vasculatures in vivo. Therefore, culturing impairs SVF cells’ 
ability to participate in neovascularization.  
While culturing reduces the number of endothelial cells in SVF, it appears to have 
no effect on the amount of PDGFR-ß1+ perivascular cells366,367. This finding corresponds 
with the observation that cultured SVF cells predominantly reside in mural positions. 
Since culturing clearly effects SVF cell dynamics, it is important to acknowledge that our 
SVF culture methods differ from those used by others to select for adipose-derived stem 
cells (ADSC)298,368. Our low-passage cultured SVF expresses markers associated with 
several mesenchymal stem cell phenotypes. We also have other phenotypes that do not 
appear to be present in the ADSC populations that others have isolated. Therefore, the 
presence of unique phenotypes in our cultured isolates may dictate SVF’s ability to 
spontaneously assemble into a functional neovasculature, though this ability is impaired 
compared to SVF cells from fresh isolates. Additionally, the effect of long-term culture 
(beyond P1) on vascular network formation is a subject for further investigation (and is 
discussed in Chapter 3). 
Again, SVF is unique because of its ability to spontaneously assemble into a 
mature, hierarchical, perfused, functional vascular system in vivo. Koh demonstrated that 
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this phenomenon was dependent on endothelial cells, and that vascular network 
formation was abrogated in the absence of endothelial cells299. Yet, endothelial cells 
alone are unable to form as dynamic a vasculature, with the aforementioned 
characteristics, in vitro316 or in vivo317. Therefore, perivascular cells appear to play a 
critical role in shaping, maturing, stabilizing, and functionalizing an SVF-derived 
developing vasculature316,318.  
While several tissues possess complex vasculatures, isolating and utilizing vessels 
from these sources does not guarantee the same level of performance as that seen with 
SVF cells. This is likely because SVF is derived from adipose tissue, which is thought to 
have a less mature vasculature with a high degree of plasticity321. Such plasticity may be 
required to meet adipose tissue’s complex metabolic needs321. 
This is the first effort that demonstrates that human and rodent adipose-derived 
SVF cells can inosculate with the host vasculature and vascularize implanted parenchyma 
(in this case, HepG2 hepatocyte model cells), to form a proof-of-principle organ-tissue 
mimic. This mimic poses several implications for a variety of organs and disease states. 
The nature of its design allows different parenchymal cells to be used to meet different 
needs. With respect to Familial Hypercholesterolemia, a disease of LDLR dysfunction, 
our liver-tissue mimic enabled the uptake of injected, circulating LDL cholesterol by 
hepatocytes within the mimic. This suggests that SVF-derived vessels can help impart 
critical functionality to implanted hepatocytes, and allows us to take a critical step 
towards developing a therapeutic device for this patient population. This mimic also 






CHAPTER IV  
WNT5A MODULATES THE SELF-ASSEMBLY OF HUMAN STROMAL 
VASCULAR FRACTION-DERIVED MICROVASCULATURES 
 
OVERVIEW  
Human adipose-derived stromal vascular fraction (hSVF) cells are an easily 
accessible, heterogeneous cell system that can spontaneously self-assemble into 
functional microvasculatures in vivo.  However, the mechanisms underlying this vascular 
self-assembly and maturation remain poorly understood. Thus, our objective was to 
identify regulatory pathways mediating this endogenous process. It has been shown that 
culture of SVF reduces its vascularization capacity. Here, we found that EC network 
densities were significantly diminished as early as two passages (P2) and was almost 
eliminated by the fourth passage (P4). For investigating vascularization mechanisms, 
subsequent experiments only used P1 cells. After exposing hSVF cells to common 
angiogenesis inhibitors, we found that the pan-Wnt inhibitor IWP2 produced the most 
significant networking decrease (~25% reduction), implicating Wnt signaling in this 
phenomenon. To determine which Wnt isoform(s) and receptor(s) may be involved, 
hSVF was screened by PCR for those isoforms associated with angiogenesis. Of these, 
only WNT5A and its receptor, FZD-4, were stably expressed. Immunocytochemistry 
showed that Wnt5a protein was expressed in hSVF cultures. To see if Wnt5a alone could 
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restore IWP2-induced EC network inhibition, recombinant human Wnt5a (0–150 ng/ml) 
was added to IWP2-treated cultures. Addition of rhWnt5a to such cultures significantly 
increased EC network area and significantly decreased the ratio of total EC network 
length to EC network area compared to untreated controls. To determine if Wnt5a 
mediates in vivo microvascular self-assembly, 3D hSVF constructs containing an IgG 
isotype control, anti-Wnt5a neutralizing antibody or rhWnt5a were implanted 
subcutaneously for two weeks. Compared to IgG controls, anti-Wnt5a treatment 
significantly reduced vessel length density by ~41%, while rhWnt5a significantly 
increased vessel length density by ~62%. However, anti-Wnt5a or rhWnt5a did not affect 
the density of segments and nodes, both of which measure vascular complexity. Taken 
together, this data demonstrates that hSVF microvascular self-assembly is mediated by 
Wnt5a. These findings also suggest that manipulating Wnt signaling could enhance 
control of hSVF vascularization in tissue engineering applications. 
 
INTRODUCTION  
 The vascularization of engineered tissues remains a significant challenge in tissue 
engineering. Adipose-derived stromal vascular fraction (SVF) is a heterogeneous cell 
population 314,319,344,369 that has been shown to spontaneously self-assemble into 
functional, hierarchical, and perfused vasculatures in vivo 9,299,370 and vessel-like 
networks in culture 371,372. These findings suggest that SVF may have potential 
applications toward the accelerated formation of new microvascular structures in 
therapeutic applications. Our lab has previously demonstrated that SVF can accelerate the 
vascularization and engraftment of co-implanted model hepatocyte cells 9 and induced 
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pluripotent stem cell-derived hepatocytes1. Spontaneous self-assembly into 
microvasculatures by the SVF cells requires the presence of endothelial cells (EC) within 
the isolate, as their removal eliminates the vascular assembly activity9,299. Yet, the 
mechanism(s) by which SVF EC assemble into a functional microvasculature is not well 
defined. 
 To date, vascular assembly in SVF has been described as being VEGF-
dependent299, but experience with other systems suggests that multiple signaling 
pathways mediate the final microvascular system316,344,345,373-375. To better understand 
how human SVF (hSVF) cells self-assemble a microvasculature, we investigated several 
angiogenesis-related signaling pathways to determine their role. Here, we used an in vitro 
model to identify Wnt5a as a potential mediator of vascular assembly. We demonstrate 
that Wnt5a affects parameters such as vessel length and area coverage – effects that were 
absent when hSVF was supplemented with canonical Wnt3a in lieu of Wnt5a. In three-
dimensional in vivo implants, the treatment of hSVF with a Wnt5a-specific neutralizing 
antibody significantly reduced hSVF EC network assembly as quantified by total EC 
length density compared to IgG controls. In contrast, the addition of recombinant human 
Wnt5a significantly increased the total EC length density. Both anti-Wnt5a and 
recombinant human Wnt5a did not significantly affect the densities of segments and 
nodes, suggesting that Wnt5a alone may not modulate vascular complexity. To our 
knowledge, this is the first report to characterize the role of Wnt5a in spontaneous hSVF 
EC microvascular self-assembly. Our data suggests that Wnt5a is a potential target for 
therapeutic angiogenic modulation to regulate hSVF vascularization. 
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MATERIALS & METHODS 
Animals and Ethics Statement. All animal procedures were conducted in 
compliance with University of Louisville School of Medicine IACUC-approved 
protocols and NIH guidelines. Isoflurane gas was administered for anesthesia. For 
analgesia, Ketoprofen was delivered subcutaneously at the time of surgery and post-
operatively every 24h for 2d. 
hSVF Isolation, Long-Term Storage, and General Culture. hSVF cells were 
isolated from the discarded lipoaspirate of three patients (identifying information was 
unavailable) obtained under IRB exemption #09.0037. The lipoaspirate was acquired and 
processed as previously described9,370. The resulting cell pellet was divided and stored in 
liquid nitrogen. Thawed cells were resuspended in hSVF growth media (M199, 1X L-
glutamine, and HEPES (Invitrogen), 10% FBS (VWR International), and EC growth 
supplement (developed in-house and augmented with heparin)) and plated into a 75cm2 
NUNC tissue culture flask (Thermo-Fisher Scientific) pre-coated with 1% gelatin 
(Sigma-Aldrich). Cells were cultured overnight at 37˚C and 5% CO2. A media change 
was performed the following morning to remove non-adherent cells, with subsequent 
media changes performed every other day. Once confluent, hSVF cells were passaged 
with 0.05% Trypsin-EDTA (Invitrogen). 
In Vitro Network Assembly. hSVF cells from passages 1 through 4 (P1 – P4) 
were plated at a density of 6x104 cells/cm2. At days 1, 3, and 5 post-plating, all 
supernatant was aspirated and the cells were fixed in 1% paraformaldehyde (PFA; 
Electron Microscopy Sciences) for 10 minutes at RT before being washed with PBS 
(Invitrogen) for 5 minutes. All wells were labeled with Ulex Europaeus Agglutinin-1 
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(UEA1; Vector Laboratories) for human EC as well as DAPI nuclear dye (Thermo 
Fisher). Cells were imaged using an IX81 inverted fluorescence microscope (Olympus).  
Inhibitor Treatment. P1 hSVF cells were plated as described and, the following 
day, subjected to treatment with the Wnt release inhibitor IWP2 (Tocris Biosciences) (at 
0, 6.25, 12.5, and 25µM; also see Table 1 and Figure 11 for a listing and the effects, 
respectively, of the other tested angiogenic inhibitors) for 5 days376. Media changes were 
performed every other day. At the end of day 5, the cells were processed and imaged as 
described above.  
Cytotoxicity Assay. hSVF cells were cultured in different IWP2 concentrations 
(0, 6.25, 12.5, 25µM, and 50µM) and assayed for cytotoxicity using CCK-8 (Dojindo 
Molecular Technologies) according to the manufacturer’s instructions. We measured 
absorbance using a Synergy 4 plate reader (BioTek). 
Gene and Protein Expression. Samples from P1 hSVF cell cultures were 
acquired on days 1, 3, and 5 and processed for mRNA isolation using QIAShredder and 
RNeasy kits (Qiagen) according to the manufacturer’s instructions. cDNA production, 
RT-PCR, and gel electrophoresis were all conducted as previously described1. RT-PCR 
reactions (primers can be found in Table 2) utilized the following settings: 25 cycles, 
with denaturation at 95˚C, annealing at 59˚C, and extension at 70˚C for 30 seconds. 
Detected bands were normalized to GAPDH via densitometry analysis with Image J 
software (NIH). For analysis of protein expression, wells were prepared for fluorescence 
microscopy as previously described1. Cells were permeabilized in 0.5% Triton X-100 
(MP Biomedicals) for 10 minutes, blocked in 5% goat serum (Thermo Fisher) for 1 hour, 
























Tocris (3533) 0, 6.25, 12.5, 
25, and 50 
µM 
Yes 
VEGF-R2 ZM323881 Tocris (2475) 0, 0.5, 2.5, 5, 
and 10 µM 
Yes 
PDGF-Rβ AG1296 Calbiochem 
(658551) 
0, 0.5, 5, 25, 
and 50 µM 
Yes 
TGF-β1 / Alk-5 SB431542 Stemcell 
Technologies 
(72232) 
0, 0.5, 1, 5, 
and 10 µM 
No 
HGF / cMet SU11274 Selleck Chemicals 
(S1080) 
0, 0.5, 1, 5, 
and 10 µM 
No 
 
Table 1. List of common angiogenic inhibitors used to isolate potential mechanisms of 
hSVF vascular self-assembly. 
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Figure 11. hSVF EC network quantification after inhibitor treatment. hSVF was 
treated with small molecule inhibitors to identify potential pathways mediating vascular 
self-assembly. For each inhibitor tested, UEA1+ network length was normalized to the 
untreated control (also see Table 4). The VEGF-R2 and PDGF-Rβ inhibitors 
significantly reduced total hSVF EC network length at their two highest concentrations 
(*p ≤ 0.05), whereas no significant differences were seen with any concentration of the 















Gene NCBI  
Reference 
Sequence 
5’ à  3’ Primer Sequence 









WNT2 NM_003391.2 CTGGCCTTTATCGCTCGCTG / 
TTCATGACCACCTGGATGG 















287 59.97 / 59.97 Yes 
WNT5B NM_030775.2 CTCAAGAGAGCGAGAAGACTGG / 
CCCTCCCCTATGTAGGCCAT 
309 60.16 / 60.18 No 
WNT7B NM_058238.2 GGAGGCTTCCACCTTTCTCC / 
TCTCCGGTACCCAGTGTAGG 










883 59.97 / 60.32 No 
FZD4 NM_012193.3 CCAACTGGGCACTTTTTCGG / 
TCTAAACAGCAGACAGCGCA 
783 59.97 / 59.97 No 
FZD5 NM_003468.3 TGCTTCATCTCCACGTCCAC / 
AGGATGACCCACCAGATGGA 
272 60.04 / 59.96 No 
ROR2 NM_004560.3 TCCTTCTGCCACTTCGTCTT / 
TTGTAGCACTGGTGGTAGCG 
266 58.95 / 60.04 No 
GAPDH NM_001289745.1 AATCCCATCACCATCTTCC / 
CATCACGCCACAGTTTCC 
382 54.14 / 56.43 No 
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Goat anti-Rabbit 594 secondary antibody (Thermo Fisher) was added the following day 
at 1:1000 for 1 hour at RT (refer to Table 3 for further details). Wnt5a was visualized 
using an IX81 inverted microscope (Olympus) and MPE FV1000 confocal microscope 
(Olympus). 
Exogenous Wnt5a Treatment. After plating overnight in hSVF Growth Media 
(GM), hSVF cells were treated with 25µM IWP2 and varying concentrations of 
recombinant Wnt5a (0, 0.75, 7.5, 75, and 150 ng/ml; R&D Systems) for 5 days. As a 
comparison, recombinant human Wnt3a was added to 25µM IWP2 in hSVF GM at the 
same concentrations. Media changes were performed every other day.  At the end of day 
















(Catalog Number)  
Purpose 
Wnt5a (1:250) Abcam (ab72583) Immunocytochemistry 
Wnt5a (20µg/ml) R&D Systems (AF-645) Neutralization 
IgG (20µg/ml) R&D Systems (AB-108-C) Control 
Fluorescein-Labeled Ulex 





DAPI (1:10000) Thermo Fisher Scientific Immunocytochemistry 
2˚ Antibody  
(Concentration) 
Manufacturer  
(Catalog Number)  
Purpose 
Goat anti-Rabbit DyLightTM 
594 (1:1000) 




Table 3. List of the antibodies, lectins, and stains used. 
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Wnt5a-Specific Neutralization and In Vivo Analysis. P1 hSVF cells were 
cultured as described in hSVF GM containing 0, 5, 10, or 20µg/ml of anti-Wnt5a 
antibody or Normal Goat IgG control antibody (R&D Systems). Of note, though the anti-
Wnt5a antibody used here is specific for mouse and rat, others have successfully used it 
to neutralize human Wnt5a as well 377-379 Media changes occurred every other day. At the 
end of day 3, all of the wells were labeled with UEA1 and quantified as previously 
described.  
To validate Wnt5a’s role in vivo, hSVF was incorporated into 3 mg/ml collagen-I 
constructs as previously described 9,370. One of three treatments was incorporated into 
each construct: (A) 20 µg/ml IgG control antibody, (B) 20 µg/ml anti-Wnt5a antibody, or 
(C) 7.5 ng/ml recombinant human Wnt5a. Constructs were placed bilaterally in the 
subcutaneous dorsum of 9 Rag1-/- C57BL6 mice (Jackson Laboratories) as previously 
described9,370. After 2 weeks, animals were sacrificed and the constructs explanted. 
Constructs were fixed in 4% PFA for 1 hour, washed, permeabilized in 0.5% Triton X-
100 (MP Biomedicals) for 15 minutes, and blocked with 5% goat serum (Thermo Fisher) 
for 1 hour. Constructs were incubated in 1:500 UEA1 overnight. The following day, they 
were washed and incubated with DAPI (1:10000) for 10 minutes. Imaging was conducted 
via fluorescence confocal microscopy (Olympus MPE FV1000).  
2-D (In Vitro) Image Analysis. Fluorescence images were analyzed using Image 
J software (NIH) with the Neuron J plugin (ImageScience.org). Images were assessed for 
total EC network length and EC area. Sheets of ECs were not considered to be discrete 
segments and were omitted from total EC network length calculations, though they were 
incorporated into EC network area measurements. With regards to calculating the EC 
 95 
area, images were first given a color threshold to identify all UEA1+ structures. A size 
threshold of 0.065 cm2 was then applied to remove background noise. Resulting areas in 
a field-of-view were automatically quantified; images containing blatant outliers (for e.g., 
UEA1+ particles not associated with a vascular structure) were manually excluded from 
EC area calculations. Regarding calculations and graphical representation, we normalized 
our in vitro rhWnt5a, rhWnt3a, and anti-Wnt5a quantitative data to their respective 0 
ng/ml or 0 µg/ml treatment controls. This was done to account for the inherent 
differences between three different hSVF isolations from three patients. Examples of 
length and area measurements are shown in Figure 12. 
3D (In Vivo) Image Analysis. Z-stacks of confocal images were combined into a 
3D composite image using AMIRA 6.0 software (FEI Visualization Sciences Group). 
After measuring UEA1+ volume, we converted UEA1+ signals into a skeleton and 
measured total EC network length, segments, and nodes. Network segments were 
considered to be structures with easily discernible origins and end points. The longest 
measurable vascular structure devoid of branching vessels was considered to be one 
segment. Each branch point was considered to be one node. All image manipulation and 
measurement was conducted based on instructions present in the AMIRA 6.0 User Guide.  
Statistics. Experiments were conducted in triplicate. Error is presented as the 
mean ± standard error of the mean (SEM). Significance was determined using the 
Student’s t-test (p < 0.05). Overall significance of each treatment was determined by one-
way ANOVA with follow-up Holm-Sidak or Tukey comparison tests, as determined by 




Figure 12. EC network tracing and area determination. (A) Image J was used to 
convert standard UEA1+ EC images to 8-bit. Images were then traced to measure total 
EC length using the NeuronJ plugin. (B) 8-bit images were also used for area 
measurement. Images were processed for size threshold (shown in red) and enumerated 
as described in the Materials and Methods. 
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RESULTS 
hSVF EC networks are reduced with increasing culture. hSVF is a 
heterogeneous single-cell suspension of ECs, fibroblasts, smooth muscle cells, 
macrophages, mural cells, and various stem cell populations 9,297-299,369. Its inherent 
ability to rapidly and spontaneously self-assemble into a complex, hierarchical, and 
branched vasculature in vivo makes it a compelling candidate for therapeutic 
vascularization. We cultured hSVF as a means of interrogating potential mechanisms 
regulating vascular self-assembly 9,381. After several days of culture, we observed the 
appearance of network-like structures in our cultures.  Labeling of the cells with UEA1 (a 
lectin that binds human endothelium) and DAPI confirmed the presence of extensive EC 
networks in hSVF surrounded by an abundant stromal support system (Figure 13A).  
 Based on prior experience working with rodent and human SVF cells, we 
observed that high-passage SVF cells lose their ability to form vasculatures in vivo9. 
Therefore, we wanted to determine if this phenomenon also occurred in vitro. We 
performed an analysis of EC network formation as a function of passage, using hSVF 
cells from passages 1 through 4.  Figure 13B shows that EC network density increased 
within a given passage over 5 days. Conversely, the overall EC density decreased with 
increasing passage. We observed significant reductions in normalized EC network length 
at day 5 as the passage number increased (Figure 13C). Normalized to P1, which 
exhibited the highest total EC length, P2, P3, and P4 cells exhibited lengths that were 
0.59 ± 0.02 (p < 0.001), 0.44 ± 0.03 (p < 0.001), and 0.26 ± 0.09 (p = 0.001) times as 
large, respectively. Thus, successive culturing decreases hSVF EC networking capacity.  
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Figure 13. Culture reduces hSVF vascularization potential. (A) Within 5 days of 
culture, hSVF displayed complex EC networks, seen here after labeling cells with UEA1, 
a lectin that binds human endothelium. Scale = 10x, 200µm.  (B) hSVF networks increase 
in complexity over time in low passage culture, but rapidly loose EC networking capacity 
with subsequent passaging. Scale = 10x, 200µm. (C) The average total hSVF EC length 
at day 5 was quantified and normalized to measurements of P1, day 5. Significant 
decreases in total hSVF hSVF EC length are seen by day 5 as a function of increasing 
passage (***p ≤ 0.001). Results shown as mean ± S.E.M. 
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While lower passages of hSVF achieved a greater quantified total EC network 
length by day 5 (Figure 13C), this self-assembly appears to be dependent on the number 
of UEA1+ EC within the culture at time of plating. As our analysis depends on having 
quantifiable EC networks, all subsequent in vitro and in vivo experiments utilized P1 cells 
due to their observed higher EC networking potential.  
 
Wnt signaling is implicated hSVF EC network self-assembly. To identify the 
mechanisms regulating the self-assembly of adipose-derived hSVF into EC networks, we 
treated hSVF cultures with angiogenic inhibitors, including those for VEGF-R2 
(ZM323881), PDGF-Rβ (AG1296), HGF receptor/cMet (SU11274), the TGF-β type-I 
receptor/Alk5 (SB431542) (Figure 11 and Table 1), and Wnt palmitoylation (IWP2) 
(Figure 14). In our preliminary tests, IWP2-induced inhibition yielded the most 
significant decreases in total EC length at the two highest concentrations (25 and 50µM; 
data not shown). Because the role of Wnt signaling in vessel assembly is not as well 
characterized as it is in cancer, stem cell, and developmental biology, we focused our 
efforts here.  
Before proceeding, we wanted to determine if our preliminary findings were due 
to IWP2-induced cytotoxicity (Figure 14A). At 50µM IWP2, cell death was determined 
to be due to cytotoxic effects (1.05 ± 0.08 AU with p ≤ 0.001), while the 25µM and lower 
concentrations displayed absorbance readings that were not significantly different from 
control cultures. Thus, we used the 25µM IWP2 dose for all subsequent experiments.   
We next wanted to determine the effect of IWP2 concentration on hSVF network 
formation (Figure 14B.i). Treatment of hSVF with 6.25 or 12.5µM IWP2 showed no  
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Figure 14. Wnt mediates hSVF vascular self-assembly. (A) The CCK-8 cell cytotoxicity 
assay demonstrated that IWP2 concentrations ≤ 25µM were not cytotoxic, whereas 50µM 
was cytotoxic (***p ≤ 0.001). All subsequent experiments utilized 25µM. (B) (i.) 
Increasing IWP2 concentrations reduce hSVF EC networking, as visualized by UEA1+ 
EC labeling. Scale = 10x, 200µm. (ii.) Quantification of hSVF EC networks shows 25µM 
IWP2 significantly decreases the total network length with respect to control (***p ≤ 
0.001). NS = not significant. Results shown as mean ± S.E.M. 
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changes in EC network formation compared to control cultures. However, after treating 
hSVF cells with 25µM IWP2, total EC network length was significantly reduced, 
measuring only 0.75 ± 0.12 times that of the untreated control (p < 0.001; Figure 14B.ii). 
These findings demonstrate that inhibition of endogenous hSVF Wnt signaling has a 
downstream effect of reducing EC self-assembly and total EC network length. 
 
Wnt5a and Fzd4 are expressed in hSVF. Since IWP2 blocks Wnt 
palmitoylation376 and all Wnt isoforms are palmitoylated382, we wanted to determine 
which Wnt isoforms were expressed in hSVF. We isolated mRNA from hSVF cultures at 
days 1, 3, 5, and ran PCR for Wnt isoforms associated with angiogenesis383-392 (Figure 
15A). In each experimental replicate, Wnt5a mRNA was consistently present with stable 
levels of expression over the 5 days of culture (Figure 16A). To determine if Wnt5a 
protein was present in hSVF, we immunolabeled cultures with anti-Wnt5a antibody and 
UEA1 (Figure 16B). We found that Wnt5a was abundant in the hSVF culture (Figure 
16B.i), and that Wnt5a was not detectable in the fluorescent secondary antibody-only 
control (Figure 16B.ii).  
 Given that Wnt5a was present in the culture, we next wanted to determine which 
Wnt5a receptors were expressed in hSVF (Figure 15B). Wnt5a has been shown to 
interact with a number of receptors, including Frizzled-4 393, -5 378,388,394, and ROR2 
395,396. Similar to our Wnt PCR, we tested hSVF cDNA from day 1, 3, and 5 cultures for 
expression of these receptors. In certain replicates, we noticed a weak expression of 
FZD5 and ROR2 (Figure 15B), but in all replicates, we observed the consistent 
expression of FZD4 (Figure 16C), whose expression (like that of Wnt5a) was stable  
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Figure 15. Wnt and Wnt5a-Receptor PCR Screening.  (A) hSVF cDNA was initially 
screened by PCR using primers for Wnt isoforms associated with angiogenesis. Of these, 
WNT5A was most strongly expressed, while WNT7B was expressed to a lesser degree 
(arrows). (B) Once WNT5A was identified, WNT5A receptors underwent similar 
screening, with a focus on FZD4, FZD5, and ROR2. FZD4 was consistently expressed for 
all experiments, while FZD5 and ROR2 expression was inconsistent. 
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Figure 16. Wnt5a and Fzd4 are highly expressed in hSVF cultures. (A) A time course 
of hSVF cDNA isolated was interrogated by RT-PCR for expression of WNT5A at days 1, 
3 and 5. WNT5A was robustly expressed at all time points. Normalization of WNT5A 
expression to the GAPDH loading control indicates stable expression of transcripts over 
5 days. (B) (i.) hSVF was examined by immunocytochemistry for Wnt5a expression. EC 
were labeled with UEA1 (green), nuclei with DAPI (blue), and the entire culture with 
 104 
anti-Wnt5a 1˚ + AF594 2˚ antibodies (red). The merged image shows robust Wnt5a 
expression throughout the culture. Scale = 20x, 100µm. (ii.) A negative control run in 
parallel used only the AF594 2˚ antibody to rule out non-specific fluorophore binding. 
Scale = 20x, 100µm. (C) Wnt5a receptor expression was also tested by RT-PCR (also see 
Figure 25B). FZD4 was stably and consistently expressed, as shown by gel 
electrophoresis. Densitometry demonstrates no change in FZD4 transcripts over 5 days. 




through day 5. These findings confirm the expression of Wnt5a and its receptor Frizzled-
4 within cultured hSVF and suggest a possible mechanism for regulating hSVF EC self-
assembly. 
Recombinant Wnt5a mediates the self-assembly of hSVF EC networks in 
IWP2-treated cultures. We next wanted to determine if Wnt5a played a specific role in 
the self-assembly of hSVF EC networks. hSVF cultures were exposed to a combination 
of 25µM IWP2 and varying concentrations (0 – 150 ng/ml) of exogenously supplied 
recombinant human Wnt5a protein (rhWnt5a; Figure 17). Since IWP2 (a) inhibits the 
release of all endogenous Wnt isoforms from hSVF cells without affecting cognate 
receptors and (b) impairs hSVF EC networking, we wanted to determine if the selective 
addition of rhWnt5a alone would restore hSVF EC network assembly.  
After five days of rhWnt5a co-administration with IWP2, we labeled hSVF 
cultures with UEA1 (Figure 17A) and quantified the magnitude of hSVF EC networking. 
As expected, the addition of 25µM IWP2 alone (negative control, with no supplemental 
rhWnt5a) inhibited EC network assembly. Supplementing the cultures with as little as 
0.75 ng/ml rhWnt5a yielded significant increases in UEA1+ area (Figure 17B) compared 
to cultures given IWP2 alone, resulting in a 2.44 ± 0.36-fold increase (p ≤ 0.01). The 7.5 
ng/ml concentration elicited the largest increase in area, measuring 3.34 ± 0.87 times (p ≤ 
0.05) larger than cultures treated with IWP2 alone, while 75 ng/ml elicited a 2.93 ± 0.76-
fold increase (p ≤ 0.05) and 150 ng/ml yielded an increase of 2.98 ± 0.72 fold (p ≤ 0.05). 
ANOVA analysis further indicated that treatment with any concentration of rhWnt5a was 
significant compared to controls lacking rhWnt5a, but that there were no significant 
differences between the various rhWnt5a treatments. 
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Figure 17. Exogenous recombinant Wnt5a mediates hSVF vascular self-assembly 
during IWP2 inhibition. All hSVF cultures were treated with 25µM IWP2 and given 
increasing concentrations of rhWnt5a. (A) Representative images of UEA1+ (green) 
labeling of hSVF EC networks are seen for all conditions. Scale Bar = 4x, 500µm. (B) 
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The UEA1+ area for each rhWnt5a-treated condition was normalized to the non-treated 0 
ng/ml rhWnt5a control. rhWnt5a significantly increased the total UEA1+ area compared 
to the control (*p ≤ 0.05; **p ≤ 0.01). (C) The total UEA1+ network length was 
normalized to the total UEA1+ area. Compared to the 0 ng/ml rhWnt5a control, 
supplemental rhWnt5a produced areas of hSVF EC sheeting, which is characterized by 
lower ratios of total EC length to EC area. Results shown as mean ± S.E.M. 
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Interestingly, while addition of rhWnt5a significantly increased UEA1+ EC area 
in the presence of IWP2, it also promoted the aggregation of EC in monolayers that 
resemble sheets To quantitatively characterize this, we measured total EC network length 
in each field-of-view and normalized this length to the measured EC area in that same 
field-of-view (Figure 17C). Compared to cultures given IWP2 alone, the addition of 0.75 
ng/ml rhWnt5a yielded ratios that were only 0.51 ± 0.06 times as large (p ≤ 0.001). 
Similarly, the 7.5, 75, and 150 ng/ml concentrations exhibited ratios that were 0.56 ± 0.08 
(p ≤ 0.001), 0.72 ± 0.1 (p ≤ 0.05), and 0.55 ± 0.09 (p ≤ 0.001) times that seen with the 
control. Thus, considering that rhWnt5a increased EC area and reduces the ratio of total 
EC length to EC area, rhWnt5a appears to specifically play a role in modulating hSVF 
vascular network assembly in a process that depends on EC proliferation. 
  Wnt signaling is divided into canonical and non-canonical pathways, which 
utilizes β-catenin or non-β-catenin pathways to transduce the signal397. Wnt5a utilizes 
multiple receptors but is generally categorized as a non-canonical Wnt379,398. To 
determine if the same effect on hSVF EC networking could be produced by a different 
Wnt, we repeated the above experiment using the prototypical canonical Wnt, Wnt3a at 
the same concentrations as those used for the rhWnt5a in vitro experiment (Figure 18A). 
The quantification of the total hSVF EC area normalized to the 0ng/ml Wnt3a control 
indicated that Wnt3a supplementation did not significantly increase networking area 
(Figure 18B) or the ratio of EC network length to EC area of IWP2-treated cultures 
(Figure 18C). Further, ANOVA analysis demonstrated that treatment with any 
concentration of Wnt3a did not yield a significant outcome. These findings suggest that 
Wnt5a alone can partially restore the assembly of hSVF EC networking when  
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Figure 18. IWP2-treated hSVF EC networks are not affected by supplemental 
rhWnt3a. (A) hSVF was treated with 25µM IWP2 for 5d and supplemented with varying 
concentrations of rhWnt3a, except where noted. Human EC were labeled with UEA1 
(green), imaged and quantified. (B) The total UEA1+ EC area seen with each treatment 
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was normalized to that for the untreated IWP2 control. Quantification demonstrates that 
rhWnt3a supplementation yielded no significant changes to network area compared to 
the IWP2 control. (C) Likewise, the normalization of total UEA1+ EC network length to 
the total UEA1+ EC area was not significantly affected by exogenous rhWnt3a addition. 
NS = not significant. Results shown as mean ± S.E.M. 
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endogenous Wnt release is prevented. It also demonstrates that the effect on network 
assembly is not universally mediated by all Wnt isoforms, since Wnt3a substitution was 
ineffective. 
 
Wnt5a mediates hSVF microvascular self-assembly in vivo. Our data supports 
that Wnt5a plays a specific role in hSVF microvascular self-assembly in vitro. Therefore, 
we wanted to determine its role in the self-assembly that others and we have reported in 
vivo 1,9,299. We initially exposed hSVF cultures to varying concentrations (0-20 µg/ml) of 
Wnt5a neutralizing antibody (referred to as anti-Wnt5a) 377,378,399 to determine an 
appropriate concentration for use (Figure 19). Compared to the negative control (0 
µg/ml), there were no significant differences observed with 5 or 10 µg/ml anti-Wnt5a, 
while treatment with 20 µg/ml significantly reduced the total EC length (0.68 ± 0.06 fold, 
p ≤ 0.05; Figure 19A) and segment number (0.52 ± 0.09 fold, p ≤ 0.05; Figure 19B). 
The addition of an IgG control antibody at the same concentrations did not affect total EC 
length or segment number (data not shown).  
Based on these in vitro findings, we utilized 20 µg/ml anti-Wnt5a in subsequent 
in vivo experiments to determine if Wnt5a modulated hSVF microvascular assembly in 
that setting as well. We combined hSVF in 3D collagen-I constructs with 20 µg/ml IgG 
isotype control antibody, 20 µg/ml anti-Wnt5a neutralizing antibody, or 7.5 ng/ml 
rhWnt5a (Figure 20). After implantation for two weeks, host animals were sacrificed and 
the constructs explanted, processed and analyzed as described in the Materials and 
Methods (Figure 20A). Each experimental condition was quantified for length density 
(i.e., a ratio of the total EC length to the 3D scan volume; Figure 20B) as well as the  
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Figure 19. Wnt5a neutralizing antibody inhibits hSVF total EC length and segments. 
The largest concentration of anti-Wnt5a (20 µg/ml) significantly reduced the (A) hSVF 
EC total length (*p ≤ 0.05) and (B) number of segments (*p ≤ 0.05). This concentration 
was used to examine Wnt5a’s role in hSVF vascular self-assembly in vivo. In both (A) 
and (B), values obtained for length and segments with each treatment were normalized to 




Figure 20. Wnt5a drives hSVF EC microvascular assembly in vivo. (A) 3D collagen-I 
constructs containing hSVF with 20 µg/ml IgG isotype control, 20 µg/ml Wnt5a 
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neutralizing antibody (anti-Wnt5a), or 7.5 ng/ml rhWnt5a were subcutaneously 
implanted in immunodeficient mice for 2w. In situ images show 2w constructs before 
harvest. Constructs were labeled with UEA1 (green) and imaged by confocal microscopy. 
Scale bar = 20x, 100µm.  (B) The total EC length was normalized to the 3D scan volume 
(length density). Construct treatment with anti-Wnt5a exhibited a significantly reduced 
length density ((2.25 ± 0.16) x 10-5 µm/µm3; *p ≤ 0.05) compared to the IgG control 
((3.81 ± 0.1) x 10-5 µm/µm3). Conversely, rhWnt5a significantly increased this ratio 
((6.17 ± 0.43) x 10-5 µm/µm3; *p ≤ 0.05) compared to the control. (C) The normalization 
of segment number to length density showed no significant affect with either the anti-
Wnt5a treatment ((1.24 ± 0.13) x 107 segments/µm/µm3) or the rhWnt5a treatment ((1.28 
± 0.34) x 107 segments/µm/µm3) compared to IgG controls ((1.34 ± 0.07) x 107 
segments/µm/µm3). (D) The ratio of node number to length density also shows no 
significant difference between the IgG control ((1.19 ± 0.07) x 107 nodes/µm/µm3), the 
anti-Wnt5a treatment (1.31 ± 0.02 nodes/µm/µm3), and treatment with rhWnt5a ((1.06 ± 
0.27) x 107 nodes/µm/µm3).  NS = not significant. Results shown as mean ± S.E.M. 
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ratios of segment (Figure 20C) and node (Figure 20D) numbers to length density. Thus, 
length density is a measure of assembly, while the segment and node ratios serve to 
characterize hSVF vascular complexity. 
IgG controls exhibited an average length density of (3.81 ± 0.1) x 10-5 µm/µm3. 
Treatment with anti-Wnt5a significantly reduced the length density ((2.25 ± 0.16) x 10-5 
µm/µm3; p ≤ 0.05), while rhWnt5a significantly increased this ratio ((6.17 ± 0.43) x 10-5  
µm/µm3; p ≤ 0.05). Put a different way, compared to the IgG control, anti-Wnt5a reduced 
total vascular length by approximately 41 ± 5.6%, while rhWnt5a increased overall 
vascular length by approximately 62 ± 15%. 
With regards to vascular complexity, the addition of anti-Wnt5a to 3D implants 
did not significantly affect the ratio of segments to length density ((1.24 ± 0.13) x 107 
segments/µm/µm3; p = 0.56) compared to IgG controls ((1.34 ± 0.07) x 107 
segments/µm/µm3). Anti-Wnt5a also bore no significant effect on the ratio of nodes to 
length density, with (1.31 ± 0.02) x 107 nodes/µm/µm3 (p = 0.22) compared to the (1.24 ± 
0.07) x 107 nodes/µm/µm3 seen with the IgG control. Also, rhWnt5a did not significantly 
influence complexity either ((1.28 ± 0.34) x 107 segments/µm/µm3 (p = 0.86) and (1.06 ± 
0.27) x 107 nodes/µm/µm3 (p = 0.67)). These results also correlate with the qualitative 
observation that 3D implants did not exhibit noticeable EC sheeting. 
ANOVA analysis indicated that the anti-Wnt5a and rhWnt5a treatments only 
imparted significant effects on EC lengths within a 3D construct. Thus, this data 
demonstrates that in a 3D implant, the supplementation of rhWnt5a in vivo significantly 
increased the overall length of the hSVF microvasculature, while the specific blockade of 
Wnt5a with a neutralizing antibody significantly reduced hSVF cells’ capability to form a 
 116 
microcirculation. Together, these findings support a role for Wnt5a in mediating hSVF 
microvascular self-assembly in vivo. 
 
DISCUSSION 
The main and novel findings of this report are that (a) human adipose SVF 
(hSVF) spontaneously forms endothelial networks in vitro, but loses this capacity due to 
a reduction in system endothelium, (b) pan-inhibition of hSVF-endogenous Wnt isoforms 
by IWP2 significantly reduces EC networking, (c) the addition of exogenous Wnt5a, but 
not Wnt3a, to IWP2-treated cultures modulates EC network assembly in vitro, (d) the 
spontaneous assembly of hSVF microvascular networks in vivo is inhibited by a Wnt5a 
neutralizing antibody and enhanced by addition of recombinant human Wnt5a protein, 
and (e) Wnt5a does not influence the complexity of hSVF-derived microvessels. 
Adipose SVF is a heterogeneous cell population that contains EC, perivascular 
cells, macrophage, fibroblasts and stem cells9,369,400. This endogenous heterogeneity is 
likely what imbues the cellular system with the specific capacity to form functional 
microvasculatures in vivo1,9,370. In prior efforts, we leveraged this functionality to support 
the engraftment of hepatic parenchymal cells1,9. Koh and colleagues demonstrated that 
the formation of vascular networks by mouse SVF (mSVF) depended on the presence of 
EC and is VEGF-dependent299. We reported that the removal of EC from rat SVF cells 
yielded a significantly altered vascular interaction9. These findings support the hypothesis 
that the heterogeneity of SVF is crucial to its biological functionality. However, the 
mechanisms regulating this functionality are poorly defined. 
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It is a common practice to subculture adipose SVF to isolate the putative ADSC 
401. This “pure” population of mesenchymal cells is explicitly void of endothelium (i.e. 
CD31-) 402. In early culture, the endogenous EC population is enriched and capably forms 
robust EC networks. This capacity diminishes rapidly with each successive passage. The 
reasons for this decrease are not clear, but could be due to EC depletion by our sequential 
network assays, differential proliferation rates between EC and stromal cells favoring the 
latter, or culture-induced loss by EC phenotypic drift. There are multiple reports in the 
literature of ADSC combined with various EC populations to create a synthetic vascular 
and stromal cell system298,403,404. Our data supports the conclusion that the hSVF cellular 
system is a complex heterogeneous cell mixture that endogenously retains the functional 
capacity for microvascular self-assembly, which the artificially generated EC-ADSC co-
culture may not fully replicate. 
To determine the mechanisms that regulate hSVF EC network self-assembly in 
vivo, we investigated several angiogenesis-associated pathways. Inhibition of receptors 
for VEGF and PDGF-B significantly reduced hSVF EC networking, while blockade of 
the TGFβ1 receptor Alk5 and HGF receptor c-Met did not. This data agrees with Koh, et 
al.299 with regards to the role of VEGF and further suggests that a blockade of PDGF-
B/PDGFR-β signaling may prevent perivascular cell recruitment as demonstrated in other 
vascular beds405-408. The lack of effect from Alk5 inhibition may be due to (a) 
TGFβ1/Alk5 having a role in later stages of vascular stabilization348,409, or (b) TGFβ1 
could be signaling through Alk1 on EC410,411. In other model systems, we demonstrated 
that HGF/c-Met signaling modulates vascular assembly and angiogenesis9,316. The lack of 
effect on hSVF could be due to limitations of our hSVF in vitro assay to mimic the stages 
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when HGF/c-Met are active. Our battery of inhibitors also included the Wnt 
palmitoylation inhibitor IWP2376, which showed a significant effect on hSVF network 
self-assembly. Though Wnt biology is extensively studied in other contexts, its functions 
in EC biology and angiogenesis have only recently been investigated392,399,412-414 with 
defined roles for canonical and non-canonical Wnt isoforms388,392,412 in vascularization.  
Since IWP2 inhibits the release of all Wnt isoforms, we tested hSVF for 
expression of Wnt isoforms previously affiliated with angiogenesis. Since our PCR panel 
identified Wnt5a as being highly expressed within hSVF, we hypothesized that Wnt5a 
mediates hSVF EC network assembly. The addition of various concentrations of 
exogenous rhWnt5a significantly increased the areas of IWP2-inhibited EC networks, 
though these treatments also significantly reduced the ratios of lengths to EC areas. These 
effects were not seen when the canonical rhWnt3a was supplemented in place of 
rhWnt5a. Together, these findings suggest that while Wnt5a is an essential modulator of 
hSVF EC network assembly in vitro, other Wnt isoforms (alone or in conjunction with 
Wnt5a) likely modulate vascular complexity (characterized by reduced EC sheeting and 
increased branching).  
To determine if our in vitro findings provided the mechanisms controlling in vivo 
microvascular self-assembly, we implanted hSVF1,9,370 in 3D constructs supplemented 
with a Wnt5a-specific neutralizing antibody378,379,415, rhWnt5a, or IgG isotype control.  
Compared to IgG controls, implants containing anti-Wnt5a exhibited reduced the 
volumetric total vessel length, whereas the numbers of nodes and segments per unit of 
length density were essentially unchanged. To contrast, constructs containing rhWnt5a 
exhibited a significantly increased length density, but like anti-Wnt5a, rhWnt5a had little 
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effect on the numbers of segments and nodes per unit of length density. This suggests that 
Wnt5a does not influence the complexity of the resulting hSVF-derived vascular system. 
This data agrees with the results from other reports in the literature that Wnt5a signaling 
modulates EC vascular assembly392, but this is the first time that this has been 
demonstrated in hSVF – a clinically relevant, natively heterogeneous population.  
Our in vivo findings also correspond with those seen in vitro, in spite of the fact 
that in vitro experiments utilized IWP2 (the pan-Wnt release inhibitor) and in vivo 
experiments did not. It is possible that a bolus delivery of rhWnt5a in a 3D implant could 
decrease, but not necessarily eliminate, the influence of other Wnt isoforms released by 
hSVF cells or host tissues, since certain Wnt isoforms can compensate for one another in 
development416. While rhWnt5a did not significantly influence hSVF microvascular 
complexity in vivo (potentially based on a compensatory, decreased influence of other 
Wnt isoforms), the incidence of EC sheeting in vivo appeared to have been mitigated 
(perhaps due to the basal presence of other Wnt isoforms or other biomolecules 
associated with angiogenesis). Though this seems paradoxical, it is clear that Wnt5a is 
only one constituent of a complex system that imparts control over hSVF spontaneous 
microvascular self-assembly. 
A key consideration in our experiments is that we obtained our hSVF cells from 
three different patient sources of discarded human lipoaspirate. Undoubtedly, the 
characteristics of adipose exhibits variability between patients. The cellular composition 
of each hSVF batch is likely to be different depending on factors such as gender, age, and 
social lifestyle (e.g. smoking, alcohol use), all of which likely have significant effects on 
cell viability and cellular function., Prior studies have indicated that the proportion of 
 120 
CD31+ EC is decreased with culture SVF cells as opposed to freshly isolated cells9,400.  In 
spite of these factors, we observed the same trends with each hSVF isolation, regardless 
of the patient demographics. This supports our finding that Wnt5a signaling may play a 
general role in mediating hSVF microvascular assembly in vivo. At this stage, it is 
unclear how Wnt5a may be involved. We show robust expression of Wnt5a within hSVF, 
but it is unknown if there is a specific cell lineage within hSVF that is responsible for 
affecting the EC response. We show robust expression of FZD4 in hSVF and Wnt5a 
utilizes this receptor in EC393, but Wnt5a also signals through FZD5388 and ROR2396,417. 
Thus, the downstream signaling events still need to be defined. Though more work is 
required to understand how the hSVF cellular system functions to self-assemble a 
microvasculature, our data identifies Wnt5a signaling as a component that potentiates this 
process. 
 In this endeavor, our goal was to define the mechanisms controlling hSVF 
spontaneous EC microvascular network formation in vivo. Our findings are novel, as this 
is the first report that identifies Wnt5a as a modulator of hSVF vascular assembly. This 
work underscores the fact that adipose SVF is a potential regenerative cell system. 
Understanding how the mixture of heterogeneous cell types within hSVF works together 
could enhance efforts to better vascularize tissues or promote the engraftment of 






 RESTORATION OF PHYSIOLOGICALLY RESPONSIVE LOW-DENSITY 
LIPOPROTEIN RECEPTOR-MEDIATED ENDOCYTOSIS IN GENETICALLY 
DEFICIENT INDUCED PLURIPOTENT STEM CELLS 
 
OVERVIEW 
Acquiring sufficient amounts of high-quality cells remains an impediment to cell-
based therapies. Induced pluripotent stem cells (iPSC) may be an unparalleled source, but 
autologous iPSC likely retain deficiencies requiring correction. We present a strategy for 
restoring physiological function in genetically deficient iPSC utilizing the low-density 
lipoprotein receptor (LDLR) deficiency Familial Hypercholesterolemia (FH) as our 
model. FH fibroblasts were reprogrammed into iPSC using synthetic modified mRNA. 
FH-iPSC exhibited pluripotency and differentiated toward a hepatic lineage. To restore 
LDLR endocytosis, FH-iPSC were transfected with a 31kb plasmid (pEHZ-LDLR-LDLR) 
containing a wild-type LDLR (FH-iPSC-LDLR) controlled by 10kb of upstream genomic 
DNA as well as Epstein-Barr sequences (EBNA1 and OriP) for episomal retention and 
replication. After six months of selective culture, pEHZ-LDLR-LDLR was recovered from 
FH-iPSC-LDLR and transfected into Ldlr-deficient CHO-a7 cells, which then exhibited 
feedback-controlled LDLR-mediated endocytosis. To quantify endocytosis, FH-
iPSC±LDLR were differentiated into mesenchymal cells (MC), pretreated with excess 
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free sterols, Lovastatin, or ethanol (control), and exposed to DiI-LDL. FH-MC-LDLR 
demonstrated a physiological response, with virtually no DiI-LDL internalization with 
excess sterols and an ~2-fold increase in DiI-LDL internalization by Lovastatin compared 
to FH-MC. These findings demonstrate the feasibility of functionalizing genetically 
deficient iPSC using episomal plasmids to deliver physiologically responsive transgenes. 
 
INTRODUCTION 
Induced pluripotent stem cells (iPSC) derived from patients are a unique, potential 
alternative for replacing diseased tissue because of their virtually unlimited supply, 
differentiation potential, and tolerance by the immune system418. However, in the context 
of treating genetic disorders, autologous iPSC are challenged by their genetic homology 
with patient DNA, as they may retain functional deficiencies. Such shortcomings must be 
addressed before these cells attain broad therapeutic value.   
Familial Hypercholesterolemia (FH) is one example of a monogenic autosomal 
dominant disorder that affects low-density lipoprotein cholesterol (LDL) metabolism419. 
In FH, LDL receptor (LDLR) deficiency (attributed to at least one of 1200 documented 
mutations420,421) impedes receptor-mediated endocytosis of LDL, resulting in 
pathologically elevated serum LDL levels. Consequently, the formation of atherosclerotic 
plaques and cardiovascular disease are both accelerated. Because healthy liver 
hepatocytes contain the body’s highest density of functional LDLR82, liver transplant is 
regarded as the only cure for FH. Yet, the number of available livers is far outstripped by 
significant demand422, while long-term transplant issues such as immunomodulation and 
transplant rejection remain key hurdles. Further, liver hepatocytes culture poorly423, 
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complicating efforts such as banking and expansion.  For such reasons, generating 
hepatocytes from patient-specific iPSC (FH-iPSC) may be a possible therapeutic 
alternative.  
We used FH as a model system for interrogating the LDLR functionalization of 
FH-iPSC. We restored FH-iPSC LDLR-mediated endocytosis using a novel 31kb 
plasmid containing (a) wild-type LDLR physiologically controlled by 10kb upstream 
genomic regulatory control sequence and (b) the minimum number of required Epstein-
Barr Virus (EBV) replication and retention sequences (Epstein-Barr Nuclear Association 
1 (EBNA1) and origin of plasmid replication (OriP))424. This large plasmid was 
transfected into iPSC via electroporation and retained as a stable episome. FH-iPSC were 
differentiated into hepatocyte-like cells (FH-HLC) and mesenchymal cells (FH-MC) to 
investigate LDL internalization. Transfected FH-iPSC derivatives demonstrated a 
significant, physiologically sensitive restoration of LDLR-mediated endocytosis 
compared to non-transfected controls. The technologies and methods discussed herein 
represent a unique approach for functionalizing genetically deficient iPSC using episomal 
plasmids that contain genomic transgene control sequences. 
 
MATERIALS & METHODS 
Ethics Statement. All animal procedures were conducted in compliance with 
University of Louisville School of Medicine IACUC-approved protocols and NIH 
guidelines. All recombinant DNA work was approved by the University of Louisville 
Institutional Biosafety Committee and performed in accordance with NIH guidelines. 
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General Cell Culture. Mouse embryonic fibroblasts (MEF) were cultured in 
MEF media comprised of DMEM-HG, 2 mM L-glutamine, and 10% standard fetal 
bovine serum (FBS; Invitrogen). Chinese hamster ovary wild-type (CHO-WT) and LDLR 
deficient (CHO-a7) cells (generously provided by Prof. Monty Krieger, Massachusetts 
Institute of Technology) were cultured in media containing DMEM/F12 (Invitrogen), 
2mM L-glutamine, and 10% standard FBS. All cells were maintained at 37˚C and 5% 
CO2 and passaged at confluence with 0.05% Trypsin-EDTA (Invitrogen).  
Parent Fibroblast Culture. Dermal fibroblasts from an FH patient (GM01355; 
Coriell Cell Repositories) were cultured in FH growth medium consisting of MEM 
(Invitrogen), 15% HyClone™ defined FBS (Thermo Fisher Scientific), 2 mM L-
glutamine, 0.1 mM Non-Essential Amino Acids (MNEAA), 50 units/ml penicillin and 50 
µg/ml streptomycin (Invitrogen). WT IMR90 fibroblasts were cultured in MEF media as 
described above. All cells were maintained in standard cell culture conditions and 
passaged with 0.05% Trypsin-EDTA.  
iPSC Generation and Culture. Reprogramming was performed in 6-well tissue 
culture dishes coated with 0.2% gelatin (Sigma-Aldrich). On Day -2, Mitomycin-C-
inactivated human foreskin fibroblast feeder cells (Nuff; GlobalStem) were plated at a 
density of 2.5x105 cells/well and cultured in Nuff growth media, comprised of DMEM-
HG, 10% HyClone defined FBS, 1% GlutaMAX, 50 units/ml penicillin and 50 µg/ml 
streptomycin (Invitrogen). On Day -1, 2.5x104 FH parent fibroblasts were seeded atop the 
Nuff feeder layer in FH growth medium. After overnight plating, fibroblasts were 
transfected daily for 20 days in Pluriton reprogramming medium supplemented with 200 
ng/ml B18R interferon inhibitor (Stemgent), the mRNA cocktail, and Lipofectamine-
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RNAiMax Transfection Reagent (Invitrogen) per the manufacturers’ instructions. Fresh 
reprogramming medium was substituted after 4 hours of incubation. Pluripotent colonies 
(FH-iPSC; TRA-1-60+ via staining with StainAlive TRA-1-60 (Stemgent)) were 
identified and manually passaged from transfected cultures onto Mitomycin C-inactivated 
(Sigma-Aldrich) MEF every three days. FH-iPSC were cultured with human iPSC 
medium (DMEM/F12 supplemented with 20% Knockout Serum Replacement (KSR), 2 
mM L-glutamine, 0.1 mM MNEAA (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma-
Aldrich) and 20 ng/ml fibroblast growth factor-2 (bFGF; Stemgent))425. For feeder-free 
culture, FH-iPSC were passaged onto hESC-Qualified Matrigel coated plates (BD 
Biosciences) and gradually adapted to mTeSR1 media (Stemcell Technologies) by serial 
transition from 20% KSR culture media over a 10-day period with daily media changes. 
Cells in feeder-free culture were used for parenchymal cell generation before the 10th 
passage426.  
FH Cell Characterization. DNA karyotyping and fingerprint analysis (Cell Line 
Genetics) was completed on FH skin fibroblasts and reprogrammed iPSC (P21) to ensure 
that both populations were karyotypically normal and maintained identical DNA 
fingerprints. To verify disease phenotype, FH fibroblasts were compared against wild-
type IMR90 fetal lung fibroblasts on the basis of their ability to internalize LDL 
cholesterol. FH-iPSC pluripotence was then assessed via in vitro spontaneous 
differentiation and in vivo teratoma assays. In vitro, FH-iPSC were plated on glass slides 
in differentiation medium (human iPSC medium without bFGF) and differentiated for 20 
days. 50% media changes were performed every other day. After 20 days, we assessed 
the iPSC for pluripotent marker expression via immunocytochemistry. For in vivo 
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teratoma generation, we utilized FH-iPSC that were passaged with 0.05% Trypsin-EDTA 
at least five times prior427. Growth-Factor Reduced Matrigel (BD Biosciences) was mixed 
with an FH-iPSC cell pellet to a final concentration of 2.5x104 cells/µl; 200 µl was loaded 
into sterile 1ml syringes with 18G needles (BD Biosciences). Control syringes containing 
only Matrigel were also prepared.  iPSC and controls were injected on opposing sides 
into the subcutaneous dorsum of isoflurane-anesthetized NOD/SCID-γ mice (Jackson 
Laboratories). Injected mixtures were allowed 15 minutes to polymerize before the 
cessation of anesthesia. At 7 weeks post injection, masses were palpable in the flanks of 
the animals; at 14 weeks, the teratomas were visualized in situ, excised with gross 
margins and processed for histological examination.   
Verification of Plasmid Functionality. To verify plasmid functionality, Ldlr-
deficient CHO-a7 cells were first plated to confluence in a 48-well tissue culture dish. 
Once confluent, CHO-a7 cells were transfected with a complex of plasmid and 
Lipofectamine 2000 (Invitrogen) in a 1 µg : 1 µl ratio in Opti-MEM (Invitrogen) per 
manufacturer instructions11. Cells were cultured overnight in standard culture conditions. 
The following day, transfection media was removed and replaced with standard CHO-
culture media (described above). 24 hours later, selection for transfected CHO-a7 (CHO-
a7-LDLR) took place via exposure to 750 µg/ml Hygromycin B in CHO culture media. 
Afterwards, cells were starved overnight in media comprised of DMEM-HG, 1X L-
glutamine and 5% lipoprotein-deficient serum (Alfa Aesar). Starvation media was 
augmented with 2 µM of Lovastatin (EMD Millipore), excess sterols (12 µg/ml 
cholesterol and 0.6 µg/ml 25-hydroxysterol; Sigma-Aldrich), or ethanol (vehicle control; 
Sigma-Aldrich)424. The following day, the starvation media was removed and replaced 
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with 5 µg/ml DiI-LDL (Alfa Aesar) in DMEM-HG for 4.5 hours, after which the cells 
were thoroughly washed with di-cationic PBS and imaged using an Olympus IX81 
fluorescence microscope. 
FH-iPSC Electroporation and Selection. We transfected FH-iPSC with the 
corrective plasmid using both decayed-exponential and square-wave electroporation 
modalities. For FH-iPSC used in decayed-exponential electroporation (conducted at 4˚C), 
cells grown in feeder-free culture were pretreated with 10 µM of Y-27632 (EMD 
Millipore) two hours prior to electroporation. The cells were treated with 1 mg/ml 
Collagenase Type IV (Invitrogen) for 10 minutes, resuspended in DMEM/F12, and 
counted. We utilized a minimum of 107 cells per electroporation. Cells were pelleted and 
resuspended in 700 µl of ice-cold (4˚C) di-cationic PBS or ES-qualified electroporation 
buffer (MEB; EMD Millipore). 100 µg of plasmid DNA (per 107 cells) was Q.S. to 50 µl 
with electroporation buffer. Cell and plasmid solutions were combined; the resulting 
750µl volume was added to a pre-chilled (4˚C) 4mm gap cuvette (BTX) and gently mixed 
by flicking. Cells were electroporated using an ECM 630 Electro Cell Manipulator (BTX; 
generously provided by Dr. Scott Whittemore, University of Louisville; see Table 4). 
Electroporated cells were incubated on ice for 5 minutes and suspended in 10 ml 
DMEM/F12 before pelleting. The pellet was resuspended in mTeSR1 with 10 µM Y-
27632 and plated into 3 Matrigel-coated wells of a 6-well tissue culture dish. For FH-
iPSC used in square wave electroporation (carried out at room temperature), cells were 
pretreated with 10 µM Y-27632 2 hours prior to electroporation. The cells were harvested 
via a 10-minute application of 1 mg/ml Collagenase Type IV and washed twice with 









Table 4. Greyed rows indicate successful decayed-exponential and square-wave 







OptiMEM. Plasmid DNA was maintained in a separate tube at 1 µg/µl in TE Buffer 
(Ambion). Recipient 6-well tissue culture dishes were pre-loaded with mTeSR1 and 10 
µM Y-27632 and kept at 37˚C. Prior to electroporation, 10 µl of plasmid was mixed with 
90 µl of iPSC (total electroporation volume = 100 µl) and transferred to an 
electroporation cuvette (NepaGene). The cuvette was gently flicked to ensure adequate 
mixture. Cells were electroporated using a NEPA21 cell electroporator (NepaGene; 
generously provided by Dr. Michal Hetman, University of Louisville; parameters are 
outlined in Table 4). Transfected cells were directly transferred into each well of the 6-
well tissue culture recipient plate. For both conditions, after electroporation, cells were 
cultured for 2 days in mTeSR1 before a 5-day selection with 10 µg/mL Hygromycin B 
and subsequent maintenance in 0.5 to 1 µg/mL Hygromycin B, indicating successful 
transfection. Media was changed daily. 
Hepatocyte-Like Cell Production. FH-iPSC were plated to confluence in 
Matrigel-pretreated wells of a 6-well tissue culture plate or 6 Permanox chamber slides 
(Sigma-Aldrich). Each well of the 6-well plate (used for PCR analysis) and each 
Permanox slide (used for immunocytochemistry) corresponded with one of the six stages 
of differentiation (including Stage 0, which represented untreated iPSC). To generate 
HLC, we used a modified version of the protocols and medias proposed by Song et al428. 
In lieu of Song’s Stage 1 media, we utilized the StemDiff definitive endoderm kit (Stem 
Cell Technologies) per the manufacturer’s instructions. Media changes were performed 
daily and cells were characterized by the end of Stage 5. 
Hepatocyte-Like Cell General Functional Assessment. Indocyanine green 
(ICG; Sigma-Aldrich; 5 mg/ml in sterile water) was used to measure overall cell 
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metabolic activity. ICG and Stage 5 media were mixed per manufacturer’s instructions 
and applied to FH-HLC for 1 hour. FH-HLC were thoroughly washed with di-cationic 
PBS to remove residual dye before being imaged on an Olympus IX81 microscope via 
phase and bright field settings. FH-HLC were then incubated in Stage 5 media overnight 
before assessment 24 hours later using the same microscope settings. An Oil-Red-O 
assay was used to evaluate cell lipid accumulation. A different population of FH-HLC 
was treated with Carnoy’s fixative for 2 minutes at RT before being washed with distilled 
water. Working Oil-Red-O solution (Sigma-Aldrich) was prepared per the manufacturer’s 
instructions and applied to FH-HLC for 30 minutes at RT. Cells were thoroughly washed 
with distilled water and imaged on an Olympus IX81 microscope with phase and bright 
field settings. 
Imaging of Hepatocyte-Like Cell LDLR-Mediated Endocytosis. FH-HLC 
derived from transfected FH-iPSC (FH-HLC-LDLR) were starved overnight in 5% 
lipoprotein-deficient serum supplemented with 2 µM of Lovastatin, excess sterols (12 
µg/ml cholesterol and 0.6 µg/ml 25-hydroxysterol), or ethanol (vehicle control). The 
following day, the starvation media was replaced with 5 µg/mL DiI-LDL in DMEM-HG 
for 4.5 hours. Cells were thoroughly washed with di-cationic PBS prior to imaging via an 
Olympus IX81 fluorescence microscope. 
Transfected Hepatocyte-Like Cell Qualitative Imaging. FH-HLC derived from 
transfected FH-iPSC (FH-HLC-LDLR) were grown in 3 wells of a 12-well tissue culture 
plate. Cells were starved overnight in 5% lipoprotein-deficient serum supplemented with 
2 µM of Lovastatin, excess sterols (12 µg/ml cholesterol and 0.6 µg/ml 25-
hydroxysterol), or ethanol (vehicle control). The following day, starvation media was 
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removed and replaced with 5 µg/mL DiI-LDL in DMEM high glucose for 4.5 hours. 
Cells were thoroughly washed with di-cationic PBS prior to imaging via an Olympus 
IX81 fluorescence microscope. 
Hepatocyte-Like Cell In Vivo Assessment. Human SVF (hSVF) was grown to 
confluence in vitro in a gelatin-coated T75 flask while FH-HLC were grown to 
confluence through end of Stage 2.  On the day of implantation, both hSVF and HLC 
were prepared using 0.05% Trypsin-EDTA.  Constructs were prepared using 106/ml HLC 
± 106/ml of SVF in a master mixture of 3 mg/ml Collagen I (comprised of Rat Tail 
Collagen I (BD Biosciences), 4X DMEM (Invitrogen; made from 10X powdered 
concentrate), Sterile Water, and 0.1N NaOH (Ricca Chemical Company)). 250 µl of the 
cellular mixture was pipetted into each well of a 48-well plate and maintained at 37˚C to 
polymerize for 30 minutes. Afterwards, the constructs were immersed in a mixture of 
50% Stage 2 HLC differentiation medium and 50% Human Complete hSVF culture 
media (comprised of Medium 199 (Invitrogen), ECGS (derived in-house), HEPES, 1X L-
glutamine (Invitrogen), and 10% heat-inactivated FBS (Thermo Fisher Scientific)). 
Constructs were implanted in the subcutaneous dorsa of isoflurane-anesthetized Rag1-/- x 
LDLR-/- double knockout mice (generously provided by Dr. Catherine Reardon-Alulis, 
University of Chicago). Animals were sacrificed at 2 weeks, at which point the implanted 
constructs were extricated and fixed in 4% PFA for 1h. Constructs were then 
permeabilized in 0.5% Triton X-100 (MP Biomedicals) for 20m and blocked in 5% Goat 
Serum (Invitrogen) for 1h. The explants were then incubated overnight in Albumin (MP 
Biomedicals) and UEA-1 biotin (Vector Labs) at 1:200 in 5% Goat Serum at 4˚C. The 
following day, the constructs were washed in di-cation-free PBS and exposed to Goat-
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anti-Rabbit 488 (Thermo Fisher Scientific; for Albumin) and Streptavidin-Cy5 
(Invitrogen; for UEA-1 biotin) at 1:1000 for 1h. Constructs were labeled with DAPI at 
1:10000 for 10 minutes prior to confocal fluorescence microscopy imaging. All animal 
procedures were conducted in accordance with University of Louisville School of 
Medicine IACUC regulations. 
Plasmid Rescue and Restriction Digest. Plasmid rescue was performed on 
transfected FH-iPSC-LDLR using methods described by Lufino and colleagues429. The 
rescued plasmid was characterized using AgeI-HF restriction enzyme (New England 
BioLabs) per manufacturer instructions. Restriction products were run on a 0.4% agarose 
gel at 20 V for 16 hours. Gels were analyzed via a Typhoon 9400 variable mode imager 
(GE Healthcare Bio-Sciences). After confirming plasmid isolation, the rescued plasmid 
was also re-transfected into Ldlr-deficient CHO-a7 cells (generously provided by Prof. 
Monty Krieger, Massachusetts Institute of Technology) via Lipofectamine 2000 to 
demonstrate non-integration and preservation of plasmid functionality after rescue. 
FH Mesenchymal Cell Generation and Culture. Mesenchymal cells were 
generated as previously described425. FH-iPSC±LDLR were passaged onto Matrigel-
coated plates using Gentle Cell Dissociation Buffer (Stem Cell Technologies) and 
introduced to 100% mTeSR1 in a graded manner. One day after passaging, transfected 
cultures received 1 µg/ml Hygromycin B to maintain selective pressure. Once confluent 
and in 100% mTeSR1, the media was changed to EGM2-MV (Lonza) for 20 days for 
differentiation into FH-MC. Once fully differentiated, FH-MC were passaged and used in 
LDL internalization assays. 
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Quantification of pEHZ-LDLR-LDLR Activity. FH-MC±LDLR were plated in 
gelatin-coated wells of a 24-well tissue culture plate. We utilized an established 
protocol430, but used fluorescent DiI-LDL (Alfa Aesar) in place of 125Iodinated-LDL. 
Specific receptor-mediated internalization was determined by subtracting the 
internalization of [DiI-LDL + 50-fold excess of unlabeled LDL (Alfa Aesar)] from the 
internalization quantified with DiI-LDL alone. Cells were then lysed with 250 µl 0.1N 
NaOH (Ricca Chemical Company). Fluorescence was quantified using a 96-well plate 
reader (BioTek), with the excitation and emission set to 514 nm and 550 nm, 
respectively. Fluorescence units were normalized to total protein content, which was 
determined via a DC Protein Assay kit (Bio-Rad). 
Polymerase Chain Reaction (PCR) and Gel Electrophoresis. Differentiating 
FH-iPSC were lysed at the end of each stage using 350 µl of 0.1% β-mercaptoethanol in 
RLT Buffer (Qiagen).  Lysates were purified using Qiashredder and RNeasy kits 
(Qiagen) according to the manufacturer’s instructions. RNA was quantified using a 
NanoDrop 1000 Spectrophotometer (generously provided by Ronald Gregg, University 
of Louisville). cDNA was generated from purified RNA via a SuperScript II Reverse 
Transcriptase kit (Invitrogen). 200 ng of stage-specific cDNA was added to 45 µl of PCR 
SuperMix (Invitrogen) and 1µl each of 10µM forward and reverse primers (Integrated 
DNA Technologies; primer sequences can be found in Table 5). PCR was performed for 
25 cycles, with denaturation at 95˚C, annealing at 58˚C, and extension at 72˚C. 
Amplicons were assessed via 3% agarose gels (Bio-Rad). 10 µl of amplicons were 
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Table 5. A listing of the primers used for RT-PCR. 
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SYBR Green 1 nucleic acid stain (Lonza). Gels were run at 70 V for 2.5 hours and 
imaged via a Typhoon 9400 variable mode imager. Gel bands were plot profiled and 
normalized to GAPDH via densitometry analysis with Image J software (US National 
Institutes of Health). 
Immunocytochemistry. For immunostaining, cells were fixed in 4% 
paraformaldehyde (PFA; Electron Microscopy Sciences) for 15 minutes at RT and 
washed with di-cation PBS. For intracellular iPSC staining, cells were permeabilized 
with 0.1% Triton X-100 (Sigma-Aldrich) and 1% Polyvinylpyrrolidone (Sigma-Aldrich), 
for iPSC analysis, in a PBS blocking solution containing 4% normal goat serum (Sigma-
Aldrich). For extracellular staining, cells were blocked in di-cationic PBS containing 4% 
goat serum. Primary antibody solutions (1:200; Table 6) were applied for 1 hour at RT 
and washed cells with di-cation PBS. Secondary antibody solutions (1:500; Table 6) 
were applied for 1 hour at RT. Cells were treated with ProLong® Gold Antifade Reagent 
containing DAPI nuclear stain (Invitrogen). Images were taken using an Olympus IX81 
fluorescence microscope using SlideBook Software (Intelligent Imaging Innovations, 
Inc., Denver, CO). To assess FH-iPSC differentiation into FH-HLC, cells were fixed and 
washed at the end of each stage as described above. After permeabilization with 0.5% 
Triton X-100 for 10 minutes, cells were blocked with 5% goat serum for 1 hour before 
being exposed to primary antibody overnight and secondary antibody the following day. 
Histology. Explanted teratomas were fixed in paraffin (Leica Biosystems) and 
sectioned via microtome. Sections were de-paraffinized with xylene (Thermo Fisher 
Scientific) for 10 minutes and sequentially hydrated with decreasing proportions of 






PRIMARY ANTIBODY (1:200) MANUFACTURER & LOCATION 
OCT4 R&D Systems, Minneapolis, MN 
SOX2 R&D Systems 
SSEA4 Developmental Studies Hybridoma Bank, 
Iowa City, IA 
TRA-1-60 EMD Millipore, Billerica, MA 
StainAliveTM TRA-1-60 (DyLightTM 488) Stemgent, Cambridge, MA 
TRA-1-81 EMD Millipore 
βIII-TUBULIN Neuromics, Edina, MN 
α – SMOOTH MUSCLE ACTIN Santa Cruz Biotechnology, Dallas, TX 
VIMENTIN BD Bioscience, San Jose, CA 
 
FLUOROPHORE (1:500) MANUFACTURER & LOCATION 
Alexa Fluor® 405 Invitrogen, Grand Island, NY 
Alexa Fluor® 594 Invitrogen 
 
End-of-stage visual assessments 
 
PRIMARY ANTIBODY (1:200) MANUFACTURER & LOCATION 
OCT4 Santa Cruz Biotechnology 
SOX17 R&D Systems 
GATA4 Santa Cruz Biotechnology 
HNF3β Santa Cruz Biotechnology 
AFP (ZSA06) Invitrogen 
Albumin MP Biomedicals, Santa Ana, CA 
 
SECONDARY ANTIBODY (1:1000) MANUFACTURER & LOCATION 
Goat anti-Mouse 488 Thermo Scientific, Waltham, MA 
Goat anti-Rabbit 488 Thermo Scientific 
Rabbit anti-Goat 594 Invitrogen 
 
Table 6.  Primary antibodies were incubated at 1:200, Fluorophores at 1:500, and 
secondary antibodies at 1:1000. 
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Gill’s Hematoxylin (Leica Biosystems) for 10 minutes. Water was applied to the sections 
for 1 minute; sections were then dipped once each in acid ethanol (comprised of 3 ml 
37% HCl (Thermo Fisher Scientific) and 300 ml 70% EtOH) and water before 15 
immersions in ammonia water (0.9 ml 30% Ammonium Hydroxide; Sigma Aldrich) and 
exposure to running water for 20 minutes. Working Eosin (Leica Biosystems) was 
applied to sections for 5 minutes before sequential dehydration with increasing 
proportions of ethanol in 2-minute increments. After two more 2-minute immersions in 
xylene, sections were mounted with coverslips and imaged via phase microscopy. 
Statistical Analysis. Experiments were conducted in triplicate with replicated 
data points per experiment. Values are presented as means ± S.E.M. Significance was 
determined using a Student’s t-test. Treatment significance was verified by one-way 
ANOVA using SigmaPlot (Systat Software).  
 
RESULTS 
FH-iPSC can be generated from FH fibroblasts. Skin fibroblasts from a patient 
with clinically homozygous FH (Coriell Cell Repositories; #GM01355) were examined to 
verify their inherent LDLR dysfunction using an LDL internalization assay (Figure 21). 
After pretreatment with Lovastatin, excess free sterols, and ethanol (vehicle control) in 
lipoprotein-deficient serum overnight, the cells were exposed to DiI-LDL the following 
day and found to be impaired in their ability to internalize LDL when compared against 
wild-type IMR90 fetal lung fibroblasts. Because concerns with iPSC generation include 
(a) genomic integration of exogenous reprogramming factors and (b) unwanted 






Figure 21. Upon receipt, source FH fibroblasts (GM03155) were compared to wild-type 
IMR90 fetal lung fibroblasts to determine their ability to internalize fluorescent DiI-LDL 
after pre-treatment with Lovastatin, excess free sterols, or ethanol (vehicle control) in 
lipoprotein-deficient media. Reduced internalization of fluorescently labeled LDL 
indicated a functional reduction in the capacity for receptor-mediated endocytosis. 
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mRNA-based reprogramming technologies. FH patient fibroblasts were obtained from 
Coriell Cell Repositories (#GM01355; Figure 22A) and transfected with synthetic 
modified mRNA431 (modRNA) (encoding OCT4, SOX2, KLF4, cMYC and LIN28432). 
Within 20 days of continuous transfection, the fibroblasts gradually attained a compacted 
morphology broadly characteristic of iPSC, with a calculated reprogramming efficiency 
of 0.012% (Figure 22B). Live-cell immunolabeling with the extracellular pluripotence 
marker TRA-1-60 (Figure 22C) suggested successful iPSC reprogramming.  
Over the next several days, we observed colonies that possessed increasingly defined 
borders and cells with high nuclear-to-cytoplasmic ratios and prominent nucleoli. These 
cell clusters were positive for the intracellular pluripotent markers OCT4 (Figure 22D) 
and SOX2 
 (Figure 22E), which co-localized (Figure 22F), giving visual credence to the fact that 
the source fibroblasts were fully reprogrammed into iPSC433. Additionally, the 
extracellular surface pluripotent markers SSEA4 (Figure 22G), TRA-1-60 (Figure 22H), 
and TRA-1-81 (Figure 22I) were also visualized. The expression of these intracellular 
and extracellular pluripotent markers coupled with the aforementioned hPSC-specific 
morphologic features suggested a successful development of FH patient-specific iPSC 
from source fibroblasts. To further characterize their lineage and normality, FH 
fibroblasts and FH-iPSC were subjected to karyotypic analysis (Figure 23) and DNA 
fingerprinting (not shown), confirming genetic homology between the two cell 
populations. This validated our production of autologous iPSC and ruled out any 




Figure 22. (A) FH parent fibroblasts attained a compacted morphology characteristic of 
(B) iPSC, which were positive for (C) the pluripotent marker TRA-1-60 during live 
imaging. FH-iPSC were positive for (D) Oct4 and (E) Sox2, which (F) co-localized to the 
cell nucleus. FH-iPSC were also positive for the pluripotence markers (G) SSEA4, (H) 
TRA-1-60, and (I) TRA-1-81. Spontaneous in vitro differentiation yielded cells positive 
for (J) β-III TUBULIN (ectoderm), (K) VIMENTIN (endoderm), and (L) α-Smooth 
Muscle Actin (αSMA, mesoderm) (Scale bar = 10 µm). In vivo differentiation of 
implanted FH-iPSC yielded teratomas positive for (M) ectoderm, (N) mesoderm, and (O) 
endoderm. 
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We next assessed FH-iPSC pluripotency by spontaneous differentiation in vitro and 
teratoma formation in vivo. After 20 days of culture without supplemental bFGF, cells 
expressed the extracellular markers β-III TUBULIN (ectoderm; Figure 22J), 
VIMENTIN (endoderm; Figure 22K) and α-SMOOTH MUSCLE ACTIN (α-SMA; 
mesoderm; Figure 22L). For in vivo testing, undifferentiated FH-iPSC were combined 
with Matrigel and injected into the right subcutaneous dorsum of NOD/SCID-γnull 
immunocompromised mice, while the left dorsum was injected with Matrigel alone as a 
negative control. Injected FH-iPSC yielded teratomas with evidence of solid tissue 
development and displayed a vasculature that anastomosed with that of the host. 
Histologic assessment of the solid tissue showed clusters of neuroepithelial cells 
(ectoderm; Figure 22M), regions of cartilage and immature bone formation (mesoderm; 
Figure 22N), and organized ciliated columnar epithelium (endoderm; Figure 22O). 
Expectedly, the Matrigel negative control yielded no teratomas (data not shown). This 
data demonstrates the utility of transient, non-integrating mRNA reprogramming vector 
systems in generating pluripotent, patient-specific iPSC. The FH-iPSC pluripotent 
potential was assessed via in vitro spontaneous differentiation and in vivo teratoma 
formation, with both assays demonstrating formation of the three germ layers (endoderm, 
mesoderm, and ectoderm). Karyotyping (Figure 23) and DNA fingerprinting (not shown) 
(a) revealed no reprogramming-attributed chromosomal abnormalities and (b) 
demonstrated homology between the FH-iPSC and their source fibroblasts. These results 
demonstrate that the GM01355 FH fibroblasts were successfully reprogrammed into 
pluripotent FH-iPSC.  
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Figure 23. (A) FH parent fibroblasts (GM01355) were tested to determine their 
karyotype. (B) After reprogramming, FH-iPSC karyotype was also determined. The 
karyotype of the starting population and reprogrammed daughter cells were both normal.  
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FH-iPSC can differentiate towards a hepatic lineage. Since FH patients benefit 
from a variety of interventions principally targeting hepatocytes, we wanted to determine 
if FH-iPSC could differentiate towards a hepatic lineage using a modified version of an 
established hepatic differentiation protocol that mimics developmental embryologic cues 
(Figure 24A)428. At the end of each stage, we conducted RT-PCR (Figure 24B) and 
immunocytochemistry (Figure 24C) to follow transcript and protein expression, 
respectively, throughout the spectrum of HLC derivation. Being undifferentiated, the FH-
iPSC at Stage 0 expressed OCT4 transcripts and protein that rapidly decreased to 
undetectable levels in the subsequent stages.  In stages 1 and 2, marked cell- specification 
into definitive endoderm and hepatic-defined lineages was evident from the nuclear 
expression of SOX17, HNF3β/4α, and GATA4. Starting in Stage 2, cells were positive 
for the hepatic markers Alpha-fetoprotein (AFP) and Albumin, which were initially 
observed as cytoplasmic clumps before attaining a more uniform distribution by Stages 3 
and 4. By the end of Stage 5, AFP and Albumin transcript and protein expression 
predominated, indicating the generation of FH-HLC. 
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Figure 24. (A) Phase microscopy demonstrates hepatocyte-like cell (HLC) morphology 
at the end of the five-stage differentiation process (Scale bar = 500 µm). (B) 
Representative gel electrophoresis image of PCR transcripts at the end of each 
differentiation stage. GAPDH was used as a loading control. (C) Immunocytochemistry 
at the end of each differentiation stage demonstrates a progressive shift in protein 
expression towards a hepatic phenotype (Scale bars = 50 µm, *100 µm, and **200 µm; 
images of varying magnifications were chosen for clarity). (D) Quantification of AFP 
(blue)- and Albumin (red)-positive cells as a fraction of the total number of cells (DAPI), 
shown for each differentiation stage as mean ± S.E.M. 
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Semi-quantitative PCR densitometry conducted at the end of each stage depicted a 
progressive change in gene expression, from pluripotence to markers associated with the 
hepatic lineage (Figure 25). The number of cells expressing AFP and Albumin at each 
stage was calculated as a percentage of all DAPI-labeled cells (Figure 24D; mean ± 
S.E.M.). We noticed the following pattern of AFP expression over the course of the 
differentiation – Stage 0: 0%, Stage 1: 0%, Stage 2: 24.74 ± 4.73%, Stage 3: 63.84 ± 
13.25%, Stage 4: 81.83 ± 11.99%, and Stage 5: 75.71 ± 4.08%. We witnessed a similar 
pattern of Albumin expression as well – Stage 0: 0%, Stage 1: 0%, Stage 2: 48.49 ± 
3.31%, Stage 3: 55.3 ± 24.69%, Stage 4: 78.03 ± 14.92%, and Stage 5: 84.26 ± 5.73%. 
Thus, with respect to differentiation efficiency, most of the cells were positive for the two 
primary hepatic markers by the end of Stage 5 differentiation. During each round of FH-
HLC production, we noticed the presence of differentiating cells that took on an 
increasingly granular, vacuolar appearance (especially present at Stage 3) that looked 
lipid-like – an observation consistent with that of Fattahi and colleagues434. To determine 
if these vacuoles were in fact accumulating lipids, we subjected the FH-HLC to Oil-Red-
O staining and subsequently confirmed the presence of numerous lipid droplets (Figure 
26A), suggesting that these cells are not impaired in their ability to store lipids, but 
perhaps only in their ability to bind and internalize LDL. This corresponds with what is 
seen clinically, as FH patients often exhibit normal liver function tests435. To determine if 
FH-HLC demonstrated any outward sign of maturation, the cells were treated with 
Indocyanine green (ICG), a clinically relevant dye that is metabolized and cleared by 
specific mature cell types including hepatocytes436. Though ICG was cleared, this 




Figure 25. Densitometry quantification of transcript expression was performed for each 
gene at the end of the differentiation stages. Transcripts were normalized to the GAPDH 





Figure 26. (A) FH-HLC were stained with Oil-Red-O to visualize lipid accumulation 
with phase and bright field (BF) microscopy. (B) FH-HLC cellular uptake (white arrows) 
of Indocyanine Green (ICG) was imaged with BF microscopy after 1 hour of treatment. 
The same site was also assessed for ICG clearance 24 hours later.  (Scale bar = 200 µm). 
(C) FH-HLC demonstrate survival and engraftment in vivo in Rag1-/- x LDLR-/- double-
KO mice when implanted with adipose-derived stromal and vascular support cells (white 
arrows indicate network formation). FH-HLC without stromal support failed to survive 
or express Albumin after the two-week implant period. (Scale bar = 50 µm). 
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differentiation protocol yielded a predominantly immature hepatic population (Figure 
26B). Still, these results indicate that FH-iPSC can differentiate down a hepatic lineage 
into FH-HLC. We then asked if FH-HLC could engraft in vivo (Figure 26C). We 
previously demonstrated the utility of adipose-derived stromal vascular fraction cells 
(SVF) in providing vital stromal and vascular support437 to implanted parenchymal 
hepatocytes within a liver-tissue mimic438. Consequently, we combined human SVF with 
FH-HLC in collagen-I constructs and implanted them subcutaneously in Rag1-/- x LDLR-
/- double-knockout mice for 2 weeks. We labeled the explanted constructs with Albumin-
488 and UEA-1-Cy5 (binds to human endothelium). Fluorescence confocal microscopy 
showed that FH-HLC had engrafted and expressed Albumin in the presence of SVF, 
whereas FH-HLC did not survive in the absence of SVF. Together, these findings suggest 
that FH-iPSC can differentiate down a hepatic lineage and, given the proper stromal and 
vascular support, survive and engraft in vivo.  
 
Verification of pEHZ-LDLR-LDLR functionality. To verify the functionality of 
pEHZ-LDLR-LDLR, we utilized CHO-a7, an Ldlr-deficient cell line424,439 (CHO-a7-
LDLR) (Figure 27). Transfected CHO-a7 were selected with Hygromycin-B then 
compared against wild-type CHO (CHO-WT) and non-transfected CHO-a7 on the basis 
of their ability to bind and internalize fluorescent DiI-LDL cholesterol. Each CHO-a7 
was treated overnight with Lovastatin, excess free sterols, or ethanol (a vehicle control) 
in lipoprotein-deficient serum. Lovastatin is an HMG-CoA reductase inhibitor that blocks 






Figure 27. Transfected CHO-a7-LDLR exhibited LDL internalization sensitive to 
Lovastatin, excess sterols, or ethanol (vehicle control). This behavior paralleled that of 
CHO-WT under the same media conditions, and both were in stark contrast to the lack of 
LDL-C uptake seen in Ldlr-dysfunctional CHO-a7. 
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production of LDL-C, Lovastatin facilitates exogenous cholesterol internalization via 
surface up-regulation of the LDLR, allowing the cell to still meet its metabolic 
requirements while having an overall therapeutic effect on serum cholesterol levels. 
Excess free sterols are membrane permeable. Consequently, they can be internalized by 
receptor-independent mechanisms that secondarily result in LDLR down-regulation441. 
Under such conditions, CHO-WT showed an expected pattern of maximum DiI-LDL 
internalization with Lovastatin treatment over the ethanol control, and almost complete 
abrogation of DiI-LDL uptake when pre-treated with excess free sterols. In contrast, 
CHO-a7 expectedly demonstrated virtually no DiI-LDL internalization regardless of the 
treatment condition. The transfected CHO-a7-LDLR exhibited DiI-LDL internalization 
that was appropriately sensitive to exogenous Lovastatin and demonstrated functional 
restoration of LDL receptor-mediated endocytosis. Exposure to excess sterols yielded a 
decrease in LDL-C internalization, while ethanol vehicle treatment yielded a slight 
increase. This behavior parallels that seen in Ldlr-competent CHO-WT under the same 
experimental conditions, validating the LDLR functionality and physiologic sensitivity of 
the episomal plasmid. 
 
FH-iPSC transfection with pEHZ-LDLR-LDLR. FH-iPSC retain the same 
genetic dysfunction as their source patient fibroblasts and therefore offer limited 
therapeutic value with regards to restoring LDLR-mediated endocytosis. Since 
constitutive LDLR transgene expression for treating FH has not yet achieved a cure442,443 
and may even be cytotoxic444,445 we elected to use the plasmid pEHZ-LDLR-LDLR to 
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impart physiological responsiveness by 10kb of up-stream genomic control 
sequences424,446,447.  
We initially confirmed pEHZ-LDLR-LDLR physiological restoration of receptor-
mediated endocytosis in the Ldlr-deficient cell line CHO-a7 (Figure 27)424,439. Because 
of the plasmid’s large 31kb size, we utilized electroporation transfection448 and tested a 
wide range of parameters using both decaying exponential and square-wave 
electroporators (Table 4).  
Using a BTX 630ECM decaying exponential electroporator with a 4mm 
cuvette448, we found that settings achieving time constants (τ) between 16 and 18ms were 
optimal for achieving iPSC survival and transfection. Smaller τ were associated with 
increased iPSC survival but inadequate plasmid delivery, while τ greater than 18ms 
resulted in cell death. We also tested the effects of temperature and buffer on 
electroporation success. For the conditions tested, pre-chilling all components was 
critical. Moreover, we found no difference with using either phosphate-buffered saline 
(PBS) or a commercially available electroporation buffer.   
We then tested the NEPA21 square-wave electroporator using a range of parameters 
for plasmid delivery to human pluripotent stem cells. From the range of settings tested, a 
voltage of 300V and pulse length time of 0.5ms facilitated iPSC survival and successful 
delivery of the 31kb plasmid. We then conducted all square-wave electroporations at 
room temperature in Opti-MEM media. 48 hours after electroporation, Hygromycin-B 
selection was initiated at 10µg/ml for at least 5 days, followed by 0.5-1µg/ml thereafter as 
a maintenance dose.  
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pEHZ-LDLR-LDLR retention and functional restoration. pEHZ-LDLR-LDLR is 
stably maintained as an episome and does not integrate into the host genome424. After 
culturing FH-iPSC-LDLR under continuous Hygromycin-B selection429 for over 6 
months, we subjected the cells to alkaline lysis and recovered the plasmid via ethanol 
precipitation. The isolated plasmid was purified and digested with the restriction enzyme 
AgeI, yielding two appropriately sized fragments measuring 18.6kb and 12.1kb (Figure 
28Ai). We then validated the functionality of the recovered plasmid by transfecting it into 
Ldlr-deficient CHO-a7 (CHO-a7-LDLR; Figure 28Aii). The recovered plasmid restored 
the physiological feedback control of LDLR-mediated endocytosis in the CHO-a7-
LDLR. These findings collectively demonstrate that (a) pEHZ-LDLR-LDLR is retained as 
an episome in human iPSC and (b) its function is independent of genomic integration. 
We next wanted to determine if pEHZ-LDLR-LDLR had an effect on the inherent 
pluripotence of our FH-iPSC. Therefore, we assessed expression of TRA-1-60 on 
transfected cells cultured for over a year under Hygromycin-B antibiotic selection 
pressure. Like their non-transfected FH-iPSC counterparts (Figure 22C), FH-iPSC-
LDLR retained a robust expression of TRA-1-60 (Figure 28Bi). Expression of NANOG 
in FH-iPSC±LDLR was also confirmed by PCR (Figure 28Bii).  These results suggest 
that transfection with the episomal plasmid pEHZ-LDLR-LDLR does not diminish iPSC 
pluripotence.  
To determine if FH-iPSC-LDLR derivatives also retained the plasmid and displayed 
functional restoration of LDLR-mediated endocytosis, we differentiated FH-iPSC±LDLR 
into FH-HLC±LDLR. The derived HLC were cultured with Lovastatin, excess free 




Figure 28. (A.i) pEHZ-LDLR-LDLR episome was recovered from FH-iPSC-LDLR and 
cleaves into expected fragment sizes after digestion by AgeI-HF restriction enzyme. (A.ii) 
Recovered plasmid transfected into Ldlr-deficient CHO-a7 demonstrates restored 
physiologic receptor-mediated endocytosis via DiI-LDL internalization. (B.i) FH-iPSC-
LDLR colonies cultured for over 12 months still exhibit iPSC-characteristic well-defined 
borders and express TRA-1-60-488 via live-labeling (Scale bar = 100 µm). (B.ii) 
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Pluripotence of long-term cultured FH-iPSC±LDLR was verified by PCR, which 
demonstrated NANOG expression. β-actin was used as a loading control. (C) FH-HLC-
LDLR displayed differential physiologic sensitivity, with highest DiI-LDL internalization 
with exposure to Lovastatin and almost complete internalization abrogation with 
exposure to excess sterols. Little internalization of DiI-LDL was detected in FH-HLC. 
Ethanol was used as a vehicle control (Scale bar = 200 µm). 
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incubation with DiI-LDL (Figure 28C). The FH-HLC demonstrated little internalization 
of DiI-LDL, indicating that without any transgene intervention, LDLR-mediated 
endocytosis of LDL remained dysfunctional. However, FH-HLC-LDLR exhibited 
markedly elevated LDL endocytosis that demonstrated the same physiological sensitivity 
to peripherally applied statin, sterols, or vehicle control as seen with the CHO-a7-LDLR 
(Figure 27). These findings indicate that pEHZ-LDLR-LDLR effectively restores 
physiological feedback control of LDLR activity in FH-iPSC derivatives. 
 
Restored receptor-mediated LDL endocytosis quantification. To facilitate the 
quantification of pEHZ-LDLR-LDLR-driven specific LDL internalization, we 
differentiated FH-iPSC±LDLR into mesenchymal cells (FH-MC±LDLR; Figure 29A) 
utilizing an established protocol from our lab425. These cells grow in a monolayer and are 
contact-inhibited, allowing quantification of specific LDL receptor-mediated endocytosis. 
FH-MC and FH-MC-LDLR were cultured in lipoprotein-deficient serum media 
supplemented with Lovastatin, excess sterols or ethanol control before exposure to DiI-
LDL (Figure 29B). The ethanol control yielded appreciable, though not significant (p = 
0.27), differences in internalization between the two groups (FH-MC: 188.57 ± 74.33 vs. 
FH-MC-LDLR: 438.82 ± 180.57 fluorescence units/mg protein (FU/mg); mean ± SEM) 
reflecting the cellular lipid requirement due to the lipoprotein-deficient media 
environment. This difference was amplified when the cells were exposed to the additional 
stimulus of Lovastatin. Transgene-expressing cells displayed a statistically significant 
increase (p = 0.035) in specific internalization versus their non-transfected counterparts 
(FH-MC: 321 ± 61.7 FU/mg vs. FH-MC-LDLR: 526.15 ± 21.18 FU/mg). As expected,  
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Figure 29. (A) Phase microscopy image of transfected FH-iPSC-derived mesenchymal 
cells (FH-MC±LDLR) (Scale bar = 500 µm) depicts a fibroblastic monolayer suitable for 
quantification studies. (B) Quantification of specific DiI-LDL internalization by FH-MC 
displayed impaired LDL internalization. Transfected FH-MC-LDLR demonstrated 
significantly greater ability to internalize DiI-LDL. Bars are depicted as means ± S.E.M., 
and these graphs characterize experiments conducted in triplicate (*,v  = p < 0.05 and 
vvv  = p < 0.001; * = significance between cell types and similar treatments, while v  
= significance within a cell type). 
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free sterols suppressed DiI-LDL internalization to a statistically equivalent level 
regardless of transgene presence (FH-MC: 56.90 ± 25.93 vs. FH-MC-LDLR: 99.15 ± 
5.80 FU/mg, p = 0.19) since free sterol internalization is receptor independent449. Within 
the transfected FH-MC-LDLR population, the suppression elicited by free sterols was 
extremely significant when compared to Lovastatin (p = 0.00004) and significant with 
regards to the ethanol control (p = 0.02). Presenting these differences another way, 
transfected FH-MC-LDLR demonstrated 1.63- and 2.33-fold increases in specific DiI-
LDL internalization over FH-MC in the presence of Lovastatin and ethanol, respectively. 
These findings suggest that the pEHZ-LDLR-LDLR plasmid functionally restores LDL 




Familial Hypercholesterolemia (FH) is a heritable disease of LDL receptor (LDLR) 
dysfunction. While the only known cure for FH is liver transplant, unfortunately, the 
availability of donor livers pales in comparison to a high demand. Furthermore, there are 
long-term issues to consider with transplant, such as compatibility, cost, quality-of-life, 
and possibly death. Because the availability of quality hepatocytes is a key issue, induced 
pluripotent stem cells (iPSC) presented us with a means of generating a sufficient 
quantity of cells that we could then differentiate into hepatocyte-like cells (HLC). In 
addition to developing a large quantity of cells, iPSC have the added benefit of being 
obtained in an autologous manner, potentially mitigating issues with rejection and 
obviating the need for immunosuppressive agents. However, a key hurdle with this 
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approach is that if we were to use FH patient-derived iPSC (FH-iPSC), these cells and 
their derivatives would contain the same LDLR dysfunction as their parent cells, and 
would therefore provide little to no therapeutic benefit.  
Thus, we developed a proof-of-concept strategy that carries broad implications for 
generating and functionally restoring genetically deficient iPSC. To do so, we utilized a 
transient reprogramming vector as well as non-viral, episomal vectors that confer 
genomic LDLR transgene control. Based on these methods, we made the following 
significant findings:  
(a) An episomal, transgene plasmid can be maintained extra-chromosomally within 
iPSC. 
(b) This plasmid does not impair the pluripotency of iPSC.  
(c) Genomic control of plasmid LDLR transgene expression restores physiologic 
functionality to genetically deficient cells. 
We used synthetic transient RNA (i.e., modRNA) to reprogram FH-fibroblasts into 
FH-iPSC. Our relatively low reprogramming efficiency with modRNA was considerably 
lower than published figures (approaching 2%234). This efficiency could result from the 
LDLR genetic deficiency of our cells, though several other reports describing FH-iPSC 
generation with viral vectors fail to mention reprogramming efficiencies89,270,450. 
Therefore, our efficiency of 0.016% could potentially be attributed to experimental 
variation. Furthermore, as iPSC are highly proliferative, overall efficiency is not a 
significant concern since, theoretically, only one iPS cell is required to generate a whole 
colony of cells. 
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Approaches to genetically correct the LDLR deficiency in FH via gene therapies 
have traditionally utilized viral vectors127,451-453. As an example, some have used the 
portal vein to dispense infectious viral particles directly to the liver. In animals, two 
distinct outcomes were observed:  
(1) Circulating LDL cholesterol levels were significantly, but transiently, reduced451.  
(2) LDL cholesterol levels did not reach targeted goals due to potential plasmid 
loss454, immune detection of transduced cells453, inactivation of the LDLR 
transgene455, or a suboptimal transduction of host hepatocytes451,452.  
Viral vectors such as adenoviruses or retroviruses have insert capacities typically 
less than 10kb. Because of this relatively small size, the options for controlling transgene 
expression are limited456. For instance, the use of Cytomegalovirus (CMV) or Rous 
Sarcoma Virus (RSV) promoters to control LDLR transgene expression led to excessive 
lipid internalization, causing cell death130,131. Lipid accumulation was observed in the 
livers of Watanabe heritable hyperlipidemia (WHHL) rabbits given a CMV-driven LDLR 
in E1-deleted adenovirus457. To contrast, recent reports have described the use of 
hepatocyte-specific promoters, such as thyroid-binding globiulin or alpha-1 anti-trypsin 
(A1AT), to constitutively drive LDLR transgene expression. In these instances, cytotoxic 
lipid accumulations were not seen127,451. Therefore, hepatocyte-specific promoters may 
ultimately protect against lipid accumulation, though their mechanism of action has not 
been specified458. However, given that functional LDL receptors are physiologically 
regulated via a feedback loop, the constitutive expression of LDLR may have long-term, 
detrimental consequences. 
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Alternatively, episomal plasmids containing genomic DNA expression control 
sequences can be used to address the LDLR deficiency in FH. These genomic sequences 
can confer precise physiological control of the LDLR transgene while enhancing long-
term LDLR expression459. We utilized the episomal plasmid pEHZ-LDLR-LDLR, which 
contains the EBV retention and replication sequences EBNA1 and oriP. These sequences 
allow pEHZ-LDLR-LDLR to be maintained as an episome6. The EBNA1 trans regulatory 
protein, in particular, is unique for two reasons. First, it is the only EBV protein required 
for retained episomal function460. Second, unlike the other EBV proteins, EBNA1 is not 
immunogenic461. Thus, host immune response to the plasmid is mitigated.  
The expression of the LDLR is tightly controlled by an endogenous feedback 
loop462. Cells regulate surface LDLR expression based on circulating LDL levels and 
membrane cholesterol content462. Prior studies demonstrate that pEHZ-LDLR-LDLR 
reestablished receptor-mediated endocytosis in FH fibroblasts and persisted long-term in 
non-dividing hepatocytes in vivo6, although the transfection efficiency was unclear. In 
our application, pEHZ-LDLR-LDLR restored physiologically sensitive receptor-mediated 
endocytosis in FH-iPSC. Additionally, this function was retained in various FH-iPSC-
derived progeny.  
To our knowledge, this is the first report demonstrating the delivery and stable 
transfection of a relatively large (38kb) episomal plasmid into human iPSC using 
electroporation. Though we could have transfected the source FH fibroblasts prior to 
reprogramming, the effect of a large 31-kb plasmid on reprogramming is unknown, as is 
the viability of the plasmid in the long term.  Transfection of FH-iPSC-derived cells was 
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also an option. However, these cells would still require long-term antibiotic selection, 
which is problematic with hepatocytes considering that they culture poorly423.  
Electroporation provided us with another alternative transfection modality. Because 
others successfully delivered plasmids to hPSC using electroporation463,464, we sought to 
do the same with FH-iPSC. Electroporation generally presents several challenges. There 
are several parameters reported in the literature, many of which depend on buffers 
utilized, temperature, cuvette size, and even the type of machine used. For instance, 
decayed-exponential electroporation has been shown to be effective for prokaryote 
transfection, while square-wave electroporation is typically used for transfection of 
mammalian cells465. We used both decayed-exponential and square-wave electroporation, 
and produced viable, transfected FH-iPSC (FH-iPSC-LDLR) that were resistant to 
Hygromycin B selection.  Though we observed relatively low transfection efficiencies, 
this phenomenon may be attributable to the sensitivity of pluripotent stem cells, which 
are difficult to transfect465, the large size of the plasmid, and the physical and chemical 
stresses of electroporation459. Further, it has been shown that the EBV plasmid 
transfection event partly destabilizes mechanisms of replication in the days following 
transfection taking about two weeks to achieve stability466. Though we were unable to 
precisely quantify transfection efficiency, an advantage of utilizing pluripotent stem cells 
is that even with low efficiency, a potentially unlimited number of transfected cells can 
be generated. Furthermore, if a sufficient quantity of cells carrying the genomic DNA-
controlled transgene could be delivered, then host homeostatic control of LDL 
metabolism could be restored without the need for constitutive LDLR expression.  
 162 
Another issue to address with our approach is plasmid retention, a common problem 
seen with using episomal viral vectors for direct gene therapy to the liver467.  EBV-based 
plasmids replicate once per cell cycle460 and, without antibiotic selection, are lost at a rate 
of 2 to 5% per cell division446. Therefore, using iPSC as a therapeutic cell source may 
require continuous selection until a stable phenotype (such as hepatocytes) can be 
derived.  To that end, two approaches could be used to achieve this goal: (a) differentiate 
FH-iPSC-LDLR in vitro with antibiotic selection until a minimally proliferative state is 
reached prior to implantation, or (b) generate a liver-tissue mimic with stromal and 
vascular support that facilitates selection and phenotype stabilization prior to 
implantation.  
Secondly, it is important to recognize that our strategy represents a functional, and 
not a genetic, correction and does not impede expression of the endogenous defective 
LDLR. There is potential for dysfunctional endogenous LDLR to interfere with the 
function of the corrected exogenous gene product.  As most FH patients do not know 
exactly what their genetic dysfunction is and since there are over 1200 reported LDLR 
mutations affecting function57, it will be necessary to determine if specific mutations or 
classes of mutations prevent phenotype recovery by pEHZ-LDLR-LDLR. Though 
clinically classified as “homozygote” (GM01355; the source patient exhibited a 
maximum LDL of 700mg/dl and presented with xanthomas), the FH cells used here 
demonstrated some LDLR activity and responsiveness to Lovastatin, suggesting that the 
patient may actually be a compound heterozygote468,469.  Transfected cells showed an 
approximate 2-fold increase in DiI-LDL internalization and no inhibitory effect from the 
defective endogenous LDLR was detected468.  This 2-fold increase in internalization is 
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potentially significant for three reasons: first, it demonstrates that internalization is being 
effected by the exogenous gene product and not just stimulation of the endogenous 
LDLR468. Second, it coincides with the observation that LDL-C internalization is LDLR 
allelic in a gene-dose dependent manner462 and third, it demonstrates physiological 
control as having an upper limit130.  The internalization data normalized to the ethanol 
control suggests a pattern of normal feedback regulation462. Put another way, though the 
non-transfected cells have a reduced capacity for LDL-C internalization, they display an 
expected physiological responsiveness paralleled by the transfected cells.  The long-term 
viability of a cell-based therapy for FH may hinge on preventing excessive LDL-C 
uptake by any one cell.  
 Though our approach specifically targets the LDLR dysfunction in FH, a strategy 
using episomes with genomic control of transgenes can be tailored to other biological 
conditions or clinical deficiency with potential for amelioration by iPSC intervention, 






SUMMARY AND CONCLUSIONS 
 
Each hepatocyte is capable of carrying out over 500 metabolic processes, making 
the liver one of the key metabolic regulatory organs in the body 145. Therefore, it is not 
surprising that liver dysfunction can be detrimental to various systemic processes, 
inducing cardiovascular disease to neurological diseases, to even multi-organ failure and 
death. In several pathologies, liver transplant remains the only curative option, though the 
availability of high-quality, compatible organs for transplant is impeded by a severely 
restricted supply. Recent research emphases now include tissue-engineered solutions that 
aim to assist or replace ailing liver organs. 
 In this project, we used the heritable disease Familial Hypercholesterolemia (FH) 
as a model for which we could develop a functional liver-tissue mimic device. Over the 
span of this dissertation project, we accomplished three goals. First, we were the first to 
develop a proof-of-concept liver tissue mimic device by combining HepG2 model 
hepatocyte cells with parenchymal support provided by adipose-derived stromal vascular 
fraction (SVF) cells. This liver-tissue mimic was able to engraft with the host vasculature 
and clear peripherally injected, circulating LDL cholesterol9.  
Second, one of the chief problems with liver transplantation (in addition to the 
inadequate supply of quality hepatocytes), and transplantation in general, is donor-host 
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compatibility. To this end, we tailored our liver-tissue mimic device to FH patients by (a) 
using patient cells to develop induced pluripotent stem cells (iPSC), potentially 
mitigating issues with parenchymal supply; (b) functionally correcting the LDL receptor 
(LDL-R) deficiency in patient-derived iPSC, allowing patient-derived cells to be restored 
in their LDL-R functionality; (c) differentiating corrected iPSC into hepatocyte-like cells 
(HLC), as hepatocytes traditionally express the highest levels of LDL-R in the body; and 
(d) promoting the engraftment of HLC in vivo by using SVF, since hepatocytes require 
vascular support for survival and function. Most importantly, functionalized HLC were 
able to internalize peripheral LDL, unlike their genetically deficient counterparts, which 
retain the LDL-R dysfunction. Here, we were the first to use entirely non-viral, non-
integrating modalities for generating and functionally correcting these cells, potentially 
mitigating adverse future outcomes associated with viral-vector usage1. Moreover, with 
further development, functionalized HLC could serve as a bridge-to-transplantation or 
mitigate transplantation entirely, since FH patients exhibit otherwise entirely normal liver 
function. 
Third, the vasculature is essential to liver-tissue mimic functionality. In our proof-
of-concept liver-tissue mimic, we observed that 3D constructs with HepG2 model 
hepatocytes lacking SVF were unable to internalize circulating LDL cholesterol. In our 
FH-specific iPSC-derived liver-tissue mimic, 3D HLC constructs lacking SVF support 
expressed significantly less albumin, suggesting that the HLC were either less functional 
(i.e., albumin output was reduced) or did not survive.  Thus, both of these findings 
suggest that SVF is essential for parenchymal cell functionality, phenotype maintenance, 
and likely even survival. Thus, we wished to examine the means by which SVF 
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spontaneously assembled into a functional vasculature, allowing it to critically support 
metabolically active cells such as hepatocytes. Here, we were the first to show that the 
Wnt signaling pathway is broadly implicated in hSVF endothelial cell (EC) vascular 
networking, and that the Wnt5a isoform in particular acts to modulate the assembly, not 
complexity, of hSVF vascular networks.  
These efforts have resulted in a methodology that can be used to create organ-
tissue autologous, iPSC-derived parenchyma supported by adipose-derived SVF. We also 
have the means to correct inherent genetic deficiency to restore functionality to these 
cells, such that these organ-tissue mimics impart a therapeutic value. Because SVF is 
critical to the ultimate functionality of these constructs (i.e., to produce a lasting, 
functional tissue-engineered device), our discovery of one regulatory mechanism in SVF 
vascular assembly provides us with a means of modulating the vasculature to meet 
different needs. Obviously, other mechanistic components are of interest, and will be 
discussed in greater detail later on. 
With respect to future efforts, it is academically reassuring to see that our findings 
raise more questions than they have answered. Several issues to examine revolve around 
our generation of a liver-tissue mimic. One topic of interest is the intricate, intimate 
relationship between normal liver hepatocytes and the sinusoidal vasculature within the 
liver. The liver vasculature not only promotes hepatocyte survival, but also plays a 
critical role in the exchange between systemic circulation and hepatocytes. Normal 
hepatocytes modulate their microenvironment to promote liver sinusoidal endothelial cell 
network formation, facilitating vital bulk transport. Our findings suggest that implanted 
hepatocytes also influence their microenvironment as demonstrated by their intimate 
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interaction with adipose-derived SVF – an interaction that was seen in 3D constructs 
using either HepG2 or iPSC-derived HLC. Thus, one logical question is how do 
hepatocytes recruit an adipose SVF-derived vasculature? To this end, we could 
investigate the patterns in vascular assembly of SVF in isolation compared to SVF in 
direct or indirect contact with hepatocytes. Several assays (such as PCR, western blot, 
ELISA, as well as proteomics to name a few) would allow us to identify the proteins that 
mediate this interaction. 
From this, a second topic to investigate would be the adaptation of the vasculature 
towards a hepatic phenotype. As mentioned in the background, embryologic development 
of the liver is actually made possible through intimate interactions with the cardiac 
mesoderm as well as the septum transversum mesenchyme. In this process, angioblasts 
(precursors to the liver sinusoids) are interspersed amongst cords of hepatoblasts (the 
precursors to hepatocytes and cholangiocytes). Thus, these two precursors are in close 
interaction throughout the liver’s development. Since HLC are regarded to be immature 
(they express a significant proportion of AFP even by the end of directed differentiation), 
their combination with SVF may ultimately form a vasculature that represents a 
sinusoidal, fenestrated system as opposed to a vascular system comprised of tight 
junctions and a continuous basement membrane. Here, we could look for liver sinusoidal 
endothelial cell (LSEC) markers (such as LYVE-1 or SE-1, for example) as well as use 
various microscopy techniques to identify a sinusoidal ultrastructure.  
A third issue lies with the development of the HLC themselves. In this regard, we 
have just stated that the HLC are, to a degree, immature. The presence of AFP and 
Albumin (in terms of gene and protein expression) suggests that our directed 
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differentiation protocols do not yield a population of cells that are uniform in their 
maturity. Thus, one question that stems from this is: do HLC need to be mature to impart 
a functional, therapeutic effect? Related to this, in the context of FH, it would be 
interesting to see if immature and mature HLC express LDL-R to varying degrees, or 
experience differences in LDL-R-mediated uptake and metabolism of LDL cholesterol. 
To this end, we have shown that HLC can perform this task, but have yet to demonstrate 
differences with respect to functional primary hepatocytes. Furthermore, if mature cells 
were desired over immature cells, would having HLC interspersed with SVF cells in 2D 
or 3D environments accelerate their maturity?  
With regards to the vasculature, an issue requiring further examination is Wnt5a’s 
role in SVF vascular assembly. For instance, with Wnt5a, we are still unaware of 
precisely which cells endogenously produce this ligand. Our data indicates that Wnt5a is 
common in hSVF cultures. As previously discussed, hSVF represents a heterogeneous 
cell population that includes endothelial cells, smooth muscle cells, fibroblasts, 
macrophages, pericytes, and various types of stem cells. Others have suggested that 
Wnt5a from macrophages, pericytes, or endothelial cells plays a role in modulating 
angiogenesis, but many of these efforts combine pure endothelial populations with 
transformed or immortalized stromal support cells. Our findings provide a basis for 
further investigation in heterogeneous populations such as SVF, but to date, the 
mechanisms by which SVF self-assembles still remains to be fully elucidated. Though 
our initial experiments with SVF show varying proportions of endothelial, perivascular, 
and stem cell populations between fresh and cultured SVF isolates, we could isolate EC 
alone using flow cytometry or MACS and see if these cells form networks of similar 
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complexity as those seen in full, heterogeneous populations. In a reductionist approach, 
we could then supplement FACS- or MACS-isolated SVF subpopulations to attempt to 
restore the extent of vascular self-assembly seen with the complete isolation. In all of 
these experiments, Wnt5a expression at the gene and protein level could be assessed to 
determine (a) which cells express the genes for Wnt5a production and/or (b) if Wnt5a 
production requires two or more cells to communicate with one another. From (b), the 
modality of communication (juxtacrine or paracrine) could also be determined. 
Our work also suggests a potential signaling axis via the prominent expression of 
the Wnt5a receptor Frizzled-4 (Fzd4). However, we do not yet know if the binding of 
Wnt5a to Fzd4 is precisely what drives changes in SVF vascular complexity. One simple 
experiment to establish the role of Fzd4 in this phenomenon would be to use a Fzd4 
blocking peptide or to knockdown Fzd4 expression via RNA interference. We could then 
determine if the resulting vascular phenotype is comparable to that seen when Wnt5a 
neutralizing antibody was utilized. If the resulting vasculature were the same phenotype 
as untreated cultures, this would indicate that Fzd4 signaling may not play a role in 
vascular patterning. If a completely different vascular assembly outcome were seen, 
different from the outcomes seen with untreated and Anti-Wnt5a-treated cultures, this 
finding would provide us with yet another mechanistic axis to pursue later on. Further, in 
this scenario, it is possible that this axis may involve other Wnt isoforms, as Fzd4 can 
also bind Wnt4470 as well as Norrin (a protein associated with retinal vascular 
development)471. Since our experimental data showed that FZD4 was expressed in hSVF 
cultures, one hypothesis could be that Wnt5a binding of Fzd4 initiates a signaling cascade 
that leads to the modulation of hSVF vascular self-assembly.  To this end, we could 
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examine the expression of downstream markers from Wnt5a-Fzd4 binding. For example, 
Umbhauer and colleagues demonstrated that Wnt5a-Fzd4 signaling activates ß-catenin472. 
Another downstream product of Fzd4 signaling (not yet shown with Wnt5a as the ligand) 
is Protein Kinase C473. These downstream markers could be used to verify upstream 
activity, such as the addition or removal of the Wnt5a ligand or receptor. 
Lastly, our results indicate that adding rhWnt5a to cultures devoid of other Wnt 
isoforms, stimulates an increase in EC sheeting. This level of sheeting was absent in 
cultures not treated with the Wnt release inhibitor IWP2. One possibility here is that other 
Wnt isoforms work with Wnt5a to promote hierarchy, branching, and overall 
organization and complexity. Wnt5a is but one mediator. Furthermore, the blockage of 
Wnt5a via a neutralizing antibody does not completely abrogate network formation, 
though this antibody may not completely block the activity of Wnt5a. Blockade of all 
Wnt isoforms via IWP2 produced a greater decrease in vascular network formation as 
opposed to blockade of just Wnt5a, though Wnt5a does play a significant role in this 
process. These observations further suggest that Wnt5a modulates vascular networking 
(Figure 30) along with other Wnt isoforms, or that Wnt5a affects the vascular complexity 
but other (non-Wnt) factors (such as VEGF, PDGF-B, etc.) mediate vascular self-
assembly. Future research efforts will likely uncover a constellation of Wnt isoforms and 
related molecules (such as Norrin, as an example) that participate in SVF self-assembly. 
Broadly speaking, we have established the methods for a complex solution. In 
addition to demonstrating that SVF-derived vasculatures support the engraftment and 
functionality of implanted hepatocytes, we provide a platform for the engraftment of 






Figure 30. We have demonstrated that Wnt5a modulates hSVF EC self-assembly into 
vascular networks. However, there are several unknowns: (1) Which cells release 
Wnt5a? (2) Which receptor(s) is required? (3) Where is this receptor located? (We 
hypothesize that the Wnt5a receptor that has a role in mediating self-assembly is found 
on endothelial cells, as shown above). (4) Does Wnt5a modulate extravascular activity, 
such as connective tissue phenotype? These are just a few examples of future research 
avenues to consider. 
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self-assembly, we also suggest that Wnt5a can be a target for manipulating derived 
vasculatures. And with respect to our final aim, in addition to generating and functionally 
restoring the LDL-R activity of autologous FH-iPSC, we provide a general platform for 
the use of non-viral, non-integrating modalities. Our efforts also provide a platform to 
generate tissue mimics for a variety of therapies. SVF cells could be utilized for vascular 
support, while iPSC-derived parenchyma could be generated and genetically 
manipulated. Lastly, we provide a strategy for gene therapy for any derived cell type, 
since iPSC can theoretically generate all cell types and can be obtained autologously. In 
sum, the data presented in this dissertation provides us with the necessary components for 
the generation and testing of a functional, therapeutic, autologous liver-tissue mimic. 
In several of these cases, we would be afforded the opportunity not only to study 
the functionalization of various components of a liver-tissue mimic, but also the 
mechanisms behind how these components interact with one another. Such a mimic 
would potentially allow us to better understand how native liver processes take place 
without having to rely on primary cell isolation. This would also facilitate the 
development and screening of various therapeutic agents. Not only would these 
investigations provide us with further insight into how a tissue-engineered liver-tissue 
mimic might function in a therapeutic, translational capacity, but it would lay the 
groundwork for the rapid development and modulation of other organ-tissue mimics as 
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